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• summary:
*1 if
A pH-profile of the absorption of [ C]carbenoxolone from the 
rat small intestine, both in vivo and in vitro, demonstrated that 
optimal absorption occurred from alkaline solutions. The pattern of 
carbenoxolone absorption was related to its water solubility, and the 
absorption-of the ionised form of the drug. The gastric absorption 
of [^C] carbenoxolone was negligible when compared to the intestinal 
absorption,and it was therefore inferred that the major site of 
absorption of this drug is the intestine.
P *] Zj. -i
An intravenous dose of L CJcarbenoxolone initially distributed
into an apparent volume of 5% of body weight, and had a plasma"
half-life of 15 minutes. A tissue, distribution study of 
r  1  ^  -lI CJcarbenoxolone showed that it was confined largely to the.
gastrointestinal tract, liver and blood plasma. The protein binding
characteristics of the drug were- of greater importance than its
lipid solubility in determining its tissue distribution. After
r1 A- -]parenteral administration of |_ CJ carbenoxolone to rats, some of the. 
radioactive drug and conjugates migrate back into the gastrointestinal 
tract, in particular to the gastric mucosa.
The interaction of carbenoxolone with endogenous, corticosteroids 
was investigated by studying the transport, metabolism, excretion 
and tissue binding of [ ^ H]corticosterone and P h] aldosterone in the 
rat. Acute carbenoxolone treatment significantly reduced (50/0 the
~JL ."Z
biliary excretion rate of [ H] aldosterone, [ Hjcorticosterone and 
their metabolites. Carbenoxolone pretreatment increased the plasma 
half-life of.[ II] aldosterone, and reduced the amount of radioactive 
metabolites in the intestinal mucosa.
The effect of carbenoxolone on the renal binding of 
[^H] aldosterone was studied both in vivo and in vitro. In control 
rats,saturation of nuclear binding occurred at a plasma aldosterone 
concentration of O .8 3 nM, whereas carbenoxolone treatment decreased 
this value to 0.52 nM. Carbenoxolone displaced
[^H] aldosterone in vitro from some nuclear binding sites, but not 
from the stereospecific mineralocorticoid-binding macromolecules 
isolated from kidney nuclei.
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Scope of the Present Research
CHAPTEITONE
There is now considerable support for the original 
observation (Doll, et«al*i 1962), that carbenoxolone will . 
promote the healing of gastric ulcers (Doll, .et.al*, 1965;
Horwich & Galloway, 1965; Robson & Sullivan, 1968), However, 
at present there is little information on the mode of action, 
and metabolic effects of this drug. The work described in this 
thesis was intended to provide some insight into the metabolic 
effects of carbenoxolone, with special regard to its interaction 
with steroid hormones. Further investigations of the absorption 
and distribution of carbenoxolone have also been carried out.
The aim of this chapter is to give a brief review of the 
chemical and biological properties of carbenoxolone, its uses 
as a therapeutic agent, and finally to review the scope of the 
present research.
1) Chemistry of Carbenoxolone -«••/
Carbenoxolone is a synthetic derivative of glycyrrhetic 
acid, a constituent of liquorice. Interest in this naturally 
occurring remedy stemmed from a statement in a botanical book 
published around 1865,commending the demulcent properties of 
liquorice root nin some stomach complaints arising from the 
deficiency of natural mucus, which should defend the stomach 
against the acrimony of the food, and the fluids secreted in it.M 
Carbenoxolone (Fig. 1.1) is obtained by synthesis from glycyrrhetic 
acid, the diglucuronide of which, glycyrrhizic-acid, occurs 
in the liquorice plant Glycyrrhiza glabra.
Fig,1-1. Formulae of Enoxolone, Glycyrrhizic acid & Carbenoxolone
Me !00H
Me
Me.
R-0
Me Me
I l8(3~Glycyrrlietic acid H^g R- H.
CQOH
II Glycyrrhizic acid. R, = OH.
OH
0
OH
:-o o h
III Carbenoxolone. R =
k C0QH
I
3 CH,
2 OHr
1 CO
18,p-Glycyrrhetic acid (approved name: enoxolone) is a
triterpenoid of the p-amyrin series, the chemistry of which has 
been reviewed by Iveson (1968). The acid is known to exist in 
two isomeric forms, differing in configuration at C-18. It is 
important that this isomerism should be recognised, as the two 
forms have different pharmacological activities, and much confusion 
has arisen from carrying out clinical research with preparations 
of unknown isomeric composition.
Carbenoxolone is prepared by refluxing anhydrous:
1 8,p-glycyrrhetic acid with succinic anhydride in pyridine 
(Turner & V/otten, 1959» unpublished method). The preparation and 
studies undertaken with carbenoxolone labelled with carbon-1 in 
the one and four positions of the succinate side chain are- 
described later.
2) Clinical Applications- of Glycyrrhetic acid and its Derivatives
a) Gastric and Duodenal Ulcers
Severs, in 19^6 and later in 19^8, reported the curative 
effect of liquorice extract on gastric ulcers. Following this: 
discovery, an extensive literature arose on various preparations 
of liquorice in the treatment of gastric ulcers and other 
gastrointestinal disorders. However, some of these early clinical 
trials were poorly designed, being conducted without proper 
controls, and with patients with ill-defined ailments. The precise 
composition of the drug preparations employed was generally unknown, 
and the nature of the isomers of glycyrrhetic acid not appreciated. 
It is not surprising that the results of these clinical trials
were often conflicting. It was not until Doll, et.al., (1962), 
in a carefully controlled clinical trial,provided evidence that 
i8,(3-glycyrrhetic acid hemisuccinate (carbenoxolone sodium) had a 
curative effect on gastric ulcers, but not on duodenal ulcers. 
Subsequent trials have confirmed the effectiveness of carbenoxolone 
in the treatment of gastric ulcers in outpatients (Doll., ejfc.al., 196-?; 
Horwich 8c Galloway, 19 6 5; Turpie & Thomson, 1969? Banks, et;.al., 196? 
Montgomery, et.al., 1969)- There are two conflicting reports on 
whether carbenoxolone (trade name; nBiogastronen) is effective in 
bed rest patients (Middleton, et.al., 1965; Doyle, et.al., 1968), 
although the great advantage of this drug is its use in ambulant 
outpatients.
The lack of effect of orally administered carbenoxolone in 
healing duodenal ulcers (Doll, £t.al*> 1962) was thought to be due 
to. insufficient quantities of the drug reaching the duodenum, 
perhaps due to gastric absorption, slow gastric emptying, or to- 
lack of absorption of the drug at the ulcerated, area of the ' 
duodenum. Therefore, a novel preparation of carbenoxolone in^a 
position-release capsule (trade name; l,DuogastroneM), which aimed ‘ 
to deliver the drug into the duodenum,was made. Some clinical trials 
with.this preparation have shown favourable results in the healing 
of duodenal ulcers (Craig, ejb.al., 1967; Cliff, 1968; Lawrence,
_et°al., 1968; Amure, 1970)» while other trials have shown no 
significant clinical advantage (Montgomery, et.al., 1968;
Colin-Jones, et.al., 19 6 8; Cliff & Milton-Thompson, 1970).
Some of this confusion is undoubtedly due to the greater difficulty 
in assessing the results of treatment in duodenal ulcers,as: 
compared with gastric ulcers. However, a long term multi-centre.
trial, which has just been completed in Great Britain (Hunt, 1971 - 
unpublished report), shows a significant clinical advantage in 
"Duogastrone" therapy.
b) Miscellaneous Therapeutic Uses
Application of glycyrrhetic acid and its derivatives as 
topical anti-inflammatory agents in dermatology was introduced by 
Adamson & Tillman (1955)* Other trials have claimed its usefulness 
in this respect (Evans, 1956} 1958; Colin-Jones, 1957? 1959} 1960). 
Enoxolone has also been used as a dental paste in the treatment, of 
dry socket (Fry & Goldman, 1958 ), and is currently 
formulated as an adhesive gel for mouth ulcers*
Glycyrrhetic acid has also been used in the treatment of
patients with Addison's Disease (Pelser, .et.al*} 1953; Card,et.al.,1953)
while a. derivative was used as an anii-tussive agent (Anderson 8c Smith, 
1961).
3) Biochemical Pharmacology
a;) Oral Ab sorption
Carlat, et.al. (1959) administered tritium labelled 
glycyrrhetic acad orally to four human subjects,and concluded it 
was poorly absorbed from the gastro-intestinal tract, as indicated 
by blood, bile and urine levels of radioactivity. The vehicle in
which the drug was administered was not mentioned, and in their'
discussion Carlat,'et.al., (1959) stated that the glycyrrhetic acid 
was of uncertain stereoisomeric structure.
Parke, jet*al. (1963) using tritium labelled l8*p-glycyrrhetic 
acid, showed that after oral administration in arachis oil to 
female rats more than'70$ of the dose of radioactivity was excreted 
in the bile in 2 -3 days,vhile after oral administration of aqueous- 
suspensions to male and female rats, an average o f 33% and 5^  
respectively of the dose of radioactivity was excreted in the bile 
in three days. After intraperitoneal administration, a 100$ of the 
administered radioactivity was excreted in the bile within 12 hours.
The rapid biliary excretion of enoxolone indicates that the 
biliary excretion rate can be taken as a measure of its degree of 
absorption. Further experimental evidence relating to the
absorption of enoxolone has been obtained by Iveson (1968), who studied
r 3 1A-in detail the metabolism of [ H Jenoxolone and [ C] carbenoxolone in
rats. When enoxolone was administered orally to rats with pyloric
ligation,only 1-6% of the dose was detected in the bile after 5 -6
hours. After intraduodenal. administration of. [ H] enoxolone to rats.
with or without .pyloric ligation, 80-90% of the dose was excreted
in the bile in 5-6 hours. Iveson (1968)'concluded that the stomach
did not appear to be the main site of absorption of enoxolone in
the rat, but the experiments involving ligation of the pylorus wou^d
inhibit gastrointestinal motility and would reduce gastric absorption.
Nevertheless, the large surface area and blood supply of the small.
intestine suggest the small intestine is the main site of absorption
of enoxolone in the. rat.
Studies on the absorption of carbenoxolone,labelled with carbon 
14 in the C-1 and G-k atoms of the succinate side chain, have been 
carried out by Iveson (1968) and Lindup (1971)* These studies 
were complicated by the gastrointestinal microflora, hydrolysing the
r^ Zf if.'
L Cj succina.te to produce Iveson (1968) found after oral
administration of [^C Jcarbenoxolone to rats, 20% of the isotope
was ‘excreted as respiratory carbon dioxide in 6 hours, with 3%
excreted in the bile. After intraduodenal administration, >^0%
of the dose was excreted as respiratory carbon dioxide and 5% the
bile after 6 hours. Lindup (1971) studied the biliary excretion of 
riA iL CJcarbenoxolone in the squirrel monkey after oral administration, 
and. found only J>% in the bile and 0. ' as respiratory carbon dioxide 
after 8 hours. These studies on.[^c]carbenoxolone absorption in 
the rat and squirrel monkey indicate that the absorption rate is 
slow. Since, in most of.the experiments mentioned,anaesthetics were, 
administered for surgical cannulation of the bile duct and of
dose remained in the stomach, gastric emptying in these experimental 
animals might have been inhibited. Therefore, in some experiments,it 
was probable that gastric absorption was being observed.
A_detailed study on the absorption of [^Cjcarbenoxolone in 
humans was carried out by Downer, et.al. (1970). Carbenoxolone,
100 or 200 mg in tablet form,was given orally to fasted patients, 
and peak blood levels of drug occurred 1 -2 hours after dosing.
However, peak blood concentrations did not occur in two patients, 
until 6 hours after dosing. In most patients the maximum concentration 
of drug in the gastric contents was always <50 (ig/ral. These low. 
concentrations of carbenoxolone in the gastric contents were 
attributed to the insolubility of the drug at the acid pH of the 
stomach, although other factors like gastric emptying,or the rate of 
disintegration of the carbenoxolone tablets may be involved. These- 
experiments show that carbenoxolone sodium is well absorbed in humans,
but do not indicate whether the stomach dr small intestine is the 
site of absorption. The rate of gastric emptying will be a. 
determining -factor, and, as discussed later in a review on absorption, 
fasting, small volumes of water, and disease will increase the rate 
of gastric emptying. Downer, et.al. (1970) found that,when the drug 
was administered in a buffer (pH 8.5 ), no extensive absorption ims 
observed during the first 2 hours. They considered this evidence 
to indicate that the major site of absorption was the low pH. 
enviroment of the stomach. However, the drug was>80?£ unionised for 
most of the experiment, because, the gastric pH was maintained above • 
pH 6 , for only 0.5 hours. Therefore no valid conclusions could be 
drawn, on the effect of an alkaline pH, on absorption of the ionised 
drug.
1Lindup, ,et®al* (1970) studied the absorption of [ Cjcarbenoxolon 
from position release capsules in three duodenal ulcer patients.
In two of the three cases observed,the capsule was seen by 
radiological screening to rupture in the region of the pylorus,
i- y
within one to three hours after administration. The carbenoxolone- 
was rapidly absorbed giving rise to high plasma concentrations of 
the drug, after an interval of one to two hours after the rupture.^  • 
of the capsule. The extent of absorption of the drug,in these two 
patients, was comparable to that observed by Downer, et.al. (1970), 
when carbenoxolone was administered orally as tablets, but the time 
patterns of the plasma concentration did not show the second peak 
characteristic of the gastric absorption of the drug. This may be 
related to differences in the site or mode of absorption of the drug, 
when given in the two preparations. .
The high blood levels obtained (63% dose, Downer,.et.al* 1970; 50° 
dose,Lindup, et.al. 1970) in these human absorption studies, suggest 
a high degree of binding of the drug to plasma proteins. Lindup 
(1971) has demonstrated that carbenoxolone is highly.bound-to plasma 
proteins. This is a factor which may enhance absorption of this drug.
b) Metabolism
Carbenoxolone and enoxolone have been shown to be excreted 
via the bile in rats, squirrel monkey and man with only traces 
(i.e. 2% of the dose) in the urine (Parke, et.al. 1963; Iveson, 1968; 
Downer, ^t*ale 1970; Lindup, 1971)*
The metabolic fate of the parent compound, enoxolone, has been 
studied in the rat. It was almost entirely excreted in the bile 
as three metabolites (Parke, et.al. 1963; Iveson, 1968), which have, 
been identified by chromatographic comparison with synthetic 
derivatives (Iveson & Parke, 1970). One was enoxolone-3-sulphate, 
the second enoxolone-30-glucuronide and the third conjugate was 
probably, enoxolone-3,30-diglucuronide (Iveson, 1968; Iveson & Parke,
1970). ;
1 ij.
When carbenoxolone, labelled with C in the C-1 and C-*f atoms, 
of the succinate moiety, was administered orally or intraperitoneally 
to intact rats (Iveson, et.al. 1966), the isotope was excreted
1 ij.
largely as respiratory CO^ (60-73% of the dose in 30 h..) and
12-36% of the radioactivity was present in the faeces. When
administered orally to rats with biliary canhulae, ^5~60% of the
1Vdose appeared as CO^, 10-^0% was in the bile, and 7% in the faeces. 
Intraperitoneal administration to rats with biliary cannulae gave
4 h.
6-20% of dose a.s CO^ and 30-60/a in the bile.
r\k nFollowing oral administration of [ CJcarbenoxolone, three 
metabolites were detected in the bile. One only was radioactive 
and therefore contained the succinate moiety. This metabolite^ 
appears to be the 30-0-glucuronide of carbenoxolone. The other 
two metabolites were..'shown to be chromatographically identical with
•z
two of the biliary metabolites of [ H]p -glycyrrhetic acid, namely 
the 3-0-sulphate ester,, and one of the glucuronides. ..
The biliary conjugates of enoxolone and carbenoxolone have: 
been shown to undergo enterohepatic re-circulation in the rats 
after intestinal hydrolysis (Iveson, 1968). Enterohepatic 
re-circulation may also occur in man, since the absorption and 
excretion studies by Downer, ejt.al. (1970), showed that drug blood 
concentration generally exhibited two maxima, at 1 -2 and 3-6 .hours 
after dosage.
The significant hydrolysis-of* carbenoxolone to enoxolone, 
which occurs in the rat, has been shown by Lindup (1971) to be due.
*■' t
to the gastrointestinal microflora. Carbenoxolone hydrolysis: m  
man and squirrel monkey is less than of the dose, the main 
carbenoxolone metabolite in the bile being the 30-glucuronide 
(Downer, ejb.al., 1970; Lindup, 1971). This interesting species: 
difference in carbenoxolone metabolism is summarised in Fig.1-II.
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Plasma.Protein Binding \
The observation that the blood concentration of carbenoxolone 
represented up to 60% of the administered oral dose in man 
(Downer, .et.al., 1970), gave the first indication that the drug 
was extensively bound to plasma proteins* Lindup (1971) has 
studied extensively the plasma protein binding of carbenoxolone 
using spectrophotometry, molecular sieve chromatography and 
ultrafiltration techniques. At therapeutic plasma levels 
(10-100 (Jg/ml) the. drug was more than 99*9% bound to plasma proteins 
of the rat, cat, dog, monkey and man* In human plasma, .
carbenoxolone (100 pg/ml) was associated with the globulins (17/0 
and the remainder (8^ /0 with albumin.
d) Uncoupling of Oxidative Phosphorylation
Whitehouse, et.al. (19&7 ) have shown that carbenoxolone, 
enoxolone and a number of similar triterpenoids are fairly potent 
uncouplers of oxidative phosphorylation. The uncoupling ability 
of carbenoxolone was completely annulled in the presence of bovine) 
plasma albumin, the binding of carbenoxolone to albumin, reducing 
the free concentration of drug required for uncoupling activity.
The potential toxic effect of uncoupling of oxidative phosphorylation, 
as shown in vitro, is probably eliminated in vivo by the high 
plasma.protein binding of this drug.
©0 Anti-inflammatory Properties
Finney & Somers (199^) demonstrated the anti-inflammatory 
activity of.glycyrrhetic acid and some derivatives in laboratory, 
animals, and found the activity to be about one'-eighth that of
hydrocortisone in the cotton pellet test. Later, Finney 8c Tarnoky 
(1960) showed the more water soluble carbenoxolone sodium to have 
an'anti-inflammatory activity 0 .2 3 times the activity of 
hydrocortisone. Further reports by Cygielman (1963)1 Khan & Sullivan 
(1968) confirmed this activity. Adrenalectomy was found to decrease 
the anti-inflammatory activity of carbenoxolone (Robinson, 19 63;
Khan &■Sullivan, 1968), while a full anti-inflammatary effect was 
still observed in hypophysectomised rats (Khan 8c Sullivan, 1968).
f) Steroid-like Effects
The side-effects of liquorice therapy were first noted by 
Revers (19^6 ), when approximately 20% of his patients developed 
oedema and hypertension. Later,Molhuysen, et.al. (1930) showed 
that the active principle of liquorice extract, glycyrrhizin, 
had a mineralocorticoid-like effect on water and electrolyte balance. 
A. very extensive literature has now been reported on fluid retention, 
oedema, hypokalemia and hypertension as. side effects of glycyrrhizin 
and glycyrrhetic acid (De Vries, £t.al., 196O; Drosdowski, et.al., 
1961; Minvielle, j3t.al., 1963; Conn, et.al., 1968; Hausmann 8e 
Tarnoky,.1968; Leohardt, 1968). These metabolic effects,known in 
early folk iore, led to early experiments in treating patients 
suffering from adrenal cortex inadequacy (Addison’s disease) with 
liquorice extracts (Groen, et.al.,1991; Pelser, ejfc.al., 1999;
Card, et.al., 1999)* It v/as possible to keep some of the patients 
in a satisfactory electrolyte balance, but in many cases, particularly 
in patients with bilateral adrenalectomy, a satisfactory clinical 
and laboratory effect was obtained only after the addition to the 
treatment of a steroid having a more powerful glucocorticoid effect.
For instance, glycyrrhetic acid and hydrocortisone are regarded 
as having a synergistic effect (Hudson, £t»al., 199^; Elmadjianj 
» 1996)* The mineralocorticoid activity of liquorice has, 
been reported to be inhibited by the aldosterone antagonist 
spironolactone (Salassa, e_fc•al., 1962).
Carbenoxolone therapy is complicated in about 20% of patients, 
by mineralocorticoid-like side effects, resulting in hypertension, 
oedema, and electrolyte disturbances v/ith sodium retention and 
hypokalaemia (Doll, et.al., 1969; Horv/ich & Galloway, 1969;
Turpie & Thomson, 1969; Hausmann & Tarnoky, 1966; Doll., Langman 
& Shawdon, 1968 ; Muir, et.al., 1969 and Forshaw, 1969)*
These side effects occur particularly in elderly patients and those 
v/ith heart disease. Reduction of the dose of carbenoxolone reduces: 
the frequency of side effects (Montgomery, 1967), but the ulcer 
healing rate also falls (Doll, ejb.al., 1968 ). Doll, Rt.al.,(1 9 6 8 ) 
also found that administration of thiazide diuretic blocked these. 
side effects and did not interfere with ulcer healing. However, 
administration of the diuretic, spironolactone, prevented the% 
development of side effects, but also blocked ulcer healing. 1
Hence,the mechanism by which carbenoxolone promotes ulcer healing 
may dep2nd on the integrity of systems involved in electrolyte.; 
transport. However, Doll, ,et»al. (1968 ) found no correlation 
between rate of healing, and fhid retention; furthermore the rate: 
of ulcer healing was not reduced in patients given thiazide diuretics.
Studies in experimental animals have confirmed that 
carbenoxolone and related compounds alter the renal control of 
v/ater and electrolytes* The compounds decrease urinary volume and 
sodium excretion, v/ith an accompanied increase in potassium excretion, 
in the normal rat and the normal cat (Finney & Somers, 195$;
Finney & Tarnoky, 196O; Cristol, et.al., 1966; Khan & Sullivan,
1968)* In adrenalectomised rats and dogs Williams, et.al. (195**-) 
and Khan & Sullivan (1968),found that the mineralocorticoid effect of 
enoxolone and carbenoxolone was retained, v/hile Cristol, et.al. (1966) 
considered the adrenal gland was necessary for the complete 
development of the mineralocorticoid.properties of enoxolone.
The clinical manifestation of hypertension and hypokalaemia 
by liquorice and carbenoxolone, mimic primary aldosteronism 
(Brown, J~t.al*» 1972). The plasma aldosterone values of these 
patients are low or subnormal(Brown, ejb•al., 1972), and aldosterone 
secretion and excretion rates are low (Baron, e^t.al., 1989; Kaplan, 
1970; V/erning, et.al., 1971)» thus placing the aldosteronism in
r? f
the secondary category. Carbenoxolone has been tested for an 
intrinsic-mineralocorticoid effect by Porter (1970) in an in vitro 
toad bladder system, where the drug had no aldosterone activity, 
but exerted a strong potentiating effect on subeffective concentrations: 
of aldosterone.
Hausmann 8c Tarnoky (19&8) put forv/ard three possible mechanisms 
for the mineralocorticoid actions of carbenoxolone; the most 
compatible now seems to be that this drug potentiates endogenous 
steroids by competing for their binding sites.
Carbenoxolone was not found to have ,any glucocorticoid activity 
in rabbits (Finney 8: Tarnoky, 1960) or humans (Fletcher, et.al., 1967;
to be impaired in man (Wynn, 1968; Swallow, 1969; Baron, et.al., 1970) 
Baron, et.al. (1 9 7 0 ),  concluded that deterioration of glucose 
tolerance may occur with- carbenoxolone and was not due to any 
glucocorticoid-like action of carbenoxolone, but was possibly due to 
the mineralocorticoid-like action producing hypokalaemia. Therefore 
apart from the anti-inflammatory action of carbenoxolone, its main 
steroid-like action resembles the mineralocorticoids.
g) Action on Gastric Mucosa ' ~
There is now increasing interest in the role of mucus in the 
aetiology of ulcers, and the possible mode of action of carbenoxolone- 
in altering the quantity and type of gastric mucus. The concept of 
a mucous barrier of the stomach is not new, and has been fully 
discussed by Hollande 1(195*0» hut how it may act, and how it may be ‘ 
influenced by drugs is only recently being discovered.
The ulcerogenic properties of steroids (Spiro & Milles, 1960), 
and anti-inflammatory drugs such as indomethacin (Hothermich, 1966) 
and phenylbutazone (Hauer, 1955) are well known. More recent studies 
have shown that administration of cortisone, aspirin, phenylbutazone 
and indomethacin to dogs and rats, is associated v/ith a reduction of 
the quantity and a change of composition of gastric mucus 
(Menguy 8c Desbaillets, 1967a, 1967b; Menguy 8c Masters, 1963* 1965; 
Johansson 8 c .Lindquist, 1971)*
Baron 8c Nabarro, 1968). However glucose tolerance has been reported
In marked contrast to other anti-inflammatory compounds, 
carbenoxolone has ulcer healing properties. The mode of action of 
carbenoxolone is not known, but Goodier and co-workers (196?, 1968), 
after macroscopic observation of tissue taken at gastrectomy from 
carbenoxolone patients, found that an increase in mucus production, 
or a change in composition had occurred. Conventional histology 
showed there was no carbenoxolone-induced changes in normal growth 
and repair processes of the gastric mucosa, but there seemed to be 
increased periodate-reactive mucin. Johnson (1968), also reported 
carbenoxolone increased mucus secretion.
Studies by Lipkin & Ludwig (1968), on the incidence and severity 
of stress-induced gastric erosions in guinea-pigs, indicated that 
carbenoxolone pretreatment decreased stress-induced erosions, and 
increased periodate-reactive mucin of gastric epithelial cells. 
Increased periodate-reactive mucin is a property the cells normally 
develope during the mature phase of their life cycle, after they 
have migrated to the surface of the mucosa and have become well- 
differentiated. Studies by Lipkin (1970) on the proliferation 
kinetics of the gastric mucosa,showed the rate of removal of DNA
r *labelled v/ith [ ''Hj thymidine from mouse gastric epithelial cells, 
was decreased by carbenoxolone pretreatment. The increased life 
span of the gastric epithelial cells and increase in periodate-reactive 
mucin that occurs v/ith carbenoxolone pre treatment, may contribute 
to the action of this drug.
When speculating on the mode of action of carbenoxolone the 
effect on other gastric secretion parameters, other than mucin, 
should be considered. Carbenoxolone-induced reduction of total 
acidity of gastric juice has been noted in man (Banks,et.al. , 1967;
Ottenjan. . & Rosch, 1970), and in the rat (Henman, 1970).
• In contrast, many studies indicate, that chronic administration 
of ulcerogenic glucocorticoids increases gastric secretion in 
experimental animals (Zubiran, ej;.al., 1952; Clarke, et.al., I960; 
Cooke 8c Crossman, 1966; Heisler 8c Kovacs, 19&7, 19&9; Jacobson & 
Price, 1969)* Administration of metyrapone, which blocks biosynthesis 
of cortisol, corticosterone and aldosterone, by inhibiting 
11-p-hydroxylation in the adrenal cortex ,was found to decrease, 
ulceration and acid secretion in dogs (Nicoloff 8c Van Nostrand, 1968). 
Aldosterone produces an opposite effect to glucocorticoids in that 
it inhibits gastric secretion (Groza 8c Ionescu, 1970)1 probably 
through the influence of hypernatraemia (ottenjan 8c Rosch, 19J70). 
Doll, et.al. (1968) have shown that the aldosterone antagonist, 
spironolactone, in conjunction with carbenoxolone, blocks both the 
beneficial effect on peptic ulceration, as well as the effects on 
sodium and-water retention. These results strengthened the hypothesis 
that the mineralocorticoid effects of carbenoxolone may be necessary 
for activity.
A. third mechanism of action has been suggested by Henman (1 9 7 0 ) , 
whose studies demonstrated the ability of carbenoxolone to inhibit 
pepsin both In  vivo and in vitro. Carbenoxolone was found to be 
more potent than glycyrrhetic acid, degraded carrageenan and at 
mixture of antacids. Thus,of those drugs currently used in the
treatment of peptic ulcers, carbenoxolone represents the most potent 
inhibitor of pepsin. Since pepsin is an albumin, the results of 
Whitehouse,- et.al., (1 9 6 7 ) and Lindup (1 9 7 0 ) showing that carbenoxolon 
binds to bovine plasma albumin, support the idea that pepsin could be 
inactivated by a similar binding mechanism. In fact, studies by
Lindup (1970)i indicated that a pronounced change in the 
conformation of*albumin occurs on binding with carbenoxolone*
Therefore the mode of action of carbenoxolone in ulcer 
healing may involve the following possible mechanisms
1) increasing mucosal defence mechanisms
2 ) preventing mucosal, injury by reducing gastric acid 
secretion, and/or peptic inhibition..
If these are the principal ways by which carbenoxolone helps to 
increase the healing of gastric ulcers, one begins to understand . 
why it may be of more value in treating gastric ulcers, but of 
less value in duodenal ulcers.
*0 Scope of the Present Research
The chemistry, clinical uses and pharmacological biochemistry 
of carbenoxolone have been reviewed in the previous sections of 
this chapter. This last section defines the aims of the present 
work and its relevance to previous investigations. A full 
introduction is given in each chapter, together with an experimental 
section and discussion of the results obtained.
Previous investigations have not determined the factors which 
affect the absorption of carbenoxolone, or its site of absorption 
from the gastrointestinal tract. It was therefore necessary to 
characterise the absorption of carbenoxolone. This has been carried 
out using in vitro, in situ.and in vivo techniques. Further studies 
on the tissue distribution of carbenoxolone, especially with regard 
to the gastric mucosa, have been carried out. Information concerning
the tissue distribution was necessary for the investigations 
(described in chapters four and five) concerning the interaction.of th
drug with steroid hormones.
The mechanism by which spironolactone, an aldosterone 
antagonist, blocks carbenoxolone-induced ulcer healing, may indicate 
the mode of action of carbenoxolone in ulcer therapy. Therefore 
the interaction of spironolactone with the metabolism and 
distribution of carbenoxolone has been studied.
The mineralocorticoid actions of carbenoxolone have been 
discussed (see section 3 f)j but the mechanisms of these actions are 
not known. An understanding of the mode of action of carbenoxolone, 
in the capricious production of mineralocorticoid side-effects, is 
needed to aid the prediction and control of susceptible patients.
The interaction of carbenoxolone with the transport, distribution, 
metabolism and excretion of steroid hormones-has not been reported 
in the literature. Therefore,it was necessary to study the effect 
of carbenoxolone on the plasma protein binding, plasma turnover, 
tissue distribution and biliary excretion of aldosterone and 
corticosterone. Since carbenoxolone exhibits mainly mineralocorticoid 
effects, the interaction of carbenoxolone with aldosterone has been 
studied in the most detail.
Porter (1970), using an in vitro toad bladder system, 
demonstrated that carbenoxolone potentiated the action of a 
biologically ineffective dose of aldosterone. It was necessary to 
determine whether this was the mechanism of the mineralocorticoid
effects of carbenoxolone in vivo* The in vivo binding of aldosterone 
to mineralocorticoid specific binding proteins in the kidney, with 
carbenoxolone treatment, has been determined*
The female rat has been chosen for all the experimental studies, 
because of availability, and the need to correlate the results*
The metabolism of carbenoxolone by the rat differs from man in 
the production of glycyrrhetic acid by the gastrointestinal microflora* 
However, there is no marked species difference* in the biochemical 
effects of carbenoxolone. Therefore the studies carried out will, 
be of value in the understanding of the mode of action of this 
drug in man.
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CHAPTER TWO *
1, INTRODUCTION
a) General Aspects of Drug Absorption
The intensity of the pharmacological response elicited by 
many drugs is probably directly related to the concentration or 
activity of the drug in the immediate vicinity of the receptor site 
in the body (Ariens, Since it is not possible to measure
this concentration directly, it is often assumed that an apparent 
distribution equilibrium is established between drug in the plasma 
and receptor compartments. Thus, the determination of drug levels 
in the plasma as a function of time after oral administration, is ... 
assumed to provide an indirect measure of the concentration of drug 
at the receptor site, and therefore allows one to-.follow the time 
course of pharmacological activity, i.e. the on-set, intensity and 
duration of drug activity. However, in the case of drugs which act 
on the gastrointestinal mucosa, the equilibrium established betx^een 
drug in the gastrointestinal fluids and the receptor compartments 
will be of importance.
Drugs must be in solution in the fluids of the gastrointestinal 
tract before they can be absorbed into the blood. When a drug is 
administered orally as a solution, the simplest kinetic scheme that 
can be employed to describe the absorption process is given by 
Scheme 1, below '
Drug in soln.
in G.I. Fluids
Drug in the Body or Blood
V
Drug metabolism 8c excretion
K and K_ represent the absorption rate and overall elimination
cl Jh
rate constants for the drug, respectively. The absorption of drugs 
from solution is frequently.a.rapid process, and in most instances; 
•the absorption rate constant is larger than the elimination rate 
constant.
Scheme 1 does not describe the absorption of relatively 
water-insoluble drugs, which are usually administered in solid dosage, 
forms. Under these conditions, the simplest model that adequately 
describes the absorption process is Scheme 2, below.
Drug in solid dosage form in ■ ' > Drug in so In. in
G.I. Fluids Kp G.I. Fluids
' ' ‘ " -Kai
4/ • :
As in Scheme 1.
K.^  represents the rate constant governing the dissolution of 
the drug in the gastrointestinal fluids. Very often << K , and. 
dissolution is the rate-limiting step in the overall absorption 
process. As a result, the extent of drug absorption or biological 
availability, may be affected by changes in the dissolution rate. .
The dissolution characteristics of drugs contained in solid 
dosage forms, from which the drug displays a dissolution rate-limited 
absorption pattern,, may be affected by many physiochemical factors 
related either to the drug itself or to the preparation of the solid 
dosage form, for example,‘ particle size, crystal form of drug, salts 
and formulation factors. These factors are discussed in detail by 
Levy (1963) and Gibaldi (1970)*
Gastrointestinal. Absorption Mechanisms
The gastrointestinal mucosa is a semipermeable membrane, across; 
which are transported various nutrients as well as foreign compounds. 
These compounds are normally absorbed across this membrane, into 
the blood, by one or more of the following mechanisms: passive
diffusion, pore transport, active transport and facilitated diffusion
Most pharmacologically important lipid-soluble drugs are 
transported across biological membranes by a simple diffusion process 
According to Pick's first lav/, the rate of diffusion or drug, 
transport (dD/dr) is proportional to the concentration gradient 
across the gastrointestinal, membrane. Since the drug is distributed 
into a large volume when it enters the blood, the concentration of 
drug in the blood will usually be quite low with respect to that in 
the gastrointestinal lumen. As a result, a fairly large- concentration 
gradient driving force is maintained during’the absorptive process, 
which may be increased if the compound binds to plasma proteins.
The proportionality constant represents the first-order rate constant 
governing the absorption process and is a function of 1) the 
permeability of the membrane to the drug in question,2) the area ' 
of the absorbing membranes, and 3) the diffusion coefficient of the 
drug.
The gastro-intestinal epithelium, like other biological membranes
is essentially lipid in nature. Consequently, it is not surprising
that it permits the passive absorption of lipid-soluble drugs but
imposes a barrier to the absorption of lipid-insoluble drug molecules.
In this, connection, most drug substances can usually be classified
* •
as weak organic acids or bases. As such, they can exist in both the
undissociated and dissociated forms in an aqueous environment.
The degree of dissociation depends on the pH of the medium and the 
dissociation constant of the drug. Since it is the unionised form 
of the drug that has the greater lipid solubility,and hence is the 
more readily absorbed form of the drug, the rate of gastrointestinal 
absorption of. weakly acidic or basic drugs is related to the fraction 
of total, drug.in solution in the un~ionised form. The rate of 
absorption is enhanced-when-pH conditions are changed so that this 
fraction is increased. These observations form the basis for the 
well-established pH - partition hypothesis, which relates dissociation 
constant, lipid solubility, and the pH at the absorption site with 
the absorption characteristics of various drugs throughout the 
gastrointestinal tract. (Schanker, et.al., 1957, 195$; Shore, e t.al» , 
1957; Hogben, _et.al., 1957, 1959).
At the low pH of the stomach, weakly acidic drugs (pKa> 2.5) 
exist primarily in the unionised form and would be readily absorbed.
On the other hand, weakly basic drugs would exist essentially in the 
ionised form, and gastric absorption would be negligible. Hogben, 
^t.al. (1959) found that gastric absorption of several drugs appeared 
to obey the pH-partition theory, whereas the intestinal absorption 
of the same drugs deviated from the theory. The later deviations, 
were explained by hypothesizing the existence of a layer at the 
intestinal mucosal surface with a pH different from that of the bulk 
intestinal lumen fluid. If the "virtual pHM at the membrane svirface 
was. assumed to be 5.3 the compounds studied by Hogben,e_b.al. (1959) 
obeyed the pH-partition theory. Other investigators (Koizumi, et» al., 
196*1-; Wagner, 1968), postulated virtual pH values of 6 or 7 to 
explain intestinal absorption data. w
Factors such as drug binding to intestinal mucosa or the 
absorption of ionised drug may also be responsible for deviations 
from the pH-partition hypothesis. For example, Kakemi, et.al. (1969a, 
1969b) found that the absorption constants for a series of' 
barbituric acids in in situ and in vitro rat intestinal preparations 
did not always follow the expected changes when pH was altered, and 
could be correlated to binding to the intestinal mucosa. Indomethacin 
has been shown to bind strongly to intestinal tissue in the process 
of absorption (Fuwa, e_t• al., 1971); furthermore binding was found 
to be pH dependent. •
Nogami, et.al. (.1962) showed that the ionised as well as the 
unionised forms of sulphonamides were absorbed through isolated rat 
intestinal segments in vitro. Similarly, Crouthamel (1971) studied 
the absorption kinetics of sulphaethidole and barbital from the rat 
stomach and rat small, intestine in situ, and noted significant 
transport of the ionised drug. Turner, ejt-al. (1970) determined the 
initial absorption rates for nine drugs, through both the everted 
and noneverted rat intestine, and concluded that drug ions do pass; (
through the in vitro rat intestine. If the pH-partition hypothesis, 
is widely applicable, acidic drugs might be ’expected to be absorbed 
preferentially from the stomach and basic drugs preferentially from 
the intestines, on the basis of the degree of ionisation at the 
various gastrointestinal sites. However, anatomical and functional 
differences such as total surface area, blood supply and transit 
time greatly influence the. rate and extent of absorption at the two 
sites; in actual practice, the intestines may be the primary 
absorption site for both weak acids and weak bases. For example, it 
would be anticipated that phenobarbital and pentobarbital, acids with 
pKa values of 7.2 and 8.1, respectively, would be more rapidly
absorbed from the stomach than from the small intestine. The 
reverse is true, however, with the percentage absorbed from the • 
small intestine in 10 minutes being 3 times that absorbed from the 
stomach in 1 hour (Magnussen, 1968). ’ _
The gastrointestinal absorption of drugs is influenced not only, 
by the degree of ionisation, but also by the lipid solubility of the 
unionised forms. Schanker (i960) 8c Kakemi, _et.al. (1967b) have 
observed excellent correlation between increasing partition 
coefficient, and increasing intestinal and gastric absorption, with’ 
a series of weakly acidic barbituric acids. However, Penniston, et.a 
(1969) predicted that too high a lipid solubility would reduce 
absorption, and recently Houston, et.al. (1972) have shown with an 
homologous series of carbamates that intestinal absorption increases 
to an optimal partition, coefficient, then declines for more lipid 
soluble compounds. The idea of an optimal partition coefficient 
for intestinal absorption has received little attention in the 
literature. In contrast, skin absorption studies have shown that 
for optimal penetration a compound must possess a certain degree of 
both water and lipid solubility (Stoughton, £t.al., 1960;
Clendenning 8« Stoughton, 19625V Marzulli, et.al., 1965).
Thus, the rate at which drugs are transported across biological 
membranes by passive diffusion will depend on such physic-chemical 
factors as lipid- and water-solubility, degree of ionisationj 
chemical stability and molecular weight. The scope of contribution 
of any one factor will vary considerably from compound to compound.
b) Physiological Factors Affecting Drug Absorption
1) Area.of Gastrointestinal Membrane
The gastrointestinal tract may be divided into three major 
sections: the stomach, the small intestine, and the large intestine 
or colon. In man, the small intestine may be subdivided into the 
duodenum, jejunum, and ileum.
Of the three major sections of the gastrointestinal tract, the 
small intestine, with its unique morphological features of the mucosal 
surface, has the greatest available surface from-which absorption can
take place. This large epithelial surface area results from the
existence of l) the. folds of Kerckring in the small intestinal mucosa 
and 2 ) finger-like projections, arising from and being part of the 
folds of Kerckring, termed villi. The folds in the intestinal mucosa 
become less evident, from the duodenum to the ileum, resulting in the. 
villi being less prominent, and the effective absorptive area per 
unit length, reduced (Wilson, 1962). This extremely large total 
surface area in the small intestine, therefore provides; one condition 
for rapid passive drug absorption.
There are no villi present in the stomach or large intestine,
/
and the available surface area in these two regions is considerably 
smaller than that of the small intestine. Although the total. 
surface area of the gastric mucosa is small, one still finds that: 
certain drugs in solution, possessing optimum physico-chemical 
characteristics for gastric absorption can be efficiently absorbed.
2) pH of Fluids in the Gastrointestinal Tract
The various regions of the gastrointestinal tract, besides 
differing in effective absorptive area per unit length, show 
significant differences in the hydrogen ion concentration of the 
fluids in contact with the absorptive sitesr in these segments.
Since many drugs are either weakly acidic or basic compounds, the; 
pH of the gastrointestinal fluids may have a. marked influence on the. 
site and rate of passive absorption*
In man, the usual pH ranges in the fluids present in the various 
segments of- the tract are: stomach, pH 1 tc 3, small, intestine,
pH 3 to 8 (increasing from a. pH range of 5 to 6 in the duodenum to 
about pH 8 in the-lower ileum); and the colon, pH 8 (V/agner, 19^1; 
Borgstrom, ejt.al., 1957)* In rat, the pH ranges are.: stomach, pH 2
to small intestine pH 5 to 6.5, and the- colon pH 6*5.
The pH of the gastric fluids in humans is; subject to a. great 
deal of variation. Some of the factors influencing the pH of these, 
fluids are:-
1) fasted state, in which the pH decreases to 1.2 to 1*8
(Martin, 1955),
2) non-fasted state, in which the pH can increase to 3 or above
(James & Pickering, 19^9),
3) gastrointestinal pathology, in which the gastric pH appears.
to decrease* with subjects having duodenal and gastric ulcers
(James & Pickering, 19^9),
* gastric pH tends to be higher in gastric ulcer patients with, 
chronic duodenal reflux.
V) drugs may influence gastric pH,either by affecting gastric 
secretions,or by neutralising gastric fluids#
These factors may significantly influence the state of 
ionisation and the water solubility of weakly acidic drugs, and hence 
influence their gastric absorption#
3) Gastric Emptying
Most drugs, regardless of whether they are weak acids, bases or 
undissociated compounds, will be optimally absorbed from the small , . 
intestine# Thus,a delay in the rate at which-.,'drugs leave the 
stomach and enter the duodenum will have a pronounced effect on 
the overall rate of drug absorption, the onset of therapeutic effect, 
and the intensity of effect# The process of gastric emptying is also 
of importance when considering drugs that are prone to chemical 
degradation in the stomach, or drugs which act directly on the gastric 
mucosa# Several factors that may affect the rate of stomach 
emptying have been reviewed (Davenport, 1961; Levy, 1963)* Some;- 
of these factors, which affect the absorption of drugs are"•' 
discussed below.
Volume of Meal;-
As the volume of liquid present in the stomach is increased, 
the rate of gastric emptying normally decreases. For example,
Hunt & MacDonald (195^) noted that following the oral administration 
of 3 3 0, 750 and 1250 ml quantities of a liquid.test meal, the 
half-lives- for human gastric emptying were 6#8 , 2 1 .9 and 5 0 *5  
minutes, respectively# •
Acidity of Duodenal Contents;-
Lagerlof, et.al# (1960) showed that the higher the acidity of 
the duodenal contents the slower the rate of emptying. These 
workers also noted that certain disease states will influence the ' 
emptying process. For example, subjects with duodenal ulcers and 
gastric hyperacidity have higher gastric emptying rates than 
healthy subjects#
Other Factors:- .
The process of gastric emptying can also be affected by whether 
the individual is lying on his right or left side, or whether he is 
ambulatory or bedridden. Some other factors affecting gastric 
emptying are the temperature, composition and viscosity of meals, 
the emotional state of the subject, and a wide variety of drugs, 
e.g. chlorpromazine.
V/hen drugs disintegrate or dissolve in gastric contents, they 
pass into the intestine in piecemeal fashion and rarely achieve asi 
high a concentration within the intestinal contents,as they'initially 
do in the gastric contents. However,the emptying times of fluids,, 
or suspensions, have been found to be shorter and less variable than 
those of tablets (Blythe, e_fc.al., 1959)* V/hen considering the 
emptying from the stomach,of enteric-coated or non-disintegrating 
tablets, terms like half-life have little meaning. The tablet is 
either in the stomach,or in the intestine. Because of the 1 all or 
none* effect encountered'with enteric unit dosage forms, there is 
considerable inter- and intra-subject variation in the absorption 
pattern, which is dependent on the factors influencing gastric 
motility (Leonards & Levy, 1965)*
*0 Intestinal Motility
. The normal, rhythmical, peristaltic motility of the small 
intestine can influence the intestinal absorption of drugs. These ' 
peristaltic movements will generally provide for more intimate, contact 
between a drug solution and a larger portion of the mucosal surface, 
area. The motility also aids the dissolution process of drugs from 
solid dosage forms. However, lowering of intestinal motility tends to 
increase the rate of absorption. The reasons for this last statement, 
becomes apparent v/hen 1) the surface area available for absorption, 
and 2) the transit time through the various segments of the smalL 
intestine are considered together.
The surface area of the small intestine decreases sharply from 
proximal to distal segments,with almost half of the total mucosal 
area being found in the proximal, quarter of the gut (Wilson, 1967). 
Thus,the proximal, part of the small intestine has the greatest 
capacity for absorption of most drugs, and dietary constituents 
(Booth, 1967)- However,the crucial factor in determining how much
r f
of a drug will be absorbed in a particular segment is not the 
absorptive capacity of that segment in isolation, but rather how long 
the material remains'in contact with that segment. The rate of 
passage of intestinal contents through the upper small intestine is 
higher than the rate of passage through the ileal segment of the 
intestine $ Inglefinger '& Abbott (19^0) found the transit times of a 
balloon through the duodenal, jejunal and ileal segments of the gut, 
to be 5, *120 and 180 to 3&0 minutes, respectively. Since the rate.- 
of passage of material along the intestine decreases quite rapidly 
as the material progresses toward the large intestine, the more 
distal portions of the gut usually become the portions in which the. 
greatest amount of drug is absorbed. Thus prolonging the time that
material is in contact with an area of greater absorptive surface, 
may increase the overall, rate of absorption, but probably will not 
alter the total amount absorbed.
5) Circulatory Systems of the Gastrointestinal Tract
Blood constitutes the major vehicle for the removal of most 
absorbed material from the gastrointestinal tract. Thus changes in 
blood flow to the mucosa may influence drug absorption. Levine (1970) 
concluded that the large blood supply of the intestine makes it 
unlikely that changes in flow will, produce significant changes in . 
rate of absorption of materials absorbed by passive diffusion.
In contrast to the intestine, changes in blood-flow to the: 
stomach can influence drug absorption. Magnussen (1968) studied the 
effect of ethanol 011 barbiturate absorption, and found that ethanol 
significantly increased barbituate absorption from the stomach, but 
not from the small intestine. The enhancing' effect of ethanol on 
barbituate absorption was mediated through an increased blood supply 
to the gastric mucosa due to peripheral vasodilatation. The lack 
of effect of ethanol on absorption from the small intestine was. 
attributed to the fact that relatively small'variations in blood 
supply could not improve already optimal conditions for absorption.
Although changes in.the rate of blood flow to the intestinal 
mucosa have little influence on drug absorption, changes in the rate; 
of flow, within the other circulatory system, the lymphatics, do 
influence the amount of material removed by the lymph (De Marco & 
Levine, 1969). Material which leaves the intestine via the lymph, 
gains access to the general blood circulation without first passing
through the liver, and thus averts metabolism prior to distribution. 
However, a much greater proportion of small, molecules are absorbed 
via the blood, than the lymph, because blood flow is at least f?00 
times that of lymph (Wilson, 1962). Absorption via the lymph does 
have some relevance to the effect of oral therapy with agents that 
are less readily absorbed, or with those which are prone to hepatic 
metabolism. In this respect, it is important to remember that the 
lymphatic route is the major pathway for absorption of large 
molecules, such as cholesterol, protein and fatty acids (Mueller, 1915 
Alexander, et.al., 1936;& Bloom, ejfc.al., 1951)*
6) Interaction of Drug ■■with Normal Gastrointestinal Components
The normal constituents of the fluids of the gastrointestinal 
tract may significantly influence drug absorption by virtue of their 
potential ability to induce physiochemical changes in the drug 
molecule,prior to absorption. Such changes include, chemical 
degradation of the administered drug into a 'pharmacologically 
inactive compound, chemical modification into a pharmacologically 
active substance, and complex formation and/or adsorption phenomena# 
For example, anticholinergic and hypotensive quaternary ammonium 
drugs bind strongly to mucin and are poorly absorbed (Levine & •
Pelikan, 19&1).
c) Absorption of Carbenoxolone
Previous studies on the absorption of carbenoxolone have 
been reviewed in chapter one, section 3 (a).» The drug has been 
shown to be well absorbed in man (Downer, e t . a l . 1970'), and 
these workers have suggested its main site of absorption is the 
stomach. The therapeutic effect of carbenoxolone, which 
qualitative evidence suggests is. an increased synthesis of 
gastrointestinal mucus, is thought to be a local action on the . 
gastric mucosa. Thus rapid absorption, resulting in high plasma 
concentrations is not necessarily beneficial for the therapeutic 
effect of this drug. High plasma levels may increase the incidence 
of mineralocorticoid side effects, because the incidence can be 
reduced with a lower dosage schedule (Doll, e_t.al., 1968). 
Furthermore the nature of the side effects may be related to the 
site or rate of absorption, since a few cases of severe hypokalemia 
have been reported with "Duogastrone" (Muir, e_t«al. , 1969; Forshaw, 
1969)* Glucuronyl transferase activity present in the stomach 
mucosa (Boiler, £t.al., 1959)» has been shown in preliminary studies; 
in this laboratory (Shillingford, 1972; personal, communication) 9 
to be increased by carbenoxolone treatment. Metabolism of 
carbenoxolone by the gastric mucosa, to its glucuronide would reduce 
the plasma concentration of active drug and perhaps reduce the 
incidence of side effects. Thus factors which, increase the transit 
time of this drug in the stomach should alter the pharmacological 
response to a given dose. That is, increase ulcer healing and 
reduce the incidence of side effect. Therefore it was necessary 
to study the absorption of carbenoxolone, to decide the major site 
of absorption from the gastrointestinal, tract, and the factors 
which affect it.
To characterise the gastrointestinal absorption of a drug, one 
must perform a number of experiments, which permit conclusions to 
be made, as to, a) the regions of the tract from.which absorption 
is optimal; b) the mechanism of absorption; c) the kinetics of 
the absorption process; d) the critical physicochemical and 
biological factors that influence absorption# The physicochemical 
properties of carbenoxolone, that is, being a weak acid (pKa 7*1 
and 6 .7 ), insoluble in water and very lipid soluble, suggest that 
on the theoretical grounds of the well-established pH-partition 
hypothesis (Shore, e_b#al#, 1957; Schanker, ojl*al* ? 1957? 5&;
Hogben, et.al., 1957* 1959) that such a compound should be readily 
absorbed from the stomach. However, the apparent partition 
coefficient for carbenoxolone at 2k° between octanol and aqueous 
buffer at pH 7»^ and pH 1o0 is 22 and >1,000, respectively. This 
extremely high lipid solubility at low pH, may be a factor limiting 
optimal absorption from the stomach (Penniston,pet.al., 1969;
Houston, et.al., 1972). Furthermore carbenoxolone is water-insoluble 
at low pH, and one would expect that the rate of dissolution of the 
drug to be the rate-limiting step in the overall absorption'process.
2. EXPERIMENTAL
a) Materials
'[h-Carbenoxolone, labelled with C in the C-1 and C-*f atoms
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of the succinate moiety,was prepared from [1,4— succinic acid . 
(Radiochemical Centre, Amersham) by the following method (due to 
Dr. J. Turner, Biorex Laboratories Ltd.).
[l Succinic acid (250 pCi, sp. activity 173 pOi/mg) was
transferred to a 50 ml round-bottom flask, diluted with unlabelled
succinic acid (0*59 Si 0.005 mol), and converted to the anhydride
with acetyl chloride (Fieser & Martin, 19^3)» When all the acid
had dissolved (1-2 hours), acetic acid and residual acetyl chloride
were removed under vacuum, anhydrous 18.,'p-glycyrrhetic acid
(2.A- g, O.OA-8 mol) was added, followed by pyridine (7«5 ml), and
the mixture was refluxed overnight. Chloroform (20 ml) was then
added and the solution washed well with cold dilute HCI, and with
water* After drying over sodium sulphate, most of the chloroform
was evaporated, and acetic acid (30 ml) was added. The solution
was boiled down to about 15 ml and left to crystallise. The
yellow-brown crystals were filtered off, washed with 2 M acetic
acid,then with aqueous alcohol (1:1 v/v) and dried in a vacuum
dessicator. Yield 1.^ - g m.p. 306-31 1°. After two recrystallisation
from glacial acetic acid, a.colourless product was obtained
(0.6 g, m.p. 312-313°j sp. activity 93pCi/g)« Unlabelled
carbenoxolone (1.0 g) v/as added to the mother liquors and after
r1 k itwo recrystallisations a.second batch of [ CJcarbenoxolone was 
obtained (l.05g, sp. activity ^8^Ci/g).
Thin-layer chromatography on plates of silica gel HF 254- 
(Merck) in the solvent butanol-ammonia. (5:1> v/v) revealed a trace 
of free glycyrrhetic acid under ultra-violet light, while counting 
of radioactivity on the plate revealed the carbenoxolone to be 
97?£ radiochemically pure*
A sample of the sodium salt was prepared by suspending the 
[^C] carbenoxolone in a small volume of water, and adding slightly 
less than the theoretical amount of sodium carbonate* Neutralisation 
was completed with sodium bicarbonate solution, and carbenoxolone 
sodium precipitated out, by addition of acetone.
Anaesthetic agents used in surgical procedures were urethane 
(British Drug Houses, B.D.H.), and pentobarbitone sodium solution 
("Nembutal") from Abbott Lab. Ltd. Cannulation tubing, internal 
dia 0.4- mm, external, dia 0.8 mm (Portex) was usedi for bilary cannula­
tion, and tubing of internal dia. 2.5 nirn; external dia 3*5 mm (Portex) jBb.» 
cannulation of the. gastrointestinal tract. Scintillator chemicals 
and radioactive standards were obtained from the Packard Instrument Co. 
Fluorescent silica gel (Kiese3.gel, HF 254-) was used for thin layer 
chromatography (Merck, AG, Darmstadt).
All other chemicals and solvents were supplied by the usual 
laboratory suppliers.
Animals were female W'istar albino rats (body wt approximately 
200 g ) and were housed in the University's Animal Unit and fed on 
Spillers Small Animal Diet and water ad.lib. However,in these- 
absorption experiments the rats were fasted overnight.
b) Methods
i) Determination of Radioactivity
Radioactivity was determined by liquid scintillation counting, 
using two Packard Tri-Carb Spectrometers (models 3320 and 24-25). 
Samples were counted in 20 ml of a naphthalene-dioxan based 
scintillator, containing!- naphthalene (60 g), 2,5~*diphenyloxasole 
(PPO) (4- g), dimethyl POPOP (0.2 g), analar methanol (100 ml),
1,2-ethanediol (20 ml) , !,Cab-0~Siln (4-0 g), made up to 1 litre with 
p-dioxan.
This scintillation mixture contained a k% W/V suspension of. 
Gab-O-Sil, a thixotropic gelling agent, which could accommodate, 
up to 10% v/v of water. However, the volumes of aqueous sample 
did not exceed 1 ml or 5% V/v of the scintillator volume. The 
following samples were added directly to the scintillator: plasma, ’
bile, silica gel, urine and tissue homogenates. Tissues were 
homogenised in water, using a. mechanical sonicator (Polytron) to 
give ahIO% ™/v homogenate. Carcasses were dissolved in 5 M~NaOH. 
in. a 40°C water bath, and aliquots, taken for counting.
14-Radioactivity excreted in the expired air as CO^ was measured
as follows. The expired air was drawn through 2 glass wash bottles,
fitted, with sintered glass aerators, each bottle containing 100 ml
of ethanolarnine :ethoxyethanol (1:2v/v)solution.Aliquots (1 ml) of
this solution from each v/ash bottle were counted for determination 
14-
of respiratory ^ 2*
Counting efficiency was determined by recounting the sample
14-after addition of 50 Kl of a [ C]toluene internal standard containing
5,000 d.p.m. Maximum counting efficiencies obtained for carbon-14- 
were of the order of. 85^*
ii) Thin-layer Chromatography
Methods were taken from Iveson (1968). Samples were examined 
for carbenoxolone and its metabolites by ascending thin layer’
(0 .2 5 mm) chromatography on plates of fluorescent silica, gel 
(Kieselgel, HF 2^4). The samples were applied in bands or spots to 
plates previously activated at 120°C, and developed in glass tanks*. 
Samples were co-chromatographed, with suitable controls and 
appropriate reference compounds.
The main solvent system used for separating the radioactive.
rlif -1
metabolites of j_ GjCarbenoxolone was:
System A: acetic acid - butan-1-ol - 1 ,2,dichloroethane - water
(:1:4: 1 by volume). The approximate R±, values of carbenoxolone.. 
and carbenoxolone-30“glucuronide are O .9 8 and 0.84 respectively, 
with succinic acid remaining in the region of the origin*
Carbenoxolone and its 30-glucuronide both contain the 
conjugated 11-oxo-12~ene structure, and can be detected by their 
absorbance of ultraviolet light (Xmax = 248 nm) on the fluorescent, 
silica gel plates. Detecting reagents also used were:-
(a). Naphthoresorcinol spray reagent (0*270 v;/v naphthoresorcinol in 
acetone and H^PO^ 9% V/v in water, mixed 5 :h by volume) which: 
detects glucuronides as blue spots., v/hen heated for TO min.
at 120°C;
(b) Spray reagent containing 0*04 g bromocresol purple in 50% 
ethanol, adjusted to pH 10 with 2 M NaOK, which detects acids 
(succinic acid) as bright yellow spots on a blue background.
Radioactivity on plates was determined by removal of strips 
of silica gel, and counting directly in the gel scintillator.
iii) Measurement of Partition Coefficients of Carbenoxolone
The partition coefficient of carbenoxolone was measured between 
n-octanol and 0,15 M citrate/phosphate buffer over, the pH range 
The organic solvent and the buffers were presaturated with the
r'] Ir­
re le v a n t aqueous or organic phase* [ CJCarbenoxolone (1 mg) was
dissolved in 20 ml of n-octanol, and this solution was added to
an equal volume of aqueous buffer in a stoppered flask for 1 hour.
The solutions were mixed using a magnetic stirrer, in a constant
temperature box (37°)» The two phases were separated and the
concentration of *0 ]carbenoxolone in 1 ml portions of each phase;
determined by scintillation counting. All determinations were done.
in duplicate.
iv) Everted Cut Sac Technique'
The general procedure was that of Wilson and Wiseman (195^)
i f
using a. sampling procedure developed by Crane and Wilson (1953).
Rats were fasted overnight, with free access to water. The rat was 
killed by a blow on the head. The abdominal region was exposed by 
means of a midline incision, and the middle region of the small, 
intestine removed. The next step was to evert the entire small 
intestine. For this purpose, a. metal rod 20 cm long and 1*5 mm in 
diameter, with a groove at one end was used. The grooved end of the, 
everting rod was carefully inserted in the proximal end of the 
intestine, and the gut was tied to the groove in the rod with cotton. 
The intestine was then gently rolled over itself until the tied 
end emerged at the other end of the intestinal segment. Four 5 cm 
segments were cut from each animal, and kept in ice-cold isotonic.
saline,,gassed with a 95/5 mixture of oxygen and carbon dioxide, 
during manipulations.
The distal end of a segment was tied and the proximal end was
attached to the cannula (see Fig. 2.1). The segment was suspended
in 8 ml of buffer containing 100 pi of an ethanolic solution of 
'ik[ C] carbenoxolone (10 mg/ml). The cannula- was adjusted to immerse 
the sac completely. About 1 ml of drug-free buffer was introduced 
via the-cannula into the serosal compartment. The mucosal solution 
was continually gassed with the 0^:00^ gas mixture and maintained 
at 37° in a water-bath. .
For determining the rate of drug transfer across the intestine, 
a sample of serosal fluid was obtained via the cannula, using a 50 pl 
syringe. Four samples were taken over a period of 40 minutes, and 
assayed for radioactivity. At the conclusion of the experiment, 
the volume of serosal fluid was measured, the gut was washed in 
buffer pH 7.4-., the surface area of the opened sac measured, and the 
gut assayed for accumulated drug. At each pH, a duplicate 
determination of drug transfer was carried out in three animals. 
Various samples of gut, serosal and mucosal .fluid were analysed for
The isotonic perfusion medium used for the everted gut sacs 
consisted of
100 ml 0.9% N a d  (0.15^ li), k. ml 1.,15# KC1 (0.15^- M)
1 ml MgSO^ (0.13^ M) and 22 ml Citric acid/Na^HPO^
buffer (0.15^ M) pH 3-8.0. Glucose was added-to give a. 0.5/6 W/v 
solution.
carbenoxolone and metabolites.
Figqg-I
APPARATUS FOR THE STUDY OF INTESTINAL 
ABSORPTION USING EVERTED GUT SACS
5r—  Of
A, 23 gauge needle fitted 
with 2 cm polythene 
tubing for sampling 
serosal fluid.
.°2
B, Everted gut sac, 4 cm 
long containing 1 ml 
serosal fluid.
C, 8 ml of mucosal. 
fluid
The solubility of carbenoxolone in the experiment described 
above was determined by dissolving [^C]carbenoxolone in the Krebs 
citrate phosphate buffer, pH 5-8 at 37°0, and centrifuging down the 
insoluble drug. The radioactivity in the resulting supernatant 
was then determined and taken as a measure of solubility.
v) In Situ @ut Technique
In this procedure, developed by Doluisio, et.al. (19&9)i female 
Wistar rats were fasted overnight, with -free access to water.
Under anaesthesia with sodium pentobarbitone (60 mg/kg i.p.), a 
uidline abdominal incision was made, and the small intestine was 
isolated and cannulated at the duodenal and ileal ends 'with' 
polyethylene cannulae (internal diameter 2 .5  mm; external diameter 
3*3 mm). A 50 ml syringe, equipped with a three-way tap, and 
containing perfusion solution at 37°» was attached to the duodenal 
cannula, and the intestinal lumen was cleared of particulate matter- 
by slowly introducing the solution from the syringe. The stomach 
and the caecum were closed off by ligature, care being taken not to 
occlude any major blood vessels. The bile duct was cannulated using 
Portex pp25 tubing. Any perfusate solution remaining in the lumen 
after the washing procedure was removed by pushing air through the 
lumen with the syringe.. The syringe was then filled with 10 ml 
of Sorensons phosphate buffer pH 7.^, 6 .8  or 5«0 containing 100 pi
r'jZf
of L CJcarbenoxolone solution (10 rag/ml), and the solution . 
introduced into the intestine. A duplicate 30 syringe was affixed 
to the ileal cannula. At 3 minute intervals, the solution
in the intestine was pumped into either syringe, and a 100 jH sample 
removed, and the volume of perfusate noted. The solution in the 
syringe was then returned to the lumen, and the time taken for the
whole sampling procedure recorded. The experiments lasted up to 
60 minutes, and bile samples were taken at 10 minute intervals.
At the conclusion of the experiment, the gut was rinsed in the 
phosphate buffer pH 7-^ and assayed for radioactivity. The entire 
experiment was carried out in a constant temperature cabinet at 
37°. Four rats were studied at each of the three pH values.
vi) In Vivo Absorption of [^cjcarbenoxolone podium
Four rats were dosed'orally with Jcarbenoxolone sodium
(20 rag/lcg, *t8 jiCi/g) in 3 ml of 0.9% saline. Each rat. had its bile 
duct cannulated under urethane anaesthesia (1.75 g/Kg s.c.)*
Each rat was placed in a separate metabolism ca&e and expired carbon 
dioxide trapped in two bottles each containing 100 ml ethanolamine: 
ethoxyethanol (1:2v/v).The rats were maintained under urethane 
anaesthesia for Zk hours 1 during which time bile and GO^ samples were 
collected for determination of radioactivity. The rats were then 
killed and the stomachs, stomach contents,and liver removed for 
measurement of radioactivity.
[^c]Carbenoxolohe in either 3 ml of buffer at pH 1 (0.1 it.HOT)
or at pH 8.5 (0.5 M NaoC0_,/NaHG0^) was adrainistered orally to four
—  2 5 ?
rats at a dose level of k mg/kg. Stomachs had previously been 
ligated under urethane anaesthesia. After 1 hr., the radioactivity 
remaining in the stomach, plasma and liver was determined.
I^^g]Carbenoxolone (k mg/kg) in 0.9% Saline, was injected 
intra-duodenally into -two rats under urethane anaesthesia. Plasma 
samples were removed at- timed intervals from the jugular veins, 
and regular bile samples collected. The bile and plasma samples were 
assayed for radioactivity.
RESULTS
rj If.
Table 2-1 * Effect of pH on | ClCarbenoxolone Absorption in
Everted Gut Sacs •
pH of Medium [*^ C ]Carbenoxolone; Absorption in Everted
Gut Sacs
2Carbenoxolone (d.p.m./cm /h. )*
in Solution 
(jag/ml)
8.0 125 ; \  10 Vi + iVl
7Jf 125 935 ± 10.
6.8 100 857 + 5S
6 . 2  20 too + 9.
5.6 2 .5 . 19V + 37
5.0 1.2 1V3 + 17
* Results are the mean of six determinations and are- given + S.E
Fig* 2-11 . Plot of Change*of Apparent Partition Coefficient
of Carbenoxolone with* pH:
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Fig, 2-V Absorption of Carbenoxolone at pH 5.0 using in Situ,
Gut Method
3.0
.3012 1o 24
Period of Absorption (min)
Fr
ac
ti
on
 
of 
Ca
rb
en
ox
ol
on
e 
Re
ma
in
in
g 
in 
Lu
me
n
Fig. 2-VI Absorption of Carbenoxolone at pH 7.4 using in Situ
Gut Method
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Table 2-III Excretion of f^ C? Carbenoxolone in Bile Fistula Rats
[^CjCarbenoxolone sodium (20 mg/Kg) in 3 ml 0*9% W/v 
saline was administered orally to rats under■urethane anaesthesia.
Results are the mean
Time after Dosing 
(h)
of 4 rats + S.E.M.
Cumulative Excretion {% dose) as:-
\ 14 . N i) C0^ m  expired air n )  in bile
1 : 0.9 + 0.1 3.2 + 1i.2.
- 3 . 2.4. + 0.5: 5.3' i  1^1
53
co•otl
-d*• 6.0 + 1.0
8 5*0 +■■ 0*3 6.1 jrr 1.0
121 6.5 + 0.3 6.6 j; 0.9
20 9.8 + 2.0 7.1 +0.8
Dose (%) recovered in:- ■/
Urine 0*4:
Stomach Contents 51*7■'+ 4.2- 
Stomach 4.5 ±  0+9
Liver 1.0 + 0.6
Total Dose Recovered 74.4^
Table 2~IV Absorption of [™C Tcarb enoxolone from the Ligated
Stomachs of Rats
Oral administration of [^C]carbenoxolone (5 £ig/£g)
3 ml buffer (pH 1 and pH 8,5) to. rats under urethane anaesthesia. 
Sesults are the mean of 2 rats.
Tissue Dose.. (%) present 1 hour after administration
pH 1 pH 8 .3
Stomach & contents 98.a 88.0 *
Total Plasma 0 >0.1=
Diver 0 > 0.1
Dose- (%) lost from Stomach 1.8 12.0
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*f. DISCUSSION
The first part of this discussion considers the results 
obtained from three different approaches to the study of 
carbenoxolone absorption* that is:-
a) everted gut sac; b) -in situ gut technique, and c) in' vivo 
absorption* The final part of the discussion considers the 
conclusions that have been drawn from these absorption studies, 
and their relevance to the therapeutic use of carbenoxolone*
Everted Gut Sac ’•
The absorption of carbenoxolone in everted gut sacs falls, 
rapidly as pH is reduced from 8.0 to 5*0 (table 2-1-and* " 
Fig*2-III). This is paralleled by a decrease in aqueous solubility 
(table 2~I) and a marked increase in the apparent partition 
coefficient (Fig*2*-II). The decrease in aqueous solubility of 
carbenoxolone with decreasing pH, is clearly one reason for the; 
decreased rate of absorption* However, in Fig.2-111, where the; * 
amount of drug in solution at various pH values has been separated, 
into ionised and unionised components (pKa 6*7), it becomes 
apparent that the decreasing absorption between pH 8*0-6.8 is.' 
associated with a decrease in the amount of ionised drug present* 
Therefore, the ionised form of carbenoxolone must be well absorbed, 
and at.least as well absorbed as the unionised species*
The apparent partition coefficient in octanol:citrate-phosphatej 
buffer was found to be pH-dependent, and increased with decrease 
in pH (Fig,2-Il)* The effect of variation of the partition 
coefficient on the uptake by, and transfer across of carbenoxoLone. 
by the everted gut sac was indicated by a plot of the
apparent partition coefficient at various pH values against,
1) total carbenoxolone lost from the mucosal fluid (a + b);
2) carbenoxolone accumulated or "bound1* in the tissue (a);
3) carbenoxolone transferred to the serosal fluid (b), which is shown
in Fig.2-1W  From the latter figure it may be seen that the amount
of drug transferred to- the serosal compartment declines with
increasing partition coefficient. The tissue "bound** drug 
increases rapidly as the partition coefficient rises above 200 
(below pH 6*8), This accumulated drug is not‘necessarily bound to 
proteins in the gut sac. The decreasing aqueous solubility of
the drug may be causing it to dissolve in the gut wall, or to
be adsorbed onto the surface* However, it is interesting to note
that carbenoxolone accumulates in the everted gut in amounts
3 to 10 times that found using a wide range of carbamates'
(Houston - personnel communication)* The total loss from the
mucosal fluid follows a similar pattern to the tissue "bound",
r 1 Jj-
and this is the main site of loss of [_ C jcarbenoxolone from .the 
mucosal fluid. At all pH values studied?no significant amounts of
/f
metabolites of [ CJ carbenoxolone, were defected.
In situ Gut Technique
Because this drug is known to be highly bound to plasma 
proteins, the lack of blood supply in the everted gut sac may.well 
givejf an anomalous picture of carbenoxolone absorption. Therefore., 
further absorption studies at pH 3»0i 6.8 and 7*^ were carried out 
using an In situ technique, where the blood supply was intact.
The absorption of carbenoxolone at pH 3*0i using the in situ gut 
method is shown in Fig.2- 'V. A plot (P) of the experimental
results was non-linear, showing that at least two processes are- 
involved in the removal of the drug from the gut lumen. The 
first process (curve A, obtained from P-B) has a half-life of 
3 min., and is considered to represent binding to the intestindl 
mucosa. The second process (curve B, obtained by extrapolation of 
linear part of P to ordinate) has a half-life of 63 min., and 
represents removal from the lumen, which approximates' to absorption. 
The absorption at pH 7*^ - is shown in Fig.2-VI. > curve was again 
obtained indicating binding to the gut mucosa. The half-life of 
the binding process (A) v/as 3 min., showing no change from the 
rate obtained at pH 3»0« However, the absorption process (B) had 
a half-life of 1 1 .3 min., showing a five fold increase over the 
absorption at pH 3*0. A comparable increase was shown in the biliary 
excretion rate of carbenoxolone administered into the gut in'situ, 
(Fig.2-VTI), the rate being increased six fold, when administered in 
buffer of' pH 7®^» instead of pH 3*0. This supports.the view that 
the rate of removal from the lumen is indeed approximately identical 
to the rate of absorption.
One ‘factor involved in this reduction of absorption of 
carbenoxolone with decrease in pH, is the decreasing aqueous 
solubility of the drug. To study the effect of ionisation on 
carbenoxolone-absorption in the In situ gut method, further studies 
were carried out at pH 6.8. At both pH 6.3 and 7»^» carbenoxolone 
(0 .1 mg/ml) is in complete solution, and any differences in the 
rates of absorption at these pH values is probably due to the .degrea 
of ionisation. Results are given in table 2-II, and show that 
absorption and the resulting biliary excretion are higher at pH. 7
than 6.8* The apparent pKa values of carbenoxolone are 6.7 and 7.1 , 
indicating that the percentage ionised is approximately at pH 
6.8 , and 75% at pH 7.^. Therefore, the increase in ionisation 
appears to lead to increased carbenoxolone absorption, confirming the 
results obtained by the everted gut sac method.
The percentage of the dose found in the total intestine at the 
termination of the in situ experiments at f^O min. was 11.6%
(S.E.M. + 1.9%) at pH 5.0, and 2.2% (S.E.M. + 0.7) at pH 7 A .
Since the half-life values for the apparent binding process at 
pH 7*^ and 5»0 are almost identical (3*0 min.), this is an 
indication that the extent of their intracellular binding is the 
same at both pH values. The increased accumulation of carbenoxolone 
in the gut at pH 5*0i may be due to physical trapping or adsorption 
of carbenoxolone onto the surface of the gut. The low aqueous 
solubility of carbenoxolone at pH 5-0, makes this likely.
The absorption data obtained for carbenoxolone, using both 
the everted gut sac and in situ gut methods, is summarised in
table 2-II. Good agreement is found between the in vitro and in situ
techniques. Both demonstrate that carbenoxolone absorption is 
5-6 times faster at pH 7.^» than at pH The decrease in
absorption rate has been related to. a clecrease in aqueous solubility,
and also to a decrease in amount of ionised drug.
Carbenoxolone Absorption and the pH-Partition Hypothesis
.On the basis of the well established pH-partition hypothesis 
(Shore, et.al. , 1957? Schanker, e_t.al., 1957 j 1958; Hogben, et.al. , 
1957* 1959)» which states that weak acids are better absorbed at 
low pH values, where they are mainly in the unionised form, one 
would expect carbenoxolone to be better absorbed at low pH.
That carbenoxolone does not obey the pH-partition hypothesis, may 
be explained by the fact that compounds which do obey the hypothesis 
are much less lipid soluble, particularly in the ionised form, 
than carbenoxolone. Penniston, et.al. (19&9) 'first suggested, and 
later Houston, et.al. (1972) demonstrated,that there is an optimum • 
lipid solubility for maximum absorption. These workers have shown, 
for a homologous series of carbamates, that absorption rates; 
increased until the apparent partition coefficient in octanol:water 
reached about 10; further increases in partition coefficient resulted 
in a decline in the absorption rate. Thus., the partition coefficient 
of carbenoxolone is nearer the ‘lipid solubility for maximum 
absorption of carbamates at pH 7*^» when it is largely ionised 
(partition coefficient 27)» than pH£5, when it is in an unionised 
state (partition coefficient >1000).
Thus the' favourable lipid solubility of ionised .carbenoxolone 
may favour its absorption. However, it was not possible to ascertain 
how the absorption rates for the ionised and unionised forme- 
compared, since when the drug was 98% unionised, only 2% of the 
carbenoxolone (0.125 mg/ml) was in solution. Absorption of the 
unionised form of carbenoxolone is limited by the rate of 
dissolution of the drug. Thus, the absorption of the ionised drug 
is a discrepancy from the widely accepted theory of the pH-dependent
absorption of drugs, which states that drugs are largely absorbed 
in their undissociated form.
Further studies were made with other drugs. Using the in situ
gut technique, the rates of absorption over a pH range of warfarin
(pKaf?) and salicylic acid (pKaj>), were investigated. Maximum
absorption of these compounds occurred at pH 6 and k for warfarin
and salicylic acid respectively, pH. values at which they were both
predominantly in an ionised state. Other evidence has been reported
for absorption of a number of acidic drugs in the ionised form,
namely, warfarin (Kekki, et.al., 1971)» salicylic acid (Nogami. &
Marsuzawa, 1961; Kakemi, et.al., 1969b) and indomethacin (Fuv/a, et.al
1971)• The reason for' the high absorption rates of ionised drugs is
still unknown. Various suggestions have been advanced, regarding
the actual pH at the surface of the intestinal epithelium
(Hogben, ejfc«al«, 1958), and in the case of salicylate absorption,
injury of the intestinal surface by salicylate has been implicated.
(Travell, i9 60). Recent studies by Kunze, et.al* (1972), using
salicylic acid and its isomers, suggest that the ionic absorption of
salicylic acid is facilitated by interaction of the drug with divalent
metals in, or on, the epithelial cells, thus'increasing the
2+permeability/to hydrophilic compounds. The removal of Ga from the 
intestinal intraluminal surface, by ethylenediaminetetraacetate, 
is known to improve absorption of hydrophilic substances, but not 
lipid-soluble compounds (Windsor & Cronheim, 1961; Schanker &
Johnson, 1961J Tidball & Peterson, 196l). Thus a drug, which 
chelates Ca^+ ions at the brush border of the intestinal epithelium , 
would increase permeability and perhaps facilitate its own ionic; 
absorption. Carbenoxolone forms insoluble calcium salts, and this may 
aid absorption of its ionic form.
These deviations from the widely accepted theory of drug 
absorption indicate the need to comprehensively study the 
physiochemical properties of a drug,before deciding the contribution 
of any one of these factors to the absorption process.
In Vivo Absorption
In vivo studies, were carried out to determine the main site of 
carbenoxolone absorption in the gastrointestinal tract. The 
excretion of oral [ G jsaf benoxolone sodium in’ rats under urethane 
anaesthesia is shov/n in table 2-III. More than 50% of the dose 
was recovered in the stomach contents at the termination of the 
experiments after 20 hours, which indicated that the urethane 
anaesthetic had inhibited gastric emptying. Therefore ,the rates of 
biliary excretion & hydrolysis of carbenoxolone observed are due to 
gastric absorption and stomach microflora respectively. The biliary' 
excretion rate of 7% in 20 hours,indicates that carbenoxolone is 
very poorly absorbed from the rat stomach. Iveson (1968) had 
similar findings for enoxolone absorption from ligated rat stomachs.
'j if
The production of 10% CC^ in 20 hours, suggests that the microflora 
are much less active in the rat stomach than has been previously 
shown for lower regions of the gastrointestinal tract (Iveson, 1968; 
Lindup, 1971)•
Further studies on absorption of [ Jcarbenoxolone from rats 
with ligated stomachs(table 2-IV), showed that the percentage of dose 
lost from the stomach after 1 hour was 1.8% and 12.0% v/hen given 
in buffers of pH 1 and 8.5 respectively. This may indicate that 
gastric absorption of carbenoxolone is higher at pH 8.5 or, at this 
pH, there is a greater loss of radioactivity through increased 
hydrolysis. However, the main conclusion from this experiment is.
that in the rat, absorption of carbenoxolone from the stomach 
into the plasma is of no significance,unless there is a considerable 
delay of gastric emptying.
In contrast to the poor gastric absorption of carbenoxolone, 
duodenal absorption is very rapid (Fig.2-VIIl), a statement which 
is supported by studies on enoxolone and carbenoxolone by 
Iveson (1968). Plasma radioactivity reached a maximum 8 minutes; 
after duodenal administration, and was shown by thin layer 
chromatography to be at least 90% carbenoxolone. The maximum 
corresponded to approximately 15% of dose; administered being present 
in the plasma, and is followed by rapid biliary excretion. 'Similar 
results were obtained when carbenoxolone was administered by the 
in situ gut technique, except that the plasma peak v/as slightly 
delayed, and higher. Therefore in vivo studies indicate that the 
intestinal absorption of carbenoxolone is significantly greater 
than the gastric absorption.
Conclusions
That the intestine is the main site of carbenoxolone absorption 
may be predicted by. a consideration of the biological factors which 
influence absorption:-
1) The pH of fluids in the gastrointestinal tract of man and rat 
have previously been discussed in the review on absorption in 
section 1a). From the criterion of pH, these studies indicate 
carbenoxolone to be 5 to 6-fold better absorbed in the lower regions 
of the gastrointestinal tract.
2) The better blood supply, and larger surface area of the intestine 
compared to the stomach, would indicate that carbenoxolone, and. 
indeed most drugs, would be potentially better absorbed from the 
small intestine.
Thus,on the basis of the biological'factors and physiochemical 
properties of carbenoxolone, it can be shown that the major site 
of absorption is the intestine. This has been supported by studies 
in the rat, and by the previous findings of Iveson (1968) and.
Lindup .(1.971) 1 (see chapter one ,section 3a). This is in conflict 
withastudy by Downer, jet.al. (1970) on absorption in humans, 
where two subjects,given carbenoxolone in buffer pH .8.5,showed 
delayed absorption, which led to the suggestion that the stomach 
was the main site of absorption.
An explanation of the findings of Downer, et.al. (1970) may. 
be found by-a closer study of their results. Firstly, the absorption 
of 200 mg carbenoxolone given with water to; patients, produced a 
peak plasma concentration of carbenoxolone, between 1 -2 hours for 
3 patients, but a fourth patient did not show a peak.plasma 
concentration until 6 hours after administration. The individual 
variation would be consistent with varying rates for gastric 
emptying, and in fact an insoluble suspension of carbenoxolone in 
the stomach is not likely to be released into the duodenum in toto, 
but in "piecemeal" fashion. Downer, ©.t.al. (1970) observed in 3 of  
the patients a second plasma maximum occurring 3 -6 hours after 
dosage, .which.'was thought to, be enterohepatic circulation. However, 
absorption of carbenoxolone from the duodenal release capsule 
(Lindup, ^t.ad., 1970) did not show a second plasma maximum. 
Therefore,an alternative explanation for the second plasma maximum 
in the studies of Downer, et.al. (1970) may be the periodic 
absorption -from the gastrointestinal tract. Moreover, the inter­
subject variation in the absorption pattern may be similarly 
attributed to variations in the rate of* release of the carbenoxolone 
from the stomach. The interpretation of the carbenoxolone absorption
studies in two subjects (Downer,' et.al., 1970) using buffer pH 8 .5  .
must be viewed with some doubt for three reasons
1) There were only two subjects, and only one of these showed any 
plasma peak within 2 hours after dosage. The duration of the 
experiment was not long enough to conclusively decide that delay in 
gastric absorption was occurring., since previous absorption studies 
shoitfed that there was a considerable inter-subject variation ,and 
one patient took 6 hours to reach a peak plasma concentration of 
carbenoxolone.
2) The absorption in the two normal subjects was compared with that 
in four gastric ulcer patients, but gastric emptying may not be
the same in normal and diseased states. Certainly, Lagerlof, et.al. 
(i960) have noted that subjects with duodenal ulcers and gastric 
hyperacidity have higher gastric emptying rates than healthy subjects.
3) Gastric pH was maintained above pH 6 for only half an hour.
Below pH 6,carbenoxolone is >85% unionised, therefore the suggestion 
that delay in absorption was due to a predominence of ionised., 
carbenoxolone is most unlikely.
Past evidence and reinterpretation of previous data,all support 
the view that the main site of absorption of carbenoxolone is the 
intestine. This may have great relevance to the therapeutic effect 
of the drug. If the action of carbenoxolone on.the gastric mucosa 
is truly local, this would imply that a higher concentration of the 
drug in the stomach lumen is of greater importance than a high 
plasma concentration in mediating ulcer healing. Furthermore, the 
high peak plasma concentration of carbenoxolone associated with the 
duodenal release capsule ,appears also to be associated with a number
of severe cases of raineralocorticoid si&e-effects. Thus a delay 
of gastric emptying, perhaps by the use of drugs, may have the 
following beneficial effects on carbenoxolone therapy
1 ) to prolong the concentration of drug in the stomach, and increase: 
ulcer healing;
2 ) to increase the amount of the; drug absorbed by the stomach, and
. thus decrease peak plasma concentration resulting, from rapid
intestinal absorption;
3 ) to increase the amount of the drug deactivated by glucuronide
conjugation in the stomach raucosa, and therefore to reduce the
plasma leve?.s of the active drug.
Antacids are used for the relief of pain in ulcer patients, and 
would be expected to affect carbenoxolone absorption by raising the; 
gastric pH, The investigations reported here, indicate that antacids 
administered with carbenoxolone would increase the water solubility 
and also the ionisation of the drug in the stomach, thereby giving • 
rise to increased uptake of the drug by the gastric mucosa. This la 
an effect which thus aids the therapeutic action of carbenoxolone, ' 
and reduces the peak plasma drug concentration,
Carbenoxolone tablets have been shown to have no healing effect 
on duodenal ulcers (Doll, et*al», 1962). A possible reason for this 
is that, as the tablets disintegrate in the stomach and become diluted 
with gastric secretions, the drug pa.sses into the duodenum in 
piecemeal fashion, as a suspension, and bypasses the more usual sites 
of duodenal ulcers. Moreover, it would not achieve as high a 
concentration within the intestinal lumen as was obtained in the 
gastric contents. The development of carbenoxolone in duodenal
release capsules has increased its efficacy for duodenal ulcers. 
However, the rapid transit time of compounds through the duodenum 
(see section 1a), as compared to the stomach, indicate that, overall., 
carbenoxolone is likely to prove more effective for stomach ulcers, 
than duodenal ulcers.
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1. INTRODUCTION
a) Distribution and Elimination of Drugs
Most drugs are distributed throughout the body in the water 
phase of the blood plasma. Therefore, in order to exert its 
pharmacological action, unless it acts topically at the site of 
application, a drug must first enter the blood. It will then 
reach the tissues of each*organ at a rate determined by the blood 
flow through that organ, and by the rate of' passage of the drug 
into the cells. The amount of drug available for diffusion out of 
the plasma will be reduced if the drug binds to plasma proteins.
As a general rule,the amount of any drug in the tissue where 
it acts is but a small part of the total drug in the body. .Most 
drugs remain in various fluid compartments in solution (water is> 
approximately 60% of body weight and 80?6 of cell mass) or are 
localized by adsorptive or partition processes at surfaces or in 
tissue components. Many highly lipid-soluble drugs, e.g. 
thiobarbiturates, halogenated anaesthetics, chlorinated hydrocarbon 
pesticides, are known to be concentrated in the body lipid depots.
A drug enters the circulation, either by being injected there 
directly, or by absorption from depots. The gastrointestinal tract 
may be regarded as one such depot after oral administration of a 
drug . Drugs absorbed by the gut pass mainly into the* portal 
blood circulation, and therefore must pass through the liver before 
reaching other organs. Compounds administered intraperitoneally
have been shown to pass primarily into the -portal, rather than the 
systemic circulation (Lukas, £t.al., 1971). With subcutaneous 
and intramuscular administration, however, absorption occurs 
mainly into the systemic circulation*
A drug is eliminated from the circulation by facilitated 
transfer into the tissues and may be accelerated by metabolism 
and excretion. The rate of each of these processes is determined 
by the physico-chemical properties of the drug and its interaction 
with the specialised tissue responsible for elimination. The two 
most important routes of excretion are the urine and bile. JTor 
certain compounds, however, other pathways such as the secretions o 
the alimentary tract, the sweat, and expired air may be important.
The kidney is well suited to the task of drug elimination, 
filtering nearly 200 1 of plasma water per day in man. A drug will 
be filtered through the glomerular membrane if:- 1) its molecular 
weight is not excessively large; 2 ) if it is free drug in plasma 
water, that is, not drug bound to plasma proteins. Once in the 
glomerular filtrate, only highly lipid soluble drugs tend to be 
readily reabsorbed. 'Thus, polar compounds and ions will be unable 
to diffuse back, and will be excreted in the urine, unless absorbed 
by an active transport system.
Excretion of compounds in the bile appears to be dependent on 
a specific carrier-mediated active transport process because
1 ) compounds are secreted into the bile against a high plasma:bile 
concentration .gradient,
2 ) a maximum transport rate can be reached^,
3 ) various organic anions compete for the biliary excretion process.
The role of molecular size, structure and polarity as a requisite 
for biliary excretion of a compound are discussed in a review by 
Millburn (1970). In general, for organic anions, there appears to be 
a minimum molecular weight which varies with species, below which' 
little, biliary excretion occurs. For the rat and dog this minimum 
value seems to be about 300-5 0 0, but is higher (probably about 
300-600) for the rabbit, guinea: pig and man. The metabolism of a 
compound generally increases the size of the molecule, and possibly 
introduces an anionic group into the structure. Therefore, the 
extent and nature of metabolism, which can vary with species, will
be involved in determining the amount of administered compound ^ 
appearing in the bile. Once excreted in the bile, a compound will. 
not only be excreted in the faeces, but may undergo reabsorption and 
enterohepatic recirculation, or be further metabolised in the 
intestine. Thus,the extent to which a compound is excreted in the 
bile and its subsequent fate in the intestine are important events 
in its overall pattern of metabolism.
b) Distribution of Carbenoxolone
At pH 7*4-» carbenoxolone is largely ionised (pKa values 
6o7 and 7*1), and has an apparent partition coefficient in octanol/water 
of 27* The solubility of carbenoxolone in aqueous,as well as lipid, 
systems at physiological pH, should enable this drug to distribute 
into total, body water. However, studies by Lindup (1971) on the 
plasma protein binding of carbenoxolone in rat, rabbit, rhesus 
monkey and man, indicated that the drug was at least 9 9*3% bound to
proteins, within the range of therapeutic plasma concentrations. 
Therefore with less than 0.1/£ unbound drug in the plasma, the amount 
of drug available for distribution in body water is very small.
This interaction of carbenoxolone with plasma proteins will control, 
both the distribution and elimination of this drug from the body.
The distribution-will be confined to the plasma, and other tissues 
which can bind carbenoxolone. The excretion of carbenoxolone via 
the urine will- be small, while its high molecular weight (570), 
and polarity are properties compatible with good biliary excretion.
The tissue distribution of [;^ C] carbenoxolone has now been 
studied by four different routes of administration. The main aims 
w e r e ~
1.) to determine the extent of carbenoxolone binding to the stomach 
mucosa,
2 ) to provide basic information for studies on the effect of acute 
carbenoxolone administration on aspects of steroid biochemistry. •
c) Carbenoxolone - Spironolactone Interaction 
Spironolactone,when given in combination with carbenoxolone 
to minimise side-effects; of the latter d?*ug, has been shown by 
Doll, e^»al* (1968) to block both the side-effectsand ulcer healing 
properties of carbenoxolone. The possible modes of action of 
spironolactone blockade of ulcer healing by carbenoxolone are:-
1 ) competing with carbenoxolone for binding sites in the 
gastrointestinal mucosa, which may be concerned with ulcer healing,
2 ) blocking the mineralocorticoid side effects of carbenoxolone, 
which may be necessary for ulcer healing,
3 ) producing ulcerogenic effects in its' own right,
k) reducing effective concentration of carbenoxolone,by inducing
its metabolism*
The use of thiazide diuretics with carbenoxolone does not 
impair ulcer healing* Furthermore, there appears to be no correlatio 
between rate of ulcer healing and the avidity of fluid retention 
(Doll, J2t*al»} 1968). Therefore the mineralocorticoid effects/of 
carbenoxolone do not appear to be essential for activity* However, 
the mechanism of action of diuretics differ considerably* 
Hydrochlorothiazide acts on renal tubules to decrease reabsorption 
of electrolytes and thus increase water excretion (Adlin & Channick, 
1965)> whereas spironolactone is a specific aldosterone competitive 
inhibitor (Beyer & Baer, 1961; Fanestil, 1968)* The ulcer healing 
properties of carbenoxolone may depend on the integrity of systems 
involved in electrolyte transport in the gut. Groza & lonescu (1970) 
have shown aldosterone to reduce gastric secretion in rats and dogs, 
v/hile other studies in humans and rats (Gilder, e_t*al*, 1966; 
Baddeley, et.al*, 19&9) Have failed to ascribe to aldosterone a 
gastro.-secretory action. Nevertheless, it is possible that a 
reduction in gastric secretion by aldosterone is involved in the 
mode of action of carbenoxolone in ulcer healing.
There are some structural similarities between carbenoxolone 
and spironolactone, and thus spironolactone may compete with 
carbenoxolone for binding sites necessary for ulcer healing activity. 
Therefore a study of the effect of spironolactone on carbenoxolone 
tissue distribution has been carried out.
Spironolactone has recently been reported to have pharmacological 
effects in addition to aldosterone-blockade. Selye, et.al* (19&9) 
have shown spironolactone pretreatment to antagonize a variety of 
toxicological and pharmacological actions of many drugs. It was 
suggested that the ability of spironolactone to reduce the responses: 
to other drugs may be related to an enhancement of their 
metabolism. Recent studies have demonstrated that spironolactone 
pretreatment induces the phase- I metabolism of drugs in rats and 
mice (Solymoss, » 19&9 & 1971; Gerald & Feller, 1970;
Stripp, et.al., 1971; Feller & Gerald, 1971)*
It is well known that a variety of structually diverse drugs 
are able to induce microsomal enzyme systems (Conney, 19&7; ^
Kuntzman, 1969)* These inducers have been divided into three 
general classes a) phenobarbital type, b) polycylic hydrocarbons, 
e.g. ^-^ethylcholanthrene, and c) steroids. The steroid spironolactone 
is unusual in its inductive capacity because* unlike other steroid 
inducing agents , it has-no marked endocrine; action (Hertz & Tullner, 
1998).
The induction of microsomal drug metabolism by spironolactone 
may increase carbenoxolone metabolism, and hence reduce the 
effective concentration of carbenoxolone in the plasma and gastric 
mucosa.. Therefore the effect of spironolactone pretreatment on 
carbenoxolone metabolism has been assessed by studying the biliary
r1*fexcretion of j_ Gjcarbenoxolone. ~
2• EXPERIMENTAL
'
a) Materials 
1[ CjCarbenoxolone (sp. activity 93 pCi/gm), anaesthetic’ 
agents, scintillation chemicals and general chemicals and solvents; 
were described in chapter two.
Spironolactone (SG-9^20) was donated by Searle & Co. Ltd.
Materials for whole body autoradiography were acacia gum 
(B.D.H.), X-ray film (Kodak Ltd.) and seamless metal boxes-,
13.5 x 6.5 cm (Surdent Manufacturing Co. Ltd.').
Heparin (Sigma Chemical Co.) was made up to 1,000 units/ml 
in 0.9% saline.
Animals, bile cannulation tubing, silica gel (HF 23*0 were 
described in chapter two.
b) Methods
/J ||
) Plasma Turnover of J~ CjCarbenoxolone
Rats (350g body wt.) were fitted with bile cannulae under
1*fpentobarbitone anaesthesia (60 mg/ltg, i.p„). [ CjCarbenoxolone
sodium (3 mg) in 1 ml of 0.9$> saline was administered by intravenous 
injection into the jugular vein. Blood samples were removed at 
3-10 min. intervals from the jugular veins with a heparinised syringe. 
Bile samples were collected at 10 min. intervals for up to 1 h.
The blood and bile samples were assayed for radioactivity. Thin-layer 
chromatography of the pooled 20, 30 and ^0 rain, blood samples, 
showed 92% of the radioactivity in the carbenoxolone band, and there 
was; no evidence of\ significant amounts of radioactivity associated
with any metabolite.
The plasma radioactivity (d.p.m./ml) was plotted against 
time on. semi-logarithmic paper and yielded a straight line. The 
apparent volume of distribution CV.^ ) of the drug was calculated by 
extrapolating the stable rate of decline back to the time of 
injection.(tQ), and determining plasma drug concentration.
• v • i d.p.m. injected
• • d in m “ d.p.m./ml at t .o
The was calculated separately for each individual rat, and
expressed as a percentage of body wt. The plasma half-life (t^) was
2
determined from the slopes of the semi-logarithmic plots.  ^ -
ii) Tissue Distribution, of Carbenoxolone
. ^CjCarbenoxolone v/as administered to rats by the following 
four routes:-
a) Intravenous injection into the jugular vein, of carbenoxolone 
sodium (25 mg/kg) in 1 ml of 0.9/» saline, to four rats under 
pentobarbitone anaesthesia (60 mg/kg, i.p.). The rats were killed 
at 0.5 and 1 h. after injection, and a sample of heparinised blood 
collected by heart puncture.
b) Oral administration by stomach tube, of carbenoxolone (10 ffig/kg)
 ^if
in propylene glycol to eight rats* CO^ v/as collected as described 
in chapter two. Rats were killed by decapitation at 0*59 1i 2 and 
k h. after doding, and samples of heparinised blood collected.
c) Intraperitoneal administration of carbenoxolone (50 mg/kg) in 
propylene glycol to eight rats. The rats were killed at 0*5? 1? 2
-jZj.
and k h* after dosing. Plasma and CO^ samples were collected 
as for b).
d) Subcutaneous administration of carbenoxolone (50 mg/kg) in 
propylene glycol to eight rats. The rats were killed at 0.5? 1? 2 
and ^ h. after dosing by decapitation, and heparinised blood samples 
collected.
In the distribution studies, after collection of blood samples,
the following tissues were removed and washed well in 0.9% saline:
liver, stomach, intestines, kidneys, lungs and adrenals. The small
intestinal lumen was washed thoroughly with 100 ml of 0.9% saline
by flushing with the aid of a 50 ml syringe. The stomach mucosa
and small intestinal mucosa was obtained by scraping with a glass
1 if
slide. Tissues, CO^ samples, gut washings and carcasses were 
assayed for radioactivity as described in chapter two. Some’-tissues 
were extracted with etherrethanol (3 :1V/v), and after drying the 
extracts, the nature of the radioactivity determined by t.l.c.,
.as described in chapter two .
rlTissue distribution of [ CJcarbenoxolone was also studied by
whole body autoradiography. Rats (100 g) were given 0.^5 pCi of
[ Jcarbenoxolone (50 rag/kg) intraperitoneally, then sacrificed at
intervals of 0.5 ? 1 ? 2 and k h. by anaesthetising in ether then
immersion in acetone and solid CO^ mixture at -78°. The deep
/  W  /frozen bodies were fixed in 5% /v aqueous solution of acacia gum, 
contained in seamless metal boxes at -78°. The portion of frozen 
rat above the level of acacia, was planed down flat by the use of 
a 2n surform rotary drum cutter, powered by an electric drill.
X-ray film was placed in contact iwith the cleaned animal surfaces, 
the boxes sealed, and stored in the deep freeze at -*f0° for six 
weeks. Negative prints were made from the developed film, so that
radioactivity appeared as darkened areas on a white background.
Colour photographs were taken of the animal surface, to be used in 
conjunction with the autoradiograph for tissue localisation of 
radioactivity.
Autoradiography of rat stomachs was also carried out. Rats
1/f(200 g) were given 0,9 pCi of [ CJcarbenoxolone (50 mg/kg) 
intraperitoneally and. killed by cervical fracture. The stomachs were 
ligated at both ends before removal from the body, and washed.'-well 
on the exterior before freezing. The stomachs were fixed in acacia, 
planed down, and put in contact with x-ray film as for whole body 
autoradiography. A period of twelve weeks was required for adequate1 
darkening of the film.
The liver and kidney subcellular distribution of
p *1 ^  II CjCarbenoxolone was investigated 0.5 h. after intraperitoneal 
administration of a 50 mg/kg dose. The liver and kidney were 
homogenised in 5 and 10 ml respectively of 0 .2 5 M sucrose per.g wet 
wt. for 15 sec., with a teflon pestle in a.glass Potter Slvehjem 
homogeniser. Subcellular fractions were then prepared by differentic" 
centrifugation at 0-4-° as follows
600 g (10 rain.) deposit = crude nuclear fraction
7*000 g (10 min.) deposit = mitochondrial fraction
100 .000 g (60 min.) deposit = microsomal fraction
100 .000 g supernatant = cytosol fraction
The crude nuclear pellets were resuspended in 0.25 M sucrose
(2 ml/g tissue), and respun before preparation of the other fractions.
Radioactivity was determined in each sub'cellular fraction, and the 
protein content measured by the method of Lowry, et.al. (1951)j 
(see chapter five).
1 Zf.
iii) Distribution and Biliary Excretion Rate of | CjCarbenoxolone 
after Spironolactone Treatment
Ten rats were dosed orally with 2 mg spironolactone, or with 
1 ml of the vehicle propylene glycol, 1 h. before intraperitoneal 
injection of 2 mg [ C Jcarbenoxolone (sp. activity 93 pCi/gm) in
1 ml propylene glycol. Thirty minutes later the rats were 
decapitated, and samples of heparinised blood were collected.
Various tissues were removed and washed twice in  0.9% saline, before 
being homogenised in water with a.mechanical sonicator (Polytron). 
Assay of radioactivity and protein content of tissues was as 
previously described.
Spironolactone (100 mg/kg) was administered once per day by 
intraperitoneal injection to rats for 3 days, while a control group 
of rats received propylene glycol only. Twenty four hours after the 
last treatment the rats were anaesthetised with urethane 
(1.75 g/i>S! subcutaneously) and their bile -ducts cannulated. When 
bile flow was regular, the rats were given an intraperitoneal 
injection of 0.09 pCi and 1 mg of ‘G Jcarbenoxolone. The bile was 
collected in preweighed tubes at 0.5 h. intervals and the volume 
determined. Samples of bile (50 pi) were taken for counting of 
radioactivity.
RESULTS
m .
Table 3-1 Biliary Excretion and Plasma Turnover of.
[~^ClCarbenoxolone after Intravenous Administration
Time after Injection Bose in Total Plasma^ Cumulative Bose in 
(min) {%) Bile (%)
5 63.6 + 5.6 —
10 49.1*4.3 4,8 + 0»5
15 : 33,3 +■ 3»3 .
20 27,7 + 3*0 18,0 + 2 ,8
30 . 18,5 + 1,9 27.1 ±  2,7
40 11.4 * 2.3 • 32.5 ± 3*4
50 - 35*5 ± 3.3
60 - 38.3 +. 3-3'
The mean values + S.E.M, of 3 rats are given; no determination
.is shown by (-),
^ Assuming mean plasma volume- of 40 ml/kg body v/t.
Apparent Volume of Distribution (V^) = 5«1 ±  0*5% body v/t.
Plasma half-life (t-i) = 14.3 + 0,6 min.
2 ~~
V^ and t^ calculated from semi-logarithrnic plot of plasma 
concentra.tion (d.p.m./ml) against time.
Table 3 - H  • Tissue Distribution of Radioactivity after
Intravenous Administration of P^O]Carbenoxolone
Tissue Radioactivity dose)
0.5 h. | 1 h.
Total Plasma^ 18.7 5.1
Liver 31.6 45.1
Stomach Contents 5.2 3.6
Mucosa 0.6 0.1
Wall- 0.1 0.1
Small Intestine Contents 16.7 29.9
J-lucosa 6.1 2.7 .
Wall 1.3 0.9
Colon . -
Kidneys 0.3 0.1
Lungs * 0.5 0i2
Adrenals - -
Carcass 15.2 7.5
Total Recovery of Dose 96.3 95*3 .
The values given are the mean- of 2 rats; values < 0.1?£ of dose
are shown by (-)• 
t Assuming mean plasma volume of 40 ml /Kg body wt.
I
Table 3-HI Tissue Distribution of Radioactivity after Oral
r1^ -i •Administration of | C|Carbenoxolone
Tissue Percentage of Dose at various Times (h) after
Administration
1
2 1. 2 h
J.
Total Plasma1 0.5 0.1 0.1
Liver 3*8 5*3 3-5 5-5
Stomach Contents 7 0 .0 8 2 .0 88.2 5^.6
Stomach 2.6 3*3 7.0 3-7
Small Intestine Contents 2.2 5-1 2.5 1-9
Small Intestine 0.8 0.6 0.3 0 .7
Respiratory CO^ , 1.2 0.8 1*9 10.7
Carcass 1 a j? 0.8 - 0 .8
Total Recovery of Dose (/o) 82 -^. 9 8 .0 103A 7 8 .0
The values given are the mean: of 2 rats; values < 0.1?£ of the
dose are shown by (-)»
^ Assuming mean plasma volume of ^fOml/Kg body v/t.
Table 3-1V' Tissue Distribution of Radioactivity after
’ r|lf ,
Subcutaneous Administration of | C [Carbenoxolone
Tissue Percentage of Dose at various Times (h) after
Administration
12' 1 2. k
Total Plasma^ 2.2 0.1 0.6 •• 0.7
Liver ‘0.2 - 0 A 0.9
Stomach Contents - k A 0.1 3*7
Stomach 0 .k 0.1 - 0.1
Small Intestine Contents - - 0.1! 3.7-
Small Intestine 0.3 0.3 0.8 k.o
Colon - ~ - -
Carcass 87.1 93*0 91.2 8 0 .7 '
Total Recovery bf Dose (/i )  9 k .6 93.6 93.1 9 6 .6
The . values given are the mean., of 2 rats; values <0.1% of the
dose are shown by (-).
* Assuming mean plasma volume of AO ml/kg body v/t*
Table 3”V * Tissue Distribution of Radioactivity after
r-'j 4
Intraperitoneal Administration of | G [Carbenoxolone
Tissue Percentage of Dose at various Times (h) after
Administration
12~ 1 2 4
To ta.1 Plasma^ 2 © 4 3.1 2.9 1.7
Liver -5*4 6.4.
rA0CO 5-3
Stomach Contents . 3.0 5.3 4.3 3.6
Stomach '•0.9 1.3 0.8 0.7
Small Intestine Contents 5.2 10.9 29.2 35®9
Small Intestine ■ 1.9 2.1 2.5 2.5
Colon 1.5 1.9 1 o 4 0.7
Kidneys 0.1 0.1 - - •
Respiratory G0^ - 1.0 4.0 8.9
Carcass 75.5 62.7 37.1 24.9
Total. Recovery of Dose (%) 95®9 94.8 91.0 84.2
The values given are the mean.- of 2 rats; values <0.1$ of the
dose are shown by (-)»
Assuming mean plasma volume of 40 ml/Kg body v/t. •
Table 3-VI ‘ Tissue Distribution of Radioactivity at Two Dose
r 1  b - iLevels of [ C jcarbenoxolone, 0,5 h after 
Intraperitoneal Administration
Radioactivity (d.p•m./rag tissue protein)
Tissue Dose of Carbenoxolone
10 mg/Kg 50 mg/Kg
Plasma 16 + 1 112 + 12
Liver 9 +. 1; 65 + 6 •
Small Intestine - 120 + 15
Stomach 29 + 2 155 ± 11
Kidney 3 9
The. values given are the mean of 5 rats ± S,E„I$,; no determination
is 'shown by (-)•
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lpig. 3 'III Autoradiography of Rat Ctomach Section after
Intraperitonea]. Administration of [ ‘C] Carbenoxolone
a) 0*5 hour after injection
'In*
b) 1 hour after injection
( T
Table 3-VII In Vitro Distribution of Radioactivity in Liver
and Kidney Cell Components, 0.5 bo after
r1 ^Intraperitoneal Infection of | C [Carbenoxolone
Liver Fraction Radioactivity 
(d*p.m./mg protein)
Percentage of Dose 
in Liver
Crude Nuclear 62 + 10 22.5
Mitochondrial 36 + 5 '9.9
Microsomal kZ  Hr 5 12.7 ■
Cytosol 106+11 55*3
Recovery (%) 103 + 2
Kidney Fraction Radioactivity
(d.p.m./mg protein)
Percentage of Dose 
in Iri-ver 
KUVc\e.^
Crude Nuclear 8 + 1 26.0
Mitochondrial, 13 + 1 16.11
Microsomal 3 5o6
Cytosol. 20 + 2 57*6 ‘
Recovery (%) 106 + 3
The values given are the mean of k rats -i- S.E.M.
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*f. DISCUSSION
Plasma Turnover
The apparent volume of distribution (V^) of a drug is the
fluid volume in which it seems to be dissolved. The value of. V,d
calculated for carbenoxolone was 5*'! '(+ 0*5) % of body weight.
(table 3-1)- The volume of circulating plasma is about of body 
weight, and corresponds closely to the final obtained for 
carbenoxolone. However two factors can operate to invalidate such 
simple and direct interpretations:-
a) If total, plasma drug concentration is determined, rather than 
the unbound drug present in plasma water, then a high degree of 
plasma protein binding may make the observed concentration unduly 
high, and the estimate value of will therefore be falsely*low.
b) The binding or sequestration of a drug at an extravascular site
can withdraw so much from the circulation that the value for V, willd
appear to be very large.
The high plasma protein binding of carbenoxolone means that 
the value of calculated v/as falsely low. The amount of unbound 
carbenoxolone in the plasma is thought to be less than 0.1%
(Lindup, 1971)i and thus the amount of drug dissolved in body water 
through equilibrium.with plasma water must be very small (<1^ of 
total dose). Therefore, the value of calculated for carbenoxolone 
demonstrates that the drug is confined to the plasma compartment 
by protein binding, and limits the amount of drug able to enter body 
water. The plasma half-life calculated for carbenoxolone v/as 
1^*3 0.6) rnin. (table 3-1 )• This is a rapid rate of removal for
a drug so highly bound to plasma proteins, and indicates that the 
liver, which, is the main site of metabolism of carbenoxolone, can
bind unbound carbenoxolone and accumulate it. The biliary excretion 
rate (table 5-1 )i shows the high ability of 'the liver to bind, 
metabolise and excrete carbenoxolone.
Tissue Distribution 
r1 If
The dose of GJ carbenoxolone located in the liver, at 0,5 and 
1 hour after intravenous administration, v/as 31 •&% and ^5*1^ 
respectively (table 3“H)» Therefore: the total amount of 
carbenoxolone removed from the plasma, by binding to the liver and 
by biliary excretion (30 and kO%) by. the liver v/as about G(f/o at/
0.5 hour and 85% at 1 hour. Since carbenoxolone is highly bound to 
plasma proteins, it is clear that the liver also has a high capacity 
for binding this drug. Other tissues which appear to have ■ 
accumulated carbenoxolone above the plasma concentration after 
intravenous administration are: the intestinal mucosa, and to a lesser 
extent the gastric mucosa. It is also interesting to note the high 
amount of drug located in the stomach lumen, a point which v/ill be 
discussed later.
Tissue distribution studies carried out after oral administration 
(table 3“IH)» showed absorption of carbenoxolone to be slow, as 
indicated by plasma concentrations. The high percentage of the dose 
remaining in the stomach lumen indicates that gastric emptying 
had not occurred k hours after dosing. Both the liver and gut 
concentrated the radioactivity above the plasma concentration, 
indicating that both these tissues bind carbenoxolone. The stomach 
contained a very high concentration of radioactivity, but this is
to be expected as the tissue is in direct contact with drug in this
In­case. The small, levels of 00^ collected, indicate that very
yo. • /
little hydrolysis of the labelled Jsuccinate from the
carbenoxolone occurred in this study. The production of 
[^CJsuccinate is not likely to interfere with the distribution 
studies of [* ‘C Jcarbenoxolone, since succinate has a. very short 
biological half-life (Lindup, 1971)* However, the nature of tissue 
radioactivity v/as determined in the distribution studies*
Plasma concentration of radioactivity after subcutaneous 
administration of [^C] carbenoxolone (table 5-IV) were highest at 
0.5 hour and lowest at 1 hour. The decline of the. initial -
absorption may be due to the drug precipitating out of solution at 
the injection site. Poor absorption by this route of administration 
resulted in very low. tissue levels of radioactivity. However, ai 
high amount of the absorbed radioactivity v/as located in the stomach 
lumen after 0.5 hour. Since no biliary excretion had occurred by 
this time, the possibility of the radioactivity reaching the stomach 
lumen by biliai*y reflux does not seem likely.
; A range of blood levels from 1.-7-3»1$> of the dose was observed
over four hours after intraperitoneal administration of 
*1 Zj.
[  c] carbenoxolone (table 3-V). Thus at a dose of 50 mg/kg, the plasma 
contains approximately 17-31 J^ S carbenoxoione/ml. Since this plasma 
concentration is sxmilar to the peak blood levels in man 
(Downer, e_t.al., 1970), intraperitoneal administration of 
carbenoxolone (50 mg/kg) to rats has been used for the acute studies . 
on carbenoxolone-steroid interaction described in chapters four:- 
and five. •
After intraperitoneal administration., drugs are absorbed mainly . 
into the portal circulation (Lukas, et.al., 1971)• Therefore tissues 
can only take up the carbenoxolone in the plasma, which remains 
after passage through the liver. The gut appears to be able to bind 
and accumulate carbenoxolone. In table 3-VI, the radioactivity 
(d.p.m./rag protein) in the small intestine and stomach at two dose, 
levels, is always higher than the corresponding plasma concentration. 
Radioactivity v/as also accumulated in the stomach lumen, as has been 
previously noted after intravenous and subcutaneous administration.
The whole body autoradiographs (Fig. 3-1 & II) give a visual
outline of the distribution of [^CJcarbenoxolone after intraperitoneal
administration, v/hich has previously been studied by scintillation
counting techniques (table 3-V). The autoradiographic method was
however, used at the limit of sensitivity as the specific activity 
1 i|.
of the [ G Jcarbenoxolone v/as of a low. order (93 (iCi/gra). The 
amount of radioactivity normally used for satisfactory autoradiography 
with carbon-1*!- is 10 jjUi per 100 g of rat body weight, but only
0.5 p.Ci/100 g woSel used in the carbenoxolone experiments. The 
autoradiographs obtained cover a four hour period and show the 
movement of radioactivity from the peritoneal.cavity, to the liver, 
and finally.to the gut lumen. No tissues, except the liver and 
stomach lining (see 2 h autoradiograph), show any marked localisation 
of radioactivity. The presence of radioactivity in the stomach 
mucosa and lumen, has been previously noted in the distribution 
studies and further confirmation- v/as obtained by autoradiography 
of rats stomachs, 0.5 and 1 hour after intraperitoneal administration
r -1 Zf -i - .
of L CJcarbenoxolone. The autoradiographs obtained are snown m  
Fig. 3-HI* They give good visual evidence, that carbenoxolone 
accumulates in the stomach lining, and in the stomach lumen in the 
pyloric region even after parenteral administration.
The accumulation of radioactivity in the stomach lumen does 
not appear to be due to biliary reflux, since*the radioactivity is
• r1 V  npresent before biliary excretion of [_ CJcarbenoxolone reaches a 
peak. Recent studies by Shillingford (personnel communication), 
indicate that carbenoxolone induces increased levels.' of glucuronyl 
transferase in the stomach mucosa. Thus if carbenoxolone is 
metabolised in the stomach, the 30-glucuronide produced can diffuse^ 
either into the plasma or into the gastric secretions. Furthermore 
once in the gastric juice, carbenoxolone or its glucuronide is 
likely to be trapped by its poor solubility in the low pH environment.
The small amount of radioactivity which v/as located in the 
stomach and small intestinal tissue, was 80/o extracted by an 
etheriethanol (3*1V/v)mixture.Thin layer chromatography of the . 
extracts revealed that up to 30/“ °f the radioactivity was not 
associated with the carbenoxolone band, but corresponded to the 
value of the 30-glucuronide. It is known that the gut can form 
glucuronides (Schachter, e_t.al. , 1959; Herz, et.al., 1961;
Hanninen, et.al,, 19^8), and thus it is likely that some conjugation 
of carbenoxolone occurs at this site. Glucuronides produced in the . 
gvit may diffuse into the gut lumen via the succus entericus, as has 
been reported for estriol-l6a -glucosiduronate (Inoue, et.al.., 19&9) 
and salicylamide glucuronide (Barr & Riegelman, 1970). Studies by 
Iveson (1968) on the excretion of £^CJcarbenoxolone, showed that 
after intraperitoneal administration to biliary cannulated rats,
7 -10% GO^ was formed. It is unlikely that the liver was responsible 
for the hydrolysis of the carbenoxolone, and thus there may have 
been diffusion or secretion of carbenoxolone into the gut, and 
subsequent hydrolysis by the gut microflora. That carbenoxolone does 
appear in the gastric juice has been shown in the distribution 
studies reported. Furthermore carbenoxolone was found in the
stomach mucosa, and futhre studies may determine if this drug 
binds to sites, of metabolism and/ or sites involved in its ulcer 
healing action.
The amount of [^C Jcarbenoxolone located in the kidneys, has. 
been shov/n by distribution studies to be not greater than 0,3% 
of the dose, Hov/ever,studies had. been carried out on the effect of 
carbenoxolone given by intraperitoneal administration, on aldosterone 
binding in the kidney. It was therefore necessary to briefly study 
the kidney intracellular location of carbenoxolone, Subcellular 
fractions were prepared by a widely used scheme (Schnieder, 19^ -8), .
although it must be pointed out that it is an in vitro method, 
which does, not necessarily reproduce the carbenoxolone distribution 
as it occurs in vivo. Approximately 0,1% of the dose administered 
was present in the kidney, of which 26% and 5-8% were, located in the. 
crude nuclear and cytosol fractions: respectively (table 3~VTI),
The cytosol, fraction had the highest specific activity (d,p,m,/mg 
protein). Both the crude nuclear and cytosol cell fractions: 
prepared, have been shown to contain aldosterone binding proteins, 
(chapter five),
rl nThe rapid uptake of [ CJcarbenoxolone from the plasma by the 
liver, followed by rapid biliary excretion (tables 3-1 & II)» made, 
it of interest to study the intracellular location of carbenoxolone 
in the liver. Furthermore, the ability of carbenoxolone to uncouple 
oxidative phosphorylation in vitro (V/hitehouse, et.al#, 1967) i but 
not in vivo, may be explained by its intracellular distribution in 
the liver. The livers used in the subcellular- fractionation 
contained approximately 5% of the dose administered, which was
shown by t.l.c. to contain k0% Jcarbenoxolone and 35% 
corresponding to the 30-glucuronide. Subcellular fractionation • 
showed the cytosol to contain 33% of the radioactivity, and this 
fraction had the highest specific activity (d.p.m./mg protein).
The mitochondrial fraction contained only 10y£ of the. radioactivity/ 
present in the liver, and had the lowest specific activity.
However, calculations from radioactivity, indicate that there is 
approximately 10 jig carbenoxolone per mitochondrial fraction/g liver. 
In the studies by Whitehouse, et.al. (19&7) bn uncoupling by 
carbenoxolone, it can be calculated from their methods (Skidmore & 
Y/hitehouse, 1965) that 0.1 - 0.2-{ig carbenoxolone per mitochondrial 
fraction/g liver was required for uncoupling of oxidative 
phosphorylation. This raises the question as to whether the in vitro 
subcellular distribution truly represents the in vivo distribution 
of carbenoxolone. Alternatively, the radioactivity in the 
mitochondrial fraction may not be [ C Jcarbenoxolone, but the .
r1 -1 .
glucuronide or [ CJsuccinate. Unfortunately this radioactivity 
which represents only Q»3% of the dose administered, was not 
examined by t.l.c. A similar liver fractionation carried out 1 hour
r -'l Zf
after intraperitoneal administration of [_ CJcarbenoxolone by 
Lindup (1971) revealed the mitochondrial fraction to have the 
highest specific activity (d.p.m./mg protein). The differences in 
the subcellular fractionations carried out at 0.5 and 1 hour' after 
dosing, may be due to the increased hydrolysis of [^CJcarbenoxolone 
to [^Cjsuccinate after 1 hour/, compared to that at 0.5 hour.
The radioactivity present in the liver, in this experiment was 
shown to be k(f% as carbenoxolone and 33% as the carbenoxolone-30- 
glucuronide, presumably bound and not available for uncoupling of 
oxidative phosphorylation. The rapid uptake of carbenoxolone from
the plasma, where it is highly bound, into the liver, suggests 
carbenoxolone-binding proteins are present in the liver. In the1 
liver, carbenoxolone is metabolised to the 30-glucuronide, and 
t.l.c. has shown this metabolite is ^0-60;^ of the radioactivity in 
the liver at 0.5-2 hours after intraperitoneal administration of 
[^GJcarbenoxolone. Since only a trace of [*^C]carbenoxolone-30- 
glucuronide was located in the plasma, it appears that movement of 
carbenoxolone from the plasma into the liver, and the subsequent* 
metabolism and excretion is a one way process.
A possible mechanism by which compounds highly bound to plasma 
proteins can be selectively transferred to the liver and rapidly 
metabolised and excreted, lias recently been studied. Binding 
proteins in rat liver cytosol, fraction have been found for:-
1) bilirubin, bromosulphopthalein and indocyanine green
(Levi, et;.al. , 19&9);
2) corticosteroids and their metabolites, and eestradiol
(Morey & Litwack, 19&9; Singer, _et.al. , 1970; Litv/ack, et.al. ,
1971);
3) azodye carcinogens, methylcholanthrene and their metabolites 
(Ketterer & Beale, 1971; Singer '& Litv/ack, 1971)*
Strong evidence presented by Litv/ack, e t.al. (1971) indicates that 
at least one of these cytoplasmic' proteins is identical for the 
three groups of compounds listed above, v/hich, because of its binding 
properties, v/as called "ligandin11. Ligandin is abundant in rat liver, 
and is about h%.of the total cell sap protein (Fleischner, et.al., 
1971)* Ligandin has also been identified in the kidney and small 
intestine, where it constitutes approximately 2% of the cytoplasmic 
protein, but is not found in plasma, bile and other tissues
Carbenoxolone has the following similarities to compounds which 
bind to ligandin:- .
1) an anion, which is highly lipid soluble;
2) highly bound to plasma proteins;
3) rapidly accumulated by the liver after intravenous administration;
k) mainly located in the. cytosol fraction of the liver;
5) rapidly eliminated in the bile after conjugation;
6) mainly located, in the cytosol fraction of the kidney;
7) binds to the small intestinal mucosa.
Therefore, carbenoxolone may bind to ligandin in the liver , and also 
perhaps in the kidney and small intestinal mucosa. If this is the 
case, then this may be a possible site of interaction of carbenoxolone 
with steroid hormones.(see chapter four), since certain steroids 
and their metabolites have been shown to associate with this binding 
protein.
Spironolactone and the Tissue Distribution and Excretion of 
I Carbenoxolone
The possibility that spironolactone competes with carbenoxolone 
for its binding sites was investigated by a tissue distribution 
study (table 3-VIII). Spironolactone did not alter the amount of 
radioactivity bound in the stomach, which is the presumed site of 
action of carbenoxolone. Furthermore, spironolactone did not affect 
the amount of radioactivity after [^CJcarbenoxolone administration 
in any of the other tissues studied, except the plasma. The plasma 
radioactivity was significantly higher in the spironolactone treated 
rats, indicating either a tissue displacment effect or a decrease in 
metabolism. However, neither, of these two possibilities was 
apparent in the distribution study carried out. No definite conclusion 
concerning the effect of spironolactone on carbenoxolone tissue
binding can be drawn from this study, because the nature of the 
radioactivity was unfortunately not determined. The binding sites 
of carbenoxolone in the gastric mucosa, possibly, involved in its 
mechanism of action, should be located, and the spironolactone- 
carbenoxolone interaction further investigated.
Spironolactone pretreatment did not appear to alter the biliary 
excretion rate of the radioactivity of fjcarbenoxolone given by 
intraperitoneal. administration. Since parenteral carbenoxolone is. 
metabolised to the 30-glucuronide in the rat, it would appear that 
spironolactone does not induce an increase in glucuronyl transferase 
activity, as do some other enzyme inducers like the barbiturates; 
(Yaffe, <3t«al», 1966; Zeidenberg, e_t.al, , 1967)* However, an 
increase in metabolism may be masked by a rate limiting step in the 
biliary excretion process*. One indication that the spironolactone 
pretreatment had induced some changes in the liver, was the 
significant 100$& increase in bile flow® This increase in bile flow, 
is not an effect produced by all microsomal drug metabolising enzyme, 
inducers. Phenobarbitone was the only inducing agent, which was 
effective in increasing bile flow in studies by Klaassen (1969)* 
Further investigations by Klaassen (1970) indicated that the ■ 
phenobarbitone-induced increase in bile flow v/as due to an enhanced 
formation of the bile salt-independent fraction of canalicular bile 
production. The increase bile flow reported here, with spironolactone 
treatment (100 mg/kg for 3 days, i.p.) is higher than the 5®% 
increase reported for phenobarbitone treatment (75 ^g/kg for h days,
i.p.) by Klaassen (1970). It is important to know whether the 
spironolactone-induced increase in bile flow is due to an enhanced
formation of the bile salt-dependent fraction of bile, since bile 
acids damage the gastric mucosal barrier (Black, ejb•al., 1971a). 
Furthermore, reflux of bile into the stomach is very common in 
gastric ulcer patients (Du Plessis, 1965; Rhodes, ejt«al. , 1969; 
Black, at.al., 1971b), and may be involved in the aetiology of the 
disease. Therefore,blockade of ulcer healing by spironolactone may 
possibly be due to damage to the gastric mucosa caused by reflux of 
increased quantities of bile.
Some other possible mechanisms for this spironolactone- 
carbenoxolone' interaction were outlined in the introduction to this 
chapter (section c). It is important that the mode of action of 
spironolactone in blocking ulcer healing by carbenoxolone . is 
further investigated, because it may provide some understanding of 
the aetiology of gastric ulcers, and the mode of action of 
carbenoxolone.
CHAPTER. FOUR.
The Interaction of Carbenoxolone with Corticosteroid Hormones
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CHAPTER FOUR
1. INTRODUCTION
a) Hineralocorticoid-like Actions of Carbenoxolone 
Pseudo-aldosteronism has been associated with the beneficial 
effects of carbenoxolone therapy in peptic ulcer disease, in a 
significant number of patients (chapter.- one, section 3f)<* This 
potential hazard in carbenoxolone therapy has been minimised,or 
avoided,by the use of the- following measures:-
1) reduction in dosage,to reduce the incidence of side effects, 
although this is accompanied by some reduction in ulcer healing 
efficacy (Doll, ejt.al., 1968).
2 ) administration of thiazide diuretics to reverse the 
niineralocorticoid side-*effects (Doll, _et«al., 1968)* However 
by this means the risk of potassium depletion is increased,
3) restriction of sodium intake to prevent development of side 
effects* Dawborn (1969) has clearly demonstrated the value of 
a moderate restriction of sodium intake, to prevent weight
gain and a negative potassium balance, during prolonged infusion 
of aldosterone to a normal subject. '
k) prediction of susceptible patients* The side-effects appear to 
be confined mainly to patients over 60 years, and particularly 
those with hypertension and/or.heart disease (Doll, et.al*, 1968).
The secretion pattern and metabolic fate of aldosterone have 
a number of .distinctive characteristics* Aldosterone is secreted in 
small, amounts (75-15-0 Mg/day in man), inversely related to dietary
sodium. Unlike other corticosteroid hormones,the hypothalmus and 
pituitary do not appear to play dominant roles in .regulation* The 
major trophic hormone for aldosterone secretion is renin from the 
juxtaglomerular apparatus of the kidney. Adrenocorticotrophic 
hormone, particularly for short periods, can also Simulate aldosterone 
secretion, and there is evidence both in vitro and in vivo, for a 
direct effect of potassium and sodium concentration on the adrenal. 
There are probably other important regulators, but these have not 
yet been well defined. The mechanisms regulating adrenocortical 
secretions have been reviewed by Ganong, et.al., (1966).
In contrast to other endogenous steroids, aldosterone is not 
bound in plasma to any specific binding proteins, although there is 
a loose association with albumin. This lack of globulin binding in 
plasma has important effects on the metabolism of aldosterone.
The half-life time is very brief,and the metabolic clearance rate is 
very high (Bougas, et.a.l. , 19^^). A sudden alteration in secretion, 
or metabolism, will be rapidly^reflected by changes in plasma 
concentration. Also, the lack of binding and the high clearance, 
result in extremely low concentrations in peripheral plasma 
(5-15 m pg/100 ml). . The mechanism of feedback control of aldosterone 
must be considered, when interpreting data on blood levels, secretion 
and excretion ratesc, 6'ince there is ample evidence that aldosterone 
levels do not directly.and acutely alter trophic influences on 
secretion. Therefore,there are situations in which clearance can be 
altered, causing major changes in plasma concentration without 
measurable alteration in either urinary excretion or secretion rates,
Some possible mechanisms for the aldosterone-like effects o:f 
carbenoxolone are discussed below. \
1) Carbenoxolone has a formal similarity to the steroid structure, 
and possesses an 11-carbonyl group, and therefore may possess 
intrinsic mineralocorticoid activity. The possibility of a direct 
mineralocorticoid action of carbenoxolone- v/as investigated by 
Porter (1970), using an in vitro toad skin preparation. Carbenoxolone, 
unlike natural and synthetic mineralocorticoid's, was found not to 
enhance sodium transport in this in vitro membrane system.
2 ) Carbenoxolone may stimulate the adrenal to produce aldosterone. 
However, published results in man show reduction of both aldosterone 
excretion (V/erning, jet.ul., 1971) and secretion (Baron, ejb*al*» 1969)* 
This is supported by similar effects of liquorice preparations in 
man, where normal or reduced values of aldosterone secretion 
(Jenny, et.al., 1961; Rovner, j^t»al., 1967) and excretion have been 
reported (Fibllaret, at.al., 1960; Jenny, et«al» » ■ 1961;. G arc in, et.al 
1961; Drosdowski, jet.al., 1961; Salassa, £t.al., 1962; Minvielle,
_ejt.al., 1963; Rovner,\et.al. , 1967)* Thus,carbenoxolone does not 
appear to increase secretion by the adrenal of the principal 
mineralocorticoid,aldosterone.
3) Carbenoxolone may reduce the metabolic deactivation of 
mineralocorticoid hormones by the liver and other tissues, and thus 
increase the half-life of the active steroids. Kumagai, et.al., (1957 
demonstrated that the in vivo and in vitro metabolism of corticoids, 
was inhibited by glycyrrhizin. Furthermore,glycyrrhetic acid has 
been shown .to inhibit the in vitro liver metabolism of progesterone
and 11-deoxycorticosterone, (Atherden, 195&). Carbenoxolone 
inhibition of steroid metabolism is consistent with the observed 
reduced secretion and excretion of aldosterone, although normal or 
reduced plasma aldosterone levels have been observed (Brown, et.al., 
1972). Metabolism of aldosterone in dog and man, is thought to occur 
in the liver, intestine, spleen and kidney, (Balikian, 1971)* 
Therefore,inhibition of mineralocorticoid metabolism in its; two main 
target organs, the kidney and intestine (Swaneck, e_t._al., 19&9;
Matty & Noble, 1972), may'increase the free steroid concentration in 
these tissues, without marked changes in plasma concentration.
A-) The drug may displace mineralocorticoid steroids from their 
protein binding sites, and shift the equilibrium between unbound and 
bound forms, thus increasing the level of the active unbound'steroid. 
Tarnoky (1970) has demonstrated displacement by carbenoxolone of 
aldosterone, from plasma protein binding sites in vitro.
Carbenoxolone has been shown to potentiate the action of sub- 
optimal concentrations of aldosterone on sodium transport in toad 
skins preparations (Porter, 1970). Since toad skin does not 
metabolise aldosterone, at least two possible mechanisms can be 
offered for this carbenoxolone-aldosterone synergism. First, 
through an allosteric interaction at receptors, carbenoxolone 
increases receptor occupancy by aldosterone molecules. Second, by 
displacing aldosterone from non-specific intracellular binding sites, 
carbenoxolone increases the concentration of aldosterone at 
receptor sites.
In order to investigate the mechanism by which carbenoxolone 
exhibits a mineralocorticoid like action, it was necessary to study 
the effect of both short term and acute carbenoxolone treatment,
*7
on the tissue distribution and metabolism of [^ II] aldosterone*
The possible interaction of carbenoxolone with aldosterone binding 
in the kidney has been investigated and these experiments are 
described in chapter five*
b) Interactions of Carbenoxolone v/ith other Corticosteroids
Several findings support the hypothesis that glycyrrhizin and - 
glycyrrhetic acid, can act synergistically on corticosteroids^,other 
than aldosterone. Glycyrrhetic acid was used in the treatment of 
Addison’s disease (Card, at*al., 19535 De Vries, ejt.al*, 1960). 
Patients with residual adrenal function could be maintained on this 
drug alone, but in those with no measurable adrenocortical steroid 
output, glycyrrhetic acid by itself had no effect* However, it 
could be rendered effective by adding a subeffective dose of cortisone 
(Hudson, at.ad.* , 195*0* Hausmann & Tarnoky (1966) described a patient 
treated with prednisolone and carbenoxolone, who showed side effects 
of prednisolone, which disappeared when the carbenoxolone was. 
withdrawn. Kuraagai, jet.al* , (1957) observed potentiation and 
prolongation of cortisone action with glycyrrhizin in patients v/ith 
acute rheumatic fever. Further investigation by Kumagai, et.al* (1957) 
showed glycyrrhizin, to increase the plasma half-life of cortisone, 
to decrease the excretion of conjugated 17-hydroxycorticosteroids 
and to increase free urinary 17-hydroxycorticosteroids. Inhibition 
of the hepatic metabolism of cortisone by glycyrrhizin in vitro has 
also been demonstrated (Kumagai, ejt.al*, 1957)» and Atherden (195^) 
has shown that glycyrrhetic acid inhibits the in vitro hepatic
metabolism of progesterone, and 11-deoxycorticosterone.
j  ' ■
There is little evidence that carbenoxolone possesses 
glucocorticoid activity per se, although it does have anti­
inflammatory activity (see chapter one, section 3e). Mattingly, et.al 
(1970) ob served a transient rise in plasma 11-hydroxycorticoids 
in patients with duodenal ulcer, following the oral administration of 
carbenoxolone. A similar rise was seen in one patient, whose 
pituitary ACTH had been acutely suppressed with dexamethasone. 
However, no rise was seen in three patients suffering from adrenal 
insufficiency. These results are suggestive that carbenoxolone can 
displace corticosteroids from tissue binding sites, or inhibit their 
metabolism. Therefore,it was of interest to investigate the effect 
of acute and short term treatment of carbenoxolone on 
the overall rate of corticosterone metabolism.
The high plasma protein binding of carbenoxolone (Lindup, 1971)y 
indicates that this drug may displace endogenous steroids from plasma 
protein binding sites, and therefore potentiate their action.
Lindup (1-971) found no effect of carbenoxolone on [ H Jcortisol 
binding in human plasma, but Tarnoky (1970) observed carbenoxolone 
displacement of [ HJcorticosterone and [ Hjaldosterone, from chicken 
plasma protein. Therefore, further studies were carried out on the 
interaction of carbenoxolone v/ith the binding of aldosterone, and 
cortisol, to human plasma.
c) Corticosteroid Metabolism in the, Rat 
The adrenal venous blood of rats contains only tv/o 
glucocorticoids, corticosterone and cortisol, in a ratio of 
approximately 8:1 (Peron, 1960). Hence corticosterone is the main 
glucocorticoid in the rat, compared to cortisol in man, while 
aldosterone is the main mineralocorticoid for both species. Reduction 
is the primary method for the metabolic deactivation of corticosterone, 
and can occur at three main!sites in the molecule, namely the
kdouble bond ( A  ), the 3-keto and the 20-keto group. Stepwise- 
reduction at these sites gives rise to, the dihydro, the tetrahydro 
and the hexahydro derivatives, which can be the a or p isomers.
In rats, there is a sex difference in the extent of reduction at
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o  and the G^, ^20 ^e'^° SrouPs» an(i in the amount of a and p
isomers produced. Female rats have twice the capacity of males to 
saturate ring A (Urquhart, et«al«, 1959), but have less capacity to 
reduce the C^q keto group (Hagen & Troop, 1960). The female rat
has the faster rate of metabolism overall, with a plasma half-life
of 12 min., compared to 22 min. in the male (Glenister & Yates, 1961). 
In contrast, in man the plasma half-life of corticosterone is 
6O-8O min. (Peterson, 1959)** In the rat the principal metabolites 
of corticosterone consist of hexahydro-derivatives, while in man, 
most of the corticosterone is metabolised to tetrahydro-derivatives 
(Peterson & Pierce, 1960; Lowy, \®t.al., 1969)*
Conjugation of hydroxylated steroids before their excretion is 
also sex dependant in rats. Sulphate conjugation is predominant in 
the female rat (Roy, 1956) while male rats have a higher capacity
for glucuronide formation (Rao & Taylor, 1967). However, in the rat,
corticosterone and its metabolites are excreted mainly by the 
bile into the intestinal tract in the form of sulphate esters, 
whilein man, this steroid is eliminated in the urine in the form of 
glucuronides (Peterson & Pierce, 1960; Lowy, et.al., 1969). The 
difference in route of excretion of steroids in various species 
can be explained by the differences in their ability to excrete 
compounds in the bile. Millburn (1970) has reviewed this subject 
and has classed the rat as a good biliary excretor of molecules 
with a minimum molecular- weight of about 300. -In man,the minimum 
molecular weight for extensive biliary excretion appears to be in 
the range 5OO-6OO. This is a possible explanation of the difference 
in the major route of excretion of corticosterone in man and rat.
In man, the major route of excretion of aldosterone and its 
metabolites (99% of dose) is via the urine (Jones, o^ t.al* , 1959?
Flood, _ot.nl., 1961). Aldosterone is metabolised much more rapidly 
than corticosterone in man, and has a plasma half-life of about 
30 min. (Tait, _et.al., 1961). The two major metabolites excreted in 
the urine are:-
1) the & *-reduced steroid, tetrahydroaldosterone glucuronide which' 
represents about 30% of secreted aldosterone;
2 ) the aldosterone 18-glucuronide, which is acid labile and 
represents about 15% of the secreted aldosterone (Luetscher, et.al.
1965).
The metabolism of aldosterone in the rat does not appear to have-; 
been reported in the literature. However, on the.basis of 
corticosterone metabolism in rat and man, the likely metabolism of 
aldosterone in the rat can be predicted. Aldosterone is a more:
polar steroid than corticosterone, and is likely to,be excreted in 
the rat as conjugated aldosterone or tetrahydroaldosterone. In fact, 
Llaurado, jet«al« (19&2) did appear to extract a large quantity of 
unchanged aldosterone from rat faeces. Conjugates of aldosterone and 
its metabolites are likely to be ester sulphates, which,on the basis 
of their molecular weight and polarity,will probably be excreted in 
t?ie bile. •
The sex difference in. steroid metabolism betv/een male and female 
rats, and the species difference between man and rat, is very 
relevant to the investigation carried out in this chapter. The plasma 
half-life values, and biliary excretion rates of corticosterone and 
aldosterone have been investigated in female rats. Thus,any effebt 
of carbenoxolone on these parameters, which may be taken to 
represent the overall rate of metabolism, will not necessarily be 
the same for the male rat or man. Furthermore, we might expect 
carbenoxolone to affect corticosterone and aldosterone metabolism in 
different ways, since in man the rate of ina&tivation of 
mineralocorticoids in liver is faster, than that of gluconbrticoids 
(Heaven, .1955)• Furthermore, aldosterone administered orally is 
inactive (Ledingham, e_t.al. , 1961; Coppage, e_b.al. , 1962), while; 
oral cortisone is just as effective as that administered 
intramuscularly. Therefore,inhibition of steroid uptake and 
inactivation by the splanchnic bed is likely to be of more 
significance for mineralocorticoids, than glucocorticoids.
2. EXPERIMENTAL
a) Materials
[1,2- ]Aldosterone (sp. activity 51*5 Ci/ra mol), total 
activity of 750 fiCi v/as obtained from New England Nuclear (N.E.N.)’ 
'Chemicals, and 250 pCi (sp. activity 17 Ci/m mol)v/as purchased 
from the Radiochemical Centre, Amersharn.
[1,2- H^]Cortisol (sp. activity 4-6.7 Ci/m mol) total activity 
250 [iCi and ['f-,-2- H^Jcorticosterone (sp. activity 39*7 Ci/m mol), 
total activity 250 |£i were obtained from the; Radiochemical Centre 
and N.E.N. Chemicals respectively.
Non radioactive cortisol, corticosterone and aldosterone'wera 
obtained from Sigma Chemicals, Small quantities of these steroids 
(0.5-2 mg) were weighed out with an electric balance (Cahn), and 
dissolved in ethanol (20-200 |_i g/ml), and then stored at 5° as stock 
solutions.
Spironolactone v/as donated by Searle & Co., carbenoxolone' and 
l8f3-glycyrrhetic acid were gifts from Biorex Laboratories Ltd.
Florisil, 60-100 mesh (B.D.H.) was used after fines had been 
removed by soaking in water, decanting fines, and drying overnight 
at 100°.
(3-Glucuronidase from bovine liver (Type 1) v/as obtained from 
Sigma. Heparin (Sigma) was made up to 1000 units/ml in 0.9% saline,
Anaesthetics, bile cannulae, scintillation chemicals, and 
general chemicals and solvents were described in chapter two*
Female V/istar albino rats (body v/t. approx* 200 g) were littered 
on wood chippings, and fed Spillers autoclaved small animal diet with 
free access to water* Adrenalectomised. rats were maintained on 
0*9% saline, and used days after bilateral adrenalectomy. '
i) Radiochemical Purity and Storage of Tritium Labelled Steroids
[ H jAldosterone was supplied in benzene:ethanol solution (9*1V/v) 
in an ampoule sealed in vacuo. The presence of ^isoaldosteronet, was 
checked by diluting an analytical sample v/i'th unlabelled aldosterone, 
then performing ascending paper chromatography in benzene: 
cyclohexane: methanol :water (9 i ' \ :S :k by vol.). The radioactivity in
0.5 cm segments of the paper chromatogram was measured by 
scintillation counting. Radiochemical purity v/as always >97:«* The 
[^H]aldosterone was stored in pyrex glassware in absolute ethanol 
(20 {jtCi/ml) at 5°. The glassware had been previously cleaned, by 
rinsing in ,fHaemasoln and deionised water, before thoroughly drying. 
The radiochemical purity of the stock solution v/as checked at 
3 monthly intervals, by t.l.c. of a sample v/ith carrier aldosterone
1
in benzene:acetone (7*3 V/v). The aldosterone spot was located under 
u.v. light, and the radioactivity in this region determined. The 
radiochemical purity of [^H]aldosterone used for experiments did not 
fall below 93/°« Experimental solutions of triimm labelled steroids 
were made up on the day, by removing an aliquot of stock solution, 
and drying down at -^0° v/ith nitrogen, before dissolving in 0*9% 
saline containing 5°% v/v ethanol.
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[ h| Cortisol and [ H]corticosterone v/ere handled similarly to 
the [^ II] aldosterone. Radiochemical purity of these two steroids was 
always y 96%, in the following two t.l.c. systems:-
1.) chloroform:ethanol (9*1 V/v)
2) chloroform:methanol:water (..185*15*1 hy vol).
b) Methods.
i) Extraction of Steroids
The amounts of pH ]aldo sterone extracted-from water, by an equal 
volume of either ethyl acetate, chloroform or dichloromethane were; 
75%i 97% and 9&% respectively. Dichloromethane was chosen for the 
extraction of aldosterone from tissue homogenates because:-
1) of its good extraction of aldosterone,
2) its low boiling point (+^2°) aliows for rapid evaporation.
The occurrence of emulsions, during extraction,, v/as reduced by 
keeping the ratio of organic solvent to biological fluid >*f:1, 
and using dichloromethane precooled to 5°* Extraction of
[ ^h] aldosterone from tissue homogenates v/ith 5 vol of dichlorome thane 
alv/ays produced >90/^  recovery. Free steroid extracts were 
chromatographed v/ith carrier aldosterone by t.l.c. in benzene:acetone 
(7*3 V/v) or chloroform: ace tone (1:1 v/v). Aldosterone was located by
u.v. light, and had approx. R^ values of 0.3 and 0.5 respectively, 
in the two t.l.c. systems. In general, mainly [ H^] aldosterone was 
found in dichloromethane extracts of tissues, traces of radioactive 
free steroid metabolites ran slower than aldosterone in t.l.c. systems 
and was probably pHjtetrahydroaldosterone.
[^H]Corticosterone was extracted frqm small plasma samples 
by 5 vol of dichloromethane, with a recovery of >95%» Extracts 
were chromatographed by t.l.c. with carrier corticosterone in 
chloroform: methanol: water (185:151'I by vol.). The value of 
corticosterone in this system v/as 0.8 approx.
- Scintillation Counting Procedure.
The scintillation mixture and general counting procedures were 
as described in chaioter two.
Dichloromethane extracts of tissues were counted, by pipetting 
5 ml of solvent into a scintillation vial, and evaporating in air. 
Scintillator was then added to the dried extract before counting.
Small aliquots (50 {il-0.5 ml) of bile, plasma and tissue homogenates 
(lg/10 ml) were added directly to the scintillator and counted v/hen 
chemiluminescence was minimal. The radioactivity in tissues 
extracted by dichloromethane was termed free steroid, while that 
remaining in the tissue after extraction, was termed the polar 
metabolites.
Counting efficiency v/as determined by the channels ratio method 
of Bush (1963). An appropriate quench curve was prepared using 
[ ^ H] toluene, v/ith samples of either bile, plasma or tissue homogenate. 
It was found in general, that the channels ratio of most samples fell- 
on one calibration curve at low quench levels. Long counting times-. 
(100 min.) were used for samples of low count rate in order to obtain 
a reasonable number of counts, and an accurate determination of the 
channels ratio. Normally,samples were counted to 10,000 c.p.m. in 
the low count window. Efficiencies of counting were normally within 
the range of 20-32$>.
iii) Protein Binding of f Cortisol and [ h ] Aldosterone in
Human Plasma
A competitive protein-binding method was used (Murphy, 19^7 & 
1970), where the test compounds were incubated v/ith a labelled steroid 
bound to plasma proteins. The labelled steroid,displaced by the 
competing test molecules, was removed by an absorbent, and the protein 
bound radioactivity still remaining was counted. The- difference, 
between this and the count with no competing compound present, 
provided a measure of the * substance1s displacing effect on the steroid
Carbenoxolone, glycyrrhetic acid and spironolactone were used as 
2,5 mM solutions in ethanol*
Cortisol binding globulin (CBG) solution was made-up as■follows 
5 ml human plasma; , 1 ml ethanol containing 0.07 Pg and 10 pCi of
y
[•^H]cortisol and distilled water to 100 ml. Aldosterone binding 
proteint(ABP) solution was made'up as follows:-
15 ml human plasma, 1 ml ethanol containing 0 .0 3 pg and 3 pOi of.
[^H]aldosterone and 0.05 M pH 7®^ phosphate buffer to 100 ml.
(Note: the plasma is added after adding most of the water to avoid,
precipitating the protein v/ith ethanol).
The competitive protein binding method for CBG v/as carried out 
as follows:-
To provide standards, 0.03-0.50 ml of a solution containing 
0.1 pg cortisol per ml ethanol, and 0.1 ml of a 2.5 mM solution of: 
either carbenoxolone, glycyrrhetic acid, or spironolactone in ethanol 
was pipetted into small centrifuge tubes, and evaporated to dryness 
in a light stream of air and at ^5°« All the test tubes
were then placed in a rack and 1 ml of QBG-isotope solution was 
added to each* After shaking for a few seconds, the rack was placed 
in a ^5° bath for 5 min., shaken again, then cooled to 0° in an 
ice water bath for 10 rnin* While at 0°, 80 mg florisil was added to 
'each tube. The rack was shaken vigorously for 1 min. and returned to 
the cold water bath for 10 min. After centrifuging for 1 min. witly 
a bench-top centrifuge, 0.5 nil of supernatant was pipetted 
into a vial containing 15 nil of dioxan-gel scintillator. .
The competitive protein binding method for ABP was carried'out
in the same way, except that 5 min. shaking was given after-adding
the florisil.
Results were expressed as:- •
d.p.m./0»5 ml when competing
Percentage undisplaced steroid =  ------------------------ ,.P.r.e.s^n.^  xJ(K
J . d.p.m./0 a5 -ml m  blank
The percentage undisplaced steroid was then plotted against 
amount of competing substance added. Semilogarithmic paper was; used 
if necessary, to accommodate a large concentration range.
iv) Plasma Turnover and Biliary Excretion of P h ]Corticosterone
Two groups of rats were treated orally for 7 days with either 
carbenoxolone sodium (25 mg/jfcg per day) or 1 ml water. On the 
eighth day the rats were weighed, then anaethetised v/ith 
pentobarbitone (60 mg/kg), and their bile ducts cannulated v/ith 4-0 cm 
of tubing. [^H]Corticosterone (2 jjCi) in saline (0 .2 5 ml) was 
injected into the jugular vein. Bile samples were collected in
counting vials, at k min. intervals, and a'ssayed for radioactivity. 
Five blood samples (0.6 ml) were removed from the jugular veins 
usingan heparinised syringe, between 10-30 min. after injection of 
the tracer dose. The blood samples were centrifuged to obtain a.
200 p.1 plasma sample. The plasma was diluted with water, and 
extradted with 5 vol. of dichloromethane in stoppered tubes.
Aliquots of the organic phase were taken for counting. A-t.l.c. 
examination of some of the pooled organic extracts containing 
carrier corticosterone v/as carried out. More than $5% of the 
radioactivity in all samples corresponded to the corticosterone band.. 
At the end of the experiments,the rats were killed and the liver and . 
adrenals removed for weighing.
The effect of an acute dose of carbenoxolone on [^h3corticosterone 
plasma turnover and biliary excretion, was determined .as above, 
except that the rats received carbenoxolone sodium (5 0 mg/kg) 
intraperitoneally 0.5 hour before the experiment.
Biliary excretion rates of [^Hjcorticosterone were determined by 
plotting the accumulated dose {%) excreted against time. A straight 
rate curve v/as obtained between 8 to 2k min. after injection from 
which the dose excreted (%) per 10 min* v/as calculated.
Plasma radioactivity was plotted as d.p.m. free steroid per ml,
against time on serailogarithmic paper. A straight line was obtained
from which the plasma half-life was determined. Extrapolation of
the line to zero time (t ) gave the concentration in d.p.m./ml ofo
the free steroid, from which the apparent volume of distribution
(V,) of the steroid was calculated:- d.
•.r . . d.p.m. injected. V, m  ml = -r— ---- /- ■   r~T"d d.p.m./ml plasma at t
The was then expressed as a percentage of the body weight of the 
rat.
The concentration of endogenous plasma corticosterone v/as 
determined in tv/o groups of rats, treated orally v/ith, either water, 
or carbenoxolone sodium (25 mg/kg). Blood samples were obtained 
after decapitation of unanaesthetised rats. Collection was complete 
within 10 seconds of seizure of the animals, and precautions were 
taken against disturbing the rats before they were killed, to avoid 
stressing. The corticosterone concentration was measured by a 
development of the method of Mattingly (1962) for 11-hydroxycortico- 
steroids. The method involves the development and measurement of 
fluorescence in sulphuric acid. Mattingly (T9&2) measured cortisol 
fluorescence after 13 min. However, it v/as found.for corticosterone 
that maximum fluorescence was not attained until after 30 min., 
and this remained stable for 10-15 min.
The following two solutions were prepared:
Corticosterone stock standard in ethanol (100 pg/ml) from 
which, three standard solutions in water were prepared (10, 20,
30 pg/100 ml). -
Fluorescence reagent:- ethyl alcohol (HR.) - conc. H^SO^. (Analar) 
in the ratio 3^7 (V/v) was prepared by adding the alcohol slowly to 
the cooled acid. The reagent was used at room temperature.
glassware v/as soaked in "Haemasol" overnight, and rinsed in 
deionised water- before use.
Procedure
To 10 ml stoppered tubes, 0*5 nil of each of the following v/as 
added;-
'!:) glass distilled water (blank)
2) corticosterone standards (10-30 pg/ml)
3) plasma samples* .
10 ml o£- chloroform was added to the tubes, which were then 
stoppered and shaken mechanically for 10 min. The tubes were allowed 
to stand, and the aqueous phase v/as discarded. The chloroform 
extracts were then shaken with 1 ml 0.1 M NaOH for 13 sec and the 
aqueous layer removed after centrifugation for 2 rain. To avoid 
destruction of corticosterone by the NaOH, this step was carried 
out quickly v/ith batches of 8 tubes.
Chloroform extracts (5 ml) were transferred to clean 10 ml 
stoppered tubes. Fluorescence reagent (2 ml) v/as added to the tubes* 
at 1 min* intervals beginning with the blank, and then the highest 
standard. Each sample was shaken for 15 secs, after the addition 
of the fluorescence reagent.
Fluorescence was measured at 526 nm using a. Baird-Atomic 
Fluorescence Spectrox/hotometer (model SF-1) v/ith excitation at 
■^70 nm.
Thirty-five minutes after adding the fluorescence reagent to 
the chloroform extracts, the lov/er layer of each sample v/as 
transferred, in turn, into the cuvettes, making, sure no air bubbles 
were formed in the solution. The fluorimeter sensitivity v/as set 
to encompass measurement of both the blank and the highest standard. 
Then at 1 min. intervals, fluorescence of the remaining standards and 
samples was measured. Plasma samples containing amounts of 
corticosterone above the concentration range of the standard curve 
were assayed again, usinga dilution of the chloroform extract. 
Results were expressed as jig corticosterone/100 ml plasma.
v) Biliary Excretion of [ H^] Aldosterone v
Carbenoxolone in .propylene glycol (^0 mg/k.g) or propylene 
glycol alone (1 ml) v/as administered by intraperitoneal injection to 
rats for 3 days. After treatment the rats were anaesthetised witljp 
urethane (1.75 an(^  their bile ducts cannulated as before.
When bile flow was regular the rats were dosed intraperitoneally with 
0.5 pCi [5H] aldosterone (sp. activity 17 Ci/m mol) in 0.9% saline.
The bile was collected in preweighed tubes at 0.5 h intervals.
Bile samples (50 pi)were then assayed for radioactivity.
Qualitative analysis of the radioactive aldosterone metabolites 
in the bile of both control and test rats was carried out. Pooled 
bile samples were extracted v/ith 3 x 5 ^1 ethyl acetate. The organic 
phase was evaporated to dryness in a scintillation vial for counting. 
The aqueous residue was made up to b ml and the following added;- 
*f. ml of 0.2 M acetate buffer pH ^ .5
1,000 Fishman units of (3-glucuronidase: .
3 drops of chloroform.
The mixture was incubated at 37° for 18 h. Hydrolysis products were 
extracted v/ith ethyl acetate (3 x 5 ml). The pooled organic phase
was evaporated in a scintillation vial for counting. To the aqueous
residue 0*7 ml conc. HC1 was added, and the mixture placed in a 
boiling water bath for 15 min. The mixture was then neutralised, 
and hydrolysis products extracted with ethyl acetate ( 3 x 5  nil).
The radioactivity in the organic phase and resulting aqueous residue
v/as then measured.
Two groups of rats were pretreated orally for 7 days with 
either carbenoxolone in propylene glycol (25 mg/kg) or propylene 
glycol alone (1 ml). The rats were then anaesthetised with 
pentobarbitone(60 mg/kg, i.p.), and their bile ducts cannulated as 
before. V/hen bile flow v/as regular, the rats were given,by
•Z
intravenous injection in the jugular vein, 0.5 pCi [ HJaldosterone 
(sp. activity 51*5 Ci/m rnol) in 0.25 ml 0.9/4 saline. Bile samples 
v/ere collected at 5 min. intervals in scintillation vials, and . 
assayed for radioactivity. The effect of acute carbenoxolone 
treatment on aldosterone biliary excretion was determined as above.
A single dose of carbenoxolone (50 mg/kg) was given by intraperitoneal 
injection, 0.1 h before the administration of [^H] aldosterone.
vi) Plasma Half-life of f^K]Aldosterone
Groups of rats v/ere pretreated orally for 7 days with either 
carbenoxolone in propylene glycol (25 mg/kg) or propylene glycol 
alone (1 ml). On day 8, the rats were anaesthetised v/ith pentobarbitone 
(60 mg/Kg, i.p.). Each rat received 0.25 ml of 0.9/ saline
~z
containing 0.5 pCi and 3*6 ng [ H] aldosterone by injection into, the
jugular vein. Five 0.6 ml blood samples v/ere then taken with an 
heparinised syringe at 5 min. intervals from the jugular veins.
At 30 min., the rat v/as killed by removing a large blood sample from 
the posterior vena cava. The blood samples v/ere centrifuged and 
plasma samples of at least 200 pi obtained. The plasma was diluted 
with v/ater and extracted with 5 vol of dichloromethane. The 
radioactivity present in aliquots of the organic extracts was 
determined. Counting times of 100 min. v/ere used to obtain at least
10,000 c.p.m. The nature-of the radioactive metabolites in some of 
the pooled dichloromethane extracts, containing carrier aldosterone 
was determined by t.l.c. -
vii) Analysis of Plasma Half-life Curve of [^ II] Aldosterone
The plasma radioactivity (d.p.m./ml) v/as plotted against the 
time for each individual animal on semilogarithmic paper. These 
disappearance curves show an initial drop in plasma radioactive 
concentration to about k% of the' injected dose per 10 ml of plasma.
The curve then became less steep, until 15 min. after injection. Ail 
this time, the plasma concentration was about 7/ of the injected/dose 
per 10 ml* plasma. The curve then became less stee>^and app.eafed to 
be a straight line. Because of the low concentration of radioactivity 
in plasma after the injection of labelled steroid, it was important 
to know the nature of the radioactivity. Pooled dichloromethane 
extracts of the 5* 10 and 15 min. plasma samples for control and test 
rats, were examined by t.l.c.. The carrier aldosterone v/as found to 
contain > 90/ of the radioactivity for test and control samples.
The pooled extracts of 20, 25 and 30 min. plasma samples were found 
by t.l.c. to contain 85/ and 80/ [ H^] aldosterone for controls and .. 
tests respectively. Thus,the disappearance curves contain
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predominantly the unaltered steroid, and can be taken as an 
approximate measure of the half-life of aldosterone.
The analysis of the plasma disappearance curves of 
[ aldosterone into kinetic components v/as as follows.
Since a curve was- obtained (see Fig. A— I), at least two processes, 
are probably occurring at different rates. The final part of the 
curve (B) is log linear, and thus it v/as assumed that this process, 
had proceeded from the start. An extrapolation was therefore made 
back to zero time (tQ). Then, the extrapolated part of curve. B v/as 
subtracted from the early experimental points on curve B, yielding 
a straight line A,.with a.much steeper slope. Thus the aldosterone 
plasma disappearance curve can be accounted for by two different 
exponential decay curves. •
The process, represented by curve A, v/ith a half-life (t-j) of
"S'
a min., presumably represents the uptake of- [^H]aldosterone \rom the 
plasma by other tissues. To estimate the volume of distribution of 
the aldosterone, before this fast process started, the line Ik. was 
moved up. at a tangent to the experimental curVe^Jt^^ slope
of A unchanged. The line was extrapolated to time zero (tQ).
n d.p.m. injectedV.,, m  ml = "2— ----7 ------dA d.p.m./ml at t.o
The value V^, represents the fluid volume the [^H] aldosterone seems 
to be dissolved in before process A begins.
The process represented by line B, with a t^  value of B minutes:
'd '
indicates the rate of elimination from the plasma of normal 
endogenous aldosterone. The volume of distribution °f the
[•^ H] aldosterone before process B. began, *was calculated as for 
The value represents the fluid volume the [^ II] aldosterone seems 
to be dissolve din, at the completion of process A. Since the value 
for V\^ g obtained exceeded the volume of total body water, it is 
probably not related to fluid compartments, but to accumulation at 
an extravascular site. The final slope of the plasma curve (B) is; 
a result of a combination of the effects of metabolism and transport
7
of the [ Hjaldosterone. Therefore this parameter, which describes 
overall elimination of aldosterone from the plasma, is likely to be 
altered by compounds which interact with this steroid.
•7
viii) Tissue Distribution of p ll\ Aldosterone *
These experiments v/ere performed in rats, which had been 
adrenalectomised 3-*^  days previously, so that normal aldosterone, 
distribution v/as observed. A subcutaneous route of administration was 
used because:- 1) absorption occurs into the systemic circulation;
2 ) normal plasma aldosterone concentration could be maintained during 
the experiment. The rats were killed 0.5 h after injection of 
labelled steroid, because tissue uptake of. pHjaldosterone was; 
maximal at this time (see chapter five).
Adrenalectomised rats v/ere maintained on 0.9% saline, and dosed 
orally with propylene glycol (1 ml) or carbenoxolone in propylene 
glycol (23 mg/kg) for 3 days. The rats were then dosed subcutaneously 
with 7 pCi'[^H] aldosterone (sp. activity 51®5 pCi/mol) diluted with 
non radioactive aldosterone to a concentration of 0 .1 pg in 0 .5  
of 0.9% saline. Rats were decapitated after 0.5 h, and a sample of 
heparinised blood collected. The small intestines were removed and 
flushed with 100 ml 0.9% saline. The mucosa was then removed by
scraping with a- glass slide. Other tissues v/ere also removed, washed:
• om  saline and weighed. The tissues, which had been stored at -20 ,
were' then homogenised in water (1 g/9 ml). Samples of homogenates,
were then assayed for total radioactivity and radioactivity
extractable into dichloromethane. The amount of radioactivity
corresponding to aldosterone in pooled dichloromethane extracts, was
determined by t.l.c. Results were expressed as:-
1) Dose (%) in tissue as polar metabolites of [ Hjaldosterone. 
Calculated by subtracting radioactivity extracted into 
dichloromethane from total radioactivity.
2) Dose (%) in tissue as free steroid, that is radioactivity extracted 
into dichloromethane.
A similar distribution study wq.s carried out after simultaneous 
intraperitoneal administration of carbenoxolone in propylene glycol 
(50 mg/kg) or propylene glycol alone (1 ml) to adrenalectomised rats. 
The amount of [-^Hjaldosterone administered subcutaneously, was 5 pCi 
and 0.15 pg in 0.5 ml of 0.9% saline. . The rest of the experimental 
procedure was as described above.
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Table 4-1 ‘ Displacement of fil] Aldosterone (9*5 x 10*"^ mol)
from Human Plasma Protein (10 mg)
Competitive Agent Amount (mol.) Displacement (%)
Aldosterone -115 X 10 v* ' 26
Carbenoxolone
o
1 x 10 17
—61 x 10 55
Glycyrrhetic Acid
o
1 x 10
—6
15
1 x 10 53 -
Spironolactone 1 x 10~7
Spironolactone 1 x 10~7 )
+' / -8 }1 x 10 )*
10
Carbenoxolone
The Values given are the mean of six determinations.
Displacement of a Tracer Amount of Cortisol from Human Plasma.
Protein (3 mg)
Competitive Agent .Amount (mol) Displacement X%)
CortisolL 2.8 x 10“11 4o
Carbenoxolone 2.5 x 10-7 3
Glycyrrhetic Acid 2.5 x 10“7 1
Spironolactone 2.5 x IQ"7 8
The values given are the mean of four determinations.
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4. DISCUSSION '
Carbenoxolone and Steroid Plasma Protein Binding
The possibility that carbenoxolone may have an effect on the
plasma protein binding of steroids was investigated by a competitive
protein binding method, from that of Murphy (1967)* In the cortisol
plasma protein binding model, tracer amounts of [^H]cortisol were
-11displaced by 3*7 x 10 mol of non-radioactive cortisol to an 
extent of ^0%, (Fig* 4-II) v/hich should be equal to the concentration 
of endogenous cortisol present* Carbenoxolone and glycyrrhetic acid 
had no displacing effect on the bound [^ II] cortisol •( table 4-1)*
A similar finding was obtained by Lindup (1971)* using an ultra 
filtration technique* Spironolactone was found in the present 
investigation to displace^xil^_10^ of the bound [^h]cortisol, at a
4concentration 10 fold that of the endogenous cortisol concentration
(table 4-1). Ddvidson, (19&2) found that larger amounts
5 /(10 fold excess) of spironolactone were required for significant 
displacement of cortisol from its specific plasma binding proteins 
(transcortin).
Aldosterone binding affinity to human plasma has been reported 
to be of a comparatively low order of magnitude, similar to that of 
the interaction between aldosterone and albumin (Daughaday, et*al*, 
19^1; Chen, * 19&1)* However, other investigations have
indicated that aldosterone does bind to other plasma proteins 
(Meyer, £t.al*, 1961; Davidson, et*al*, 19&2). The aldosterone 
binding model used,contained an amount of [^H] aldosterone, 20 times 
that of the- endogenous aldosterone concentration* In this model, 
where the [ ^ H] aldosterone was about J>0% bound,' a 30 fold excess of 
unlabelled aldosterone had to be added, to produce a 2.5% displacement
of the labelled steroid (Fig. *f-III). Therefore,the capacity of 
human plasma for binding hldosterone is very high. Carbenoxolone,
which binds avidly to albumin, was shown to displace 20 to 50%
i-3-i kof the L HJaldosterone, at molar concentrations ranging from 10 to
• 610 times that of the labelled steroid (Fig. IV). The parent 
compound,glycyrrhetic acid, produced similar displacement effects 
(table 1). No significant aldosterone displacement by spironolacton
5was observed, at molar concentration up to 10 times that of 
aldosterone. The displacement of aldosterone by spironolactone, was 
not enhanced in the presence of carbenoxolone, as was reported by 
Tarnoky (1970). The results of the aldosterone binding study 
reported here are not in general agreement with the findings of 
Tarnoky (1970).- Using a competitive protein binding assay Tarnoky 
showed
1) carbenoxolone, but not glycyrrhetic acid, would displace 
aldosterone;
2) spironolactone at 100 times the molar concentration of aldosterone 
would produce displacment. This is in conflict with the findings 
of Davidson, et.al. (19^2), who extensively studied spironolactone 
aldosterone protein interaction;
3) spironolactone displacement was enhanced, by addition of a small
amount of carbenoxolone. 1
The reported concentration of aldosterone used in these experimenta.
—10was 1 x 10 mol/3 mg protein, which is 7,000 times the normal 
physiological concentration. This questions the validity or value^of^ 
the studies by Tarnoky.
The data obtained from studying steroid plasma protein binding.
is summarised in table 4— 1. The only significant finding was that
carbenoxolone or glycyrrhetic acid'-would, in molar concentrations 
4 . •
>10 times that of aldosterone, significantly displace this steroid
from human plasma proteins. Such relative concentrations of
carbenoxolone to aldosterone are found in circulating plasma in man,
-1 0  ■with a normal aldosterone concentra.tion of 3 x 10 M, and
• —5
carbenoxolone reaching levels of 30 pg/ml plasma (5 x 10. M).
However in the study reported here, a high capacity for aldosterone
plasma binding was demonstrated, even though the amount of
[^H]aldosterone used was 20 times the normal physiological range.
Thus the aldosterone at a physiological concentration may be very
difficult to displace from the many binding sites available in the.
plasma. Furthermore, one must question the role of aldosterone plasma
protein binding in regulating its metabolic activity. Studies; on the
plasma turnover of aldosterone in man (Tait, e_t.al. , 1961) and in the
rat,reported here, show that this steroid distributes into a fluid
volume greater than body water. Thus,plasma binding of aldosterone
reported to be in the region of 60/a (Siegers thaler, ej;«al. , 1964),
*
does not restrict the distribution of this steroid. Therefore, ’ 
displacement of aldosterone from transport proteins in the plasma, 
is unlikely to produce clinical side effects by increasing the normal 
rapid movement of this steroid into tissue compartments.
Distribution and Metabolism of Steroids in the Rat 
The plasma turnover of a tracer dose of [^h]corticosterone, and 
a physiological dose of [ H^] aldosterone, have been investigated in 
the female rat. The apparent volume of distribution (V^) of the
[^H]corticosterone was about A-8% of body weight, and the plasma 
half-life (ti) was 9»^ min. These are in agreement with the findings 
of Glenister & Yates, (1961), who also found that the half-life was
much longer in the male rat (tj_ = 22.2 min*). The plasma turnover in
2
*
man of both corticosterone and cortisol is markedly different from
the rat, with a value of approximately 20/b of body weight, and a
t-i = 60~8q min. (Peterson, 1959)-* The reason for the much larger.
2*
volume of distribution of corticosterone in the rat, compared to man, 
is not fully understood. .The volume of distribution of a compound, 
depends on its physio-chemical properties, but the apparent value of 
calculated, is also dependant on the plaisma binding and 
sequestration or binding at an extravascular site. The rapid biliary 
excretion (table 4-III) of corticosterone in the rat and elimination 
via the faeces highlights a functional difference between the rat 
liver and that of man, since the major route of steroid excretion in 
man is in the urine.
The plasma disappearance curve obtained for [^H] aldosterone in
the female rat, required at least a.two compartment model for
interpretation. The pharmacokinetic values obtaine'd were:-
1st process V, A = 38% body weight; t1 = 3 min. dA-
2nd process, = 20S% body weight; t^ = 13 min.
The final V, value obtained for aldosterone exceeded the entire d
fluid volume and body weight of the rat. Clearly, this large value
for V, is due to withdrawal of aldosterone from the circulation by d .
binding or sequestration in tissues. As for corticosterone, the 
values of for aldosterone in the rat . are nearly double those.'
observed in man. Tait, et.al. (19&1) found aldosterone distributed 
in man, initially into a volume of 25% of body weight, and then into 
a total apparent space of 120;o of body weight. The rapid biliary 
excretion; of aldosterone in the rat (table'4-VI) demonstrates the 
marked ability which the liver has for removal of plasma aldosterone.
The plasma half-life of aldosterone was 13 min. in the rat, 
compared to 33 Win. reporte'd for man (Tait, _et.al. 1961). Thus both 
corticosterone and aldosterone are metabolised faster in the rat than 
in man. It was surprising that the half-life values obtained for the 
female rat, showed corticosterone and aldosterone to have similar 
plasma disappearance times, since this is not the case for mail. 
Nevertheless the female rat is exceptionally fast in metabolising 
corticosterone, compared to the male rat. Y/hatever the interpretation
7
of the disappearance curve of [ H]aldosterohe in the rat, undoubtedly 
this steroid distributes into much larger volumes than corticosterone- 
in both rat and man. This difference may be related to the lower 
binding of aldosterone to plasma proteins (Davidson, et.al., 19&2), 
compared with corticosterone (Slaunwhite . & Sandberg, 1959)» resulting 
in a: more rapid diffusion from the plasma, into tissue compartments.
A preliminary investigation was made of the nature of aldosterone 
metabolites in the bile (table WVII). This does not appear to have 
been previously reported. Less than b% of tha dose appeared to be 
conjugated with glucuronic acid, while the majority of the dose 
seems to be conjugated with sulphate. The extent of biliary excretion 
of steroids in various species has been fully reviewed by Millburn 
(1970), although the extent of corticosterone and aldosterone biliary 
excretion in the rat was not reported. The present investigations
■2
indicate that,after an intravenous dose of [ H]corticosterone or\ . 
[^H] aldosterone, to rats, 85-95% of the dose is excreted in the bile 
in hours. In contrast, after intravenous administration of these 
•two steroids to man, 20-30% of the [H]corticosterone (Migeon, et.al., 
195^) and 1-5% of the [^H]aldosterone (Peterson, 196^), is excreted 
in the bile after ^8 hours. This species difference in biliary 
excretion of corticosterone and aldosterone, is very much more..' 
striking than has been previously observed for progesterone, estrone 
and estriol (Millburn, 1970). The pattern of steroid biliary 
excretion may, in part, be due to species variation in metabolism. !■ 
Nevertheless, the rat and man do appear to differ greatly, in the 
ability to transport the metabolites/ of aldosterone and corticosterone 
from liver to the bile*
"Z
The tissue distribution of [ il]aldosterone as free steroid, and 
polar metabolites in the rat, has been investigated (table VIII & 
IX). In general for all tissues studied, the radioactive free steroid
•Z
extracted into dichloromethane was always } 90% [h]aldosterone, 
except for the liver, where only about k0% //as associated with the: 
aldosterone fraction. The most interesting finding of this 
distribution study was the high amount of polar metabolites, of 
aldosterone located in the small intestine, which was comparable in 
amount- with that in the liver. This suggests- that the intestine 
may contribute to the metabolism of aldosterone. On the basis o^ f past 
studies in man, it was generally agreed (Luetscher, et.al., 19&5> 
Bougas, et.al., 196*0 that 85% of aldosterone metabolism takes place 
in the liver and 15% in the kidneys, and that metabolism by other 
organs is negligible. However, recently Balikian (1971) found in the 
dog that the mean percentage extractions of free [^H] aldosterone for
the hepatic‘vein, superior mesenteric vein and splenic vein were.
^5%» 53% and 16% respectively. From these studies.,Balikan concluded 
that the intestine and spleen contribute significantly to the total 
splanchnic metabolism of aldosterone. In view of evidence for the 
metabolism of estrogens by splanchnic organs, other than the liver 
(Collins, et.al., 1970) , it. seems likely that the intestine contribute 
substantially to the metabolism of aldosterone. The uptake pattern 
of aldosterone by the splanchnic bed, reported by Balikan (1971)* 
indicates that compounds inhibiting aldosterone uptake in the 
intestine, would increase the amount of aldosterone in the £>lasma 
available for hepatic extraction and biliary excretion. This point 
will be discussed later in relation to aldosterone biliary excretion 
in rats after short term carbenoxolone treatment.
The splanchric extraction reported in man for aldosterone is 
over 90% (Peterson, 196*+), while, in contrast, this parameter has been 
estimated to be only 5“10% i°r th© more highly plasma-bound cortisol 
and corticosterone (Tait & Tait, 1962). This difference in rate of
inactivation beiween aldosterone and glucocorticoids, is relevant to
* #
a study on the inhibition of steroid metabolism. A. compound which
inhibits both aldosterone and corticosterone metabolism, will produce 
a more physiologically significant increase in the plasma concentratio 
of aldosterone than of glucocorticoids.
The present studies of the distribution and metabolism of 
[^H]aldosterone in the rat, which has not been the subject of previous 
study, may be summarised as follows:-
a) The plasma disappearance of [^H]aldosterone in the rat shows 
that aldosterone is distributed into a larger volume than in man.
The plasma half-life was shorter in rat, than in man; the finding 
of a similar difference for the corticosterone plasma turnover in 
rat and man has been reported,
b) [ II] Aldosterone was rapidly excreted in the bile, probably as 
ester-sulphate conjugates,'
7 ‘
c) Polar metabolites of [H]aldosterone were located in the 
intestinal mucosa, in amounts, similar to that found in the liver,
Carbenoxolone and the Plasma Turnover and Excretion of
r^HlCorticosterone
Acute carbenoxolone' treatment significantly increased the plasma^ , 
half-life of [^Hjcorticosterone (table *f-II). A possible cause is 
the reduction of hepatic uptake, and/or metabolism of corticosterone. 
In chapter three, section k , the presence of an hepatic protein called 
”ligandinM (Litwack, et.al,, 1971)» involved in the selective and 
rapid transfer of a wide range of compounds, from tlie plasma into 
the liver, was discussed. Ligandin, which is also found in the 
intestine, has been shown to bind both corticosteroids and their 
metabolites (Morey & Litwack, 1969; Singer, ejh.al. , 1970)* The 
possibility that carbenoxolone binds to ligandin, was discussed in 
chapter three. Thus carbenoxolone, which, after acute administration, 
is mainly distributed in the gut and liver, may compete with 
corticosterone for tissue binding-proteins.’ It may be significant 
that the volume of distribution for the [^Hjcorticosterone, was 
slightly lower in the carbenoxolone treated groups (table ^-11),
The presence of an unsaturated ketonic group, at the 11 position 
in carbenoxolone, may enable it to inhibit the reduction of ring'A 
of unsaturated ketonic steroid like corticosterone* Atherden (195^), 
found glycyrrhetic acid to inhibit the reduction of both progesterone 
and 11- deoxycorticosterone, by rat-liver homogenates. Similar 
studies by Kumagai, et.al* (1957)» found both glycyrrhizin and 
glycyrrhetic acid, to inhibit the reduction of the 3- and 20-keto 
groups of cortisol, by rat liver homogenates. Glycyrrhetic acid was 
found to be less effective than glycyrrhizin'. Kumagai, et.al. (1957)» 
also investigated the influence of glycyrrhizin and glycyrrhetic acid 
on the plasma turnover of 17~hydroxycorticosteroids, after intravenous 
administration of cortisol to dogs. Plasma half-life was markedly 
increased, with only small doses (3 mg/kg) of glycyrrhizin or 
glycyrrhetic acid given intramuscu^larly. There are two possible 
reasons why Kumagai, et.al* (1957)» observed a more marked effect 
on corticosteroid plasma disappearance, than was found in the present 
investigations
1. Kumagai, measured 17~hydroxycorticosteroid plasma disappearance, 
which.can be delayed by inhibition of a) tissue uptake; . • .
b) phase X metabolism (reduction); c) phase II metabolism
7
(conjugation). The plasma turnover study of [H]corticosterone 
in rat, measured mainly the non-metablised free steroid, and 
thus is not likely to be altered by inhibition of phase II 
metabolism.
2* The metabolism of corticosteroids in the dog,, differs greatly
from that in the rat., in that the latter exhibits a greater rate 
of Corticosteroid phase I metabolism. .Furthermore, corticosteroid 
conjugates are mainly sulphates in the rat, and glucuronides in 
the dog. Thusi since carbenoxolone and glycyrrhizin are
metabolised to glucuronides, they are more likely to inhibit 
conjugation of corticosteroids in the dog, than in the rat.
Other studies on the biliary excretion of ["*H] corticosterone 
(tables f^-II Sc III), show that acute carhenoxolone administration 
produces a 50^ reduction in the biliary excretion rate. This 
inhibition of corticosterone excretion by carbenoxolone, is more 
marked than the inhibition observed for plasma disappearance.
This indicates that carbenoxolone1s main site, of action is not in th 
processes involved in hepatic uptake and phase I metabolism, but in 
phase II metabolism and the biliary excretion mechanism. Since 
corticosterone metabolites are mainly sulpjba.te conjugates in the rat, 
it does not seem likely that carbenoxolone would inhibit phase II 
metabolism. However traces of glycyrrhetic acid may be present, 
through hydrolysis of carbenoxolone in the gut, which may compete 
v/ith corticosterone for sulphate conjugation. The possibility that 
carbenoxolone competes with steroids for a biliary excretion mechanism 
is discussed later in the section concerning aldosterone, where 
additional information is available.
Short-tf.rm, continuous treatment (7 days) wit]! carbenoxolone, did 
not significantly alter the plasma half-life, or biliary excretion
•7
rate of [ H]corticosterone (table II), although there was a 
slight trend towards an increased rate of plasma disappearance, and 
biliary excretion. Lindup (1971) found,with carbenoxolone 
pretreatment, that there was a tendency for an increase in botfc
r  3urinary and biliary excretion, of [ H]cortisdl in rats. Therefore, it 
is possible that carbenoxolone or glycyrrhetic acid in the rat, 
produces a slight induction in one or more of the following: the 
processes involved in corticosteroid, hepatic uptake; phase I 
metabolism; phase II metabolism and
biliary excretion. Lindup (1971)» investigated carbenoxolone for 
inductive effects on drug metabolising enzymes, both in vitro and 
in vivo., and found
a) Carbenoxolone did not induce hepatic phase I drug metabolism,
as judged by biphenyl-4-hydroxylase activity and cytochrome P-k^O 
content.
b) Carbenoxolone pretreatment caused a consistently, slight increase 
in hepatic glucuronyl transferase activity.
c) Carbenoxolone or glycyrrhetic acid pretreatment, did not 
significantly effect the duration of hexobarbitone hypnosis times, 
in male and female rats.
Other hepatic microsomal drug-metabolising enzyme activities 
have been measured after 12 months of carbenoxolone treatment, and 
no evidence of major changes observed (Dr. C. Rhodes - personnel 
communication). However, significant carbenoxolone stimulation of 
glucuronyl transferase activity- in the stomach mucosa, has been 
observed recently (Mr. J. Shillingford - personnel communication).-
* 9
The. plasma concentration of endogenous corticosterone was 
slightly decreased in carbenoxolone pretreated rats (table f^-IV). 
Gupta, .et.al. (19&9) found a significant reduction of plasma 
corticosterone, with six days pretreatment of rats with glycyrrhetic 
acid at a high dose level (100 mg/kg). The slight increase in plasma
•Z
disappearance of [ H]corticosterone, in carbenoxolone pretreated rats 
(table II),'may be the cause of a reduced level of endogenous 
plasma corticosterone, providing adrenal secretion rate is normal.
The mean adrenal weight, after carbenoxolone pretreatment (table 4— IV 
& V), appears to be slightly reduced. Thus, an alternative
explanation -for the reduced corticosterone plasma concentration is
a reduced secretion rate, brought about by inhibition of
corticosterone metabolism and excretion,by carbenoxolone, and therefore
potentiating the activity of this steroid.
In these investigations, overall metabolism and excretion 
parameters of [^H]corticosterone in rats with various .carbenoxolone 
treatments, have been studied. An acute dose of carbenoxolone 
(5 0 -mg/kg), given half-an hour before the injection of 
[•^Hjcorticosterone, was found to significantly reduce the metabolism 
and excretion of [^ II] corticosterone. The Jcarbenoxolone
distribution studies described in chapter four, indicate that the 
acute dose of carbenoxolone (50 mg/kg), used in these experiments, 
produces plasma concentrations of carbenoxolone similar to that • 
observed in man 1-2 hours after oral administration, Therefore, it 
is likely that carbenoxolone can produce effects on corticosterone 
metabolism in man, similar to those observed in the rat. Nevertheless, 
the differences in corticosterone metabolism, between the two species, 
must be considered,
.• >
In man, an acute rise in plasma 11-hydroxycorticosteroid 
concentration, occurred in duodenal ulcer patients, between 20 and 
60 minutes after receiving a. single dose of carbenoxolone (Mattingly, 
at.al,, 1970). It was further suggested by Mattingly, e_t.al. (1970)* 
that carbenoxolone increased endogenous steroid production, by a 
direct action on. the adrenal cortex, since no similar rise in 
11-hydroxycorticosteroids was seen in patients suffering from adrenal 
insufficiency, although in these patients the basal plasma 
11~hydroxycorticosteroids v/ere below those of normal subjects.
On the basis of the investigations reported in this thesis, two 
alternative mechanisms are suggested, for this transient rise in 
endogenous plasma 11-hydroxycorticosteroid concentrations
1, The increase of plasma 11-hydroxycorticosteroids occurred
within about 30 mins. of taking the oral carbenoxolone, in the 
majority of patients# Investigations on the absorption of 
carbenoxolone in man indicate that peak plasma concentrations of 
this drug occur about 1 hour after administration.
Therefore, it is possible that during absorption from the/ 
intestine, carbenoxolone displaces steroids from binding sites 
in the gut into the blood stream#
2. Carbenoxolone may temporarily block the uptake, and metabolism 
of corticosteroids by the liver# This would produce a transient 
rise in corticosteroid levels, because adrenal secretion rate, 
would continue as normal, until reduced by feed-back control.
In the patients with adrenal insufficiency, their plasma 
corticosteroid concentration is always on the decline, after the 
absorption of their oral dose of steroid. Therefore,one would not 
expect carbenoxolone to raise the 11-hydroxycorticosteroid 
concentrations in these patients, but possibly to increase the plasma 
disappearance time.
Carbenoxolone and the Distribution, Metabolism and Excretion
of PHI Aldosterone 
The possible interaction of carbenoxolone with [^Hjaldosterone 
has been studied in rats, after acute and short term continuous 
treatment with carbenoxolone* The short term continuous treatment 
involved 7 days oral administration of carbenoxolone (25 mg/kg) to 
normal rats, or 3 days pretreatment to adrenalectomised rats* The 
experimental rats v/ere used 20 hours after the last dose, by which 
time, the carbenoxolone w.ould have, been largely metabolised.
to free glycyrrhetic acid, and the glucuronide and sulphate; 
conjugates of glycyrrhetic acid* Carbenoxolone (50 mg/kg), given 
intraperitoneally half-an hour before the injection of [^II]aldosterone 
to normal and adrenalectomised rats, was termed acute administration. 
The tissue distribution of carbenoxolone»after acute treatment, 
was reported in chapter four* These studies indicated that the 
majority of the dose will be present as carbenoxolone and its 
glucuronide, while the plasma concentrations of the drug in rat will 
be similar to that achieved in man,after oral dosing of carbenoxolone 
(3 nig/kg).
• #
The plasma disappearance of free steroid, mainly as.;
[ h] aldosterone ( > 80%) , after intravenous, administration of 
[^H]aldosterone, was studied in normal rats, after short term 
treatment with carbenoxolone (table b -V), (Fig. h - l ) . The half-life
-z
of plasma elimination of the [ H]aldosterone, was 50% longer in.the 
treated group of rats, while other pharmacokinetic parameters of the 
disappearance curves were unchanged* The cause of the reduced plasma. 
clearance of this steroid, with short term carbenoxolone treatment,
was further investigated by a tissue distribution study of 
pHJaldosterone and its metabolites, half-an hour after subcutaneous 
administration to adrenalec.tomised rats, (table 4-VIII & IX)* The 
plasma concentration of free steroid ( > 90% [ H^] aldosterone), tended 
to be higher in the treated group of rats, presumably because of the1
reduced metabolic clearance observed for this steroid. The amount of
-2 * 
free steroid (>"90/o [ II] aldosterone), was higher in the kidney ,
intestinal mucosa and colon (P<0*05) of the treated group (table VII
probably because of the hi-gher plasma concentration. Since these
three tissues are the main target organs for aldosterone in the rat
(Swaneck, £t.al., 1969} Alberti & Sharp, 1970), carbenoxolone
treatment, appears to potentiate the action of aldosterone in the rat*
The liver concentration of free steroid ( < k-0% [^ II] aldosterone) and *
polar metabolites, was slightly higher in the carbenoxolone treated
rats, as was the radioactivity found in the intestinal lumen*
Therefore, the metabolism of [Hjaldosterone by the liver does not
appear to he impaired in the treated group* However, the possihle
metabolism of pHJaldosterone in the intestine does appear to be
impaired in the treated group, since the concentration of polar
* » 
metabolites In the intestinal wall and mucosa, are slightly lower in
the treated, chan in the control group* Therefore, glycyrrhetic acid
may be inhibiting conjugation of aldosterone, in the intestine.
In the plasma turnover studies of this steroid, mainly [Hjaldosterone
vo.
was being measured*. To explain the involment of the intestine in 
the reduced aldosterone metabolism, one must assume that some of the 
steroid does not undergo phase I metabolism, but is conjugated directly 
Evidence that unchanged aldosterone is excreted as. conjugates, has 
indeed been reported in man (Luetscher, jet.al•, 1965) > the rat
(Llaurado, £t.al*j 19&2). Further studies on the biliary excretion 
of [ ll] aldosterone, after Intravenous administration ( table A-VI),.- 
showed that short term carbenoxolone treatment did not inhibit 
liver metabolism and excretion of [^Hjaldosterone• However, the 
initial biliary excretion of [ H^] aldosterone, tended to be higher 
in the treated group, compared to controls. On the basis of the 
tissue distribution studies, the slight increase in biliary excretion 
of [^Hjaldosterone may be‘due to the slightly higher plasma 
concentration in the treated group. Furthermore, a reduction in
7 . .
intestinal metabolism of ["^Hjaldosterone, would increase the
7
concentration of [^Hj aldosterone reaching the liver, by the splanchnic 
blood flow..
Short term, continuous carbenoxolone treatment produced a. 
significant increase in'plasma.half-life of [ Hjaldosterone, while 
changes observed in tissue distribution, and excretion of this steroid 
were only, slightly changed. Therefore, further investigations were 
carried out after acute administration of carbenoxolone, where: a. 
much higher tissue concentration of drug was available for interaction 
with the^[^Hjaldosterone.
Tissue distribution studies of [ ^ H] aldosterone, half-an hour 
after subcutaneous administration to adrenalectomised rats 
(table *{— X & XI), showed acute carbenoxolone treatment to produce 
similar, but more marked changes, than was observed for the short 
term treatment. The treated group, showed an S0% reduction, in the 
amount of polar metabolites of [^Hjaldosterone, present in the 
intestinal tissue. [^H]Aldosterone in the plasma was higher in the
treated rats, while concentrations in the intestine and kidney were 
slightly lowered. Thus,the higher plasma level of.[ ^ H] aldosterone 
suggests that carbenoxolone is reducing tissue uptake, and metabolism 
of this steroid. The uptake of [^Hjaldosterone into its target 
tissues, the intestine and kidney, appears to be impaired, and 
further investigations are described in detail in chapter five.
In the distribution study, acute carbenoxolone treatment 
significantly reduced (P<?*0.01) the radioactivity in the intestinal
*7 *
lumen, presumably from [Hjaldosterone excreted in the bile. This was 
further investigated, by studying the biliary excretion of
■z
radioactivity, after intravenous administration of [Hjaldosterone 
(table VI). The biliary excretion of [^Hjaldosterone is nearly 
50/o reduced by acute carbenoxolone treatment. However, the amount of 
free steroid (< k0% [ ^II] aldosterone), or polar metabolites of 
["^Hjaldosterone in the liver (table X & XI), was not found to be 
altered. Therefore, the reduction in biliary excretion of 
[■^Hjaldosterone does not appear to be due to reduced uptake, or 
conjugation of this steroid in the liver. Two possible causes of 
reduced [^Hjaldosterone excretion in the bile are discussed below.
1) Carbenoxolone may inhibit aldosterone conjugation in the
intestinal mucosa, and therefore reduce amounts of metabolised 
aldosterone reaching the liver, by the superior mesenteric vein. 
Tissue distribution studies of [^H] aldosterone have demonstrated , 
that the amount of conjugated aldosterone in the intestinal 
tissue, is significantly reduced by acute carbenoxolone treatment
2) Carbenoxolone may inhibit, or compete for, the biliary excretion 
mechanism. However, the processes involved‘in biliary exchetion 
are poorly understood. The uptake by hepatic proteins 
(including ligandin), and the plasma disappearance of 
sulphobromophthalein (BSP), were not altered by acute bile duct 
ligation (Reyes, et.al., 1971). Thus, hepatic uptake proteins, 
do not appear to be involved in the biliary excretion mechanism. 
That compounds can compete for biliary excretion, has been observed 
(Kupferberg, et.al., 196*1-; Hart & Schanker, 1966; Guarino & 
Schanker, 1968). Since carbenoxolone increased the plasma
concentration of polar metabolites of [^H] aldosterone (table *f-XI),
it appears that carbenoxolone is inhibiting the biliary excretion 
of the aldosterone conjugates, and not the earlier processes 
involved in hepatic uptake and metabolism of aldosterone.
Therefore, there is a need to further investigate the effect of 
acute carbenoxolone treatment on the composition and volume of bile, 
and on the biliary excretion of other drugs and endogenous, compounds. 
Since the biliary excretion route appears to be more important in the
rat than in man for organic anions in the molecular weight range
300 -500 (Millburn, 1970), the effect of carbenoxolone on excretion of 
steroids may be species dependent.
The short term treatment with carbenoxolone was shown to reduce 
the plasma disappearance of [^Hjaldosterone, probably through the
action of glycyrrhetic acid. This reduction in aldosterone metabolism
3 •appeared to increase the concentration of [Hjaldosterone in its
target tissues in .the rat. Although both aldosterone and carbenoxolone
metabolism, are different in man to the rat, a similar effect of 
carbenoxolone therapy would help to explain the production of the 
mineralocorticoid side-effects observed in some patients.
These studies indicate that carbenoxolone and/or glycyrrhetic 
acid, can potentiate the action of aldosterone in the rat, by 
decreasing its metabolism and rate of excretion. The main site of 
carbenoxolone, and/or glycyrrhetic acid interaction with aldosterone - 
appeared to be:-.
a) the intestinal mucosa, which is involved in the uptake of 
aldosterone, and possibly in its phase II metabolism;
b) the biliary excretion process, which is the main route of steroid 
excretion in the rat.
V/liether carbenoxolone interacts with aldosterone in the same way in 
man, to cause the capricious, production of aldosterone-like side 
effects, depends on differences between man and. rat in respect of 
carbenoxolone metabolism, a3.dosterone metabolism, and the biliary 
excretion mechanism.
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CHAPTER FIVE
1. INTRODUCTION
a) Carbenoxolone Potentiation of Aldosterone Action
Some aspects of the aldosterone-like action of carbenoxolone-- 
were evaluated by Porter (1970), using isolated membranes from 
Bufo marinus. By measuring active sodium transport in vitro, 
carbenoxolone was found not to possess inherent mineralocorticoid 
activity, but to potentiate the mineralocorticoid effect of 
aldosterone. The possible mechanisms for the synergistic action of 
carbenoxolone on aldosterone in toad skin, are discussed below,
A currently accepted model of trans-epithelial sodium transport 
(Leaf, 1963) consists of passive sodium entry at the mucosal.surface, 
in series; with an energy utilising sodium pump at the serosal surface. 
Steroid-induced protein might stimulate sodium transport in three 
ways : a) by increasing the quantity or activity of the sodium pump;
b) by increasing mucosal surface sodium permeability, thereby 
increasing the quantity of sodium available to a sodium-limited 
pumping mechanism (the ’’permease” theory, Sharp & Leaf, 19663.;
Sharp, et.al,, 1966); c) by increasing the activity of one or 
several metabolic steps, leading to an increased rate of synthesis of 
ATP (the ’’energy’1 theory, Edelman, et,al., 1963; Fimognari, et.al. , 
1 96 7a)* Fanestil (1969). reviewed the evidence regarding the action 
of aldosterone-induced protein, and concluded that the energy theory 
was the most plausible, but permease, and pump effects could hot be 
conclusively excluded. In fact, in a system where a permease., 
pump and energy are all required, it is quite likely that the cell 
nucleus, under hormonal regulation, directs a co-ordinated multi-locus 
control of sodium transport.
Carbenoxolone tested in vitro in a toad skin preparation 
(Porter, 1970), did not possess any intrinsic mineralocorticoid/ 
effects, nor did it act synergistically with vasopressin, a substance 
which increases the cell permeability to sodium. Therefore, 
carbenoxolone potentiation of aldosterone action in toad skin, is 
unlikely to be due to a direct action of carbenoxolone on the sodium 
pump or membrane permeability, Carbenoxolone was found not to 
potentiate aldosterone action in toad skin, if added before the 
aldosterone to the in vitro system. Thus, it. appears that 
carbenoxolone does not alter the nature of aldosterone receptor sites, 
or the activity or amount of aldosterone induced protein.
Aldosterone is not metabolised by toad skin (Sharp 8c Leaf, 1966b),and 
thus carbenoxolone-inhibition of its rate of tissue removal can also 
be excluded as an explanation for the potentiation effect.
Carbenoxolone may increase the unbound concentration of 
aldosterone in the cell,by displacing aldosterone from non-specific 
binding sites, and therefore increasing the amount of aldosterone 
available to receptors sites. This hypothesis,for the mechanism of 
aldosterone potentiation by carbenoxolone in an jln vitro toad skin 
preparation, is consistent with the following findings of Porter (1970
a) carbenoxolone did not potentiate a maximum,physiologically 
effective concentration of aldosterone, possibly because receptor 
occupancy is already at a maximum,
b) carbenoxolone did not potentiate aldosterone, if added-to the. 
system before the aldosterone, possibly because there is no 
bound aldosterone available for displacement,
c) 176-estradiol was also shown to potentiate aldosterone action in 
the toad skin preparation. Studies by Swaneck, ejt.al. (1969)* 
using specific mineralocorticoid-binding proteins extracted from 
rat tissues, demonstrated enhanced binding of [^Hjaldosterone, 
when treated v/ith steroids possessing no mineralocorticoid 
activity, e.g. 17(3-estradiol. Thus, increased binding of 
aldosterone to; specific mineralocorticoid-binding proteins, 
perhaps by displacement from non-specific binding sites, appears 
to be related to increased physiological-activity.
Clearly, it is of importance to investigate ~ whether the 
synergistic action of carbenoxolone upon suboptimal concentrations of 
aldosterone in the' in vitro toad skin preparation, can similarly 
occur in vivo in experimental animals. Such a synergistic action 
would provide a possible explanation for the aldosterone-like side., 
effects.’, which occur with carbenoxolone therapy. With this aim in 
mind,,the effect of carbenoxolone on the renal binding of 
[•^ H] aldosterone in vivo and in vitro, has been investigated..
b ) Renal Aldosterone-binding Proteins >
There is experimental support for the hypothesis that 
aldosterone regulates sodium transport in the rat kidney and toad 
bladder, by inducing de novo synthesis of proteins at the 
transcriptional level (Williamson, 19^3» Edelman, ejt.al**. 1963* 
Porter, jet• al., 196*1-; Castles & Williamson, 1963; Fanestil & 
Edelman, 1966a; Fimognari, et.al., 1967b; Rousseau Sc Crabbe, 1968) 
However, a study on the mechanism of action of mineralocorticoids 
requires identification of the first step in the process, the
interaction of the steroid hormone with its specific subcellular 
targets. Autoradiography of [pH]aldosterone in toad bladder ' 
suggested that the nucleus was the subcellular target for 
mineralocorticoids (Edelman, et.al., 1963)* Later, toad bladder 
epithelial cell nuclei, isolated in dense sucrose, were found to 
contain approximately 60/£ of the hormone binding capacity of the 
tissue (Ausiello 8c Sharp, 1968).
Extrapolation of these findings to mammalian systems presented 
a more complex problem, since the intact mammal, unlike the isolated-
X
toad bladder, rapidly, metabolises [ Hjaldosterone to physiologically 
inactive products. Fanestil & Edelman .(1966b)separated unmetabolised 
aldosterone from aldosterone metabolites in kidneys of adrenalectomised 
rats by partitioning with dichloromethane. They found that the 
pattern of uptake of both aldosterone and its metabolites into three 
cell fractions (mitochondria, microsomes and cytosol.) was consistent 
with a passive diffusion process,dependent solely on solubility in 
the various cell fractions. In contrast, the uptake of aldosterone 
by a purified nuclear fraction did not show this pattern and 
indicated a combination of a’high affinity binding, which was 
saturable, coupled with a lower affinity non-saturable component*
The relevance of this nuclear binding to hormone action was indicated 
by a) the ability to saturate the nuclear binding at concentrations 
of plasma aldosterone within the physiological range; b) the 
competitive inhibition of aldosterone nuclear binding by 
mineralocorticoids. Later, aldosterone binding proteins were, 
isolated and purified from both nuclear and•cytosol fractions of 
kidney (Herman, ejb.al., 1968; Ludens 8c Fanestil, 1971 )* and they
p n g g p g g p fi m any n-P p i‘npffyf.T a a  t n  hr> r>v p r t f  .qpfim’ f i n
mineralocorticoid receptors (Swaneck, et.al., 1989)*
As mineralocorticoids are believed to act via stimulation of 
DNA-dependant BNA synthesis, it is possible that macromolecules which 
bind mineralocorticoids function, at the transcriptional level, as 
repressors in the absence of steroid, but that their role as 
repressors becomes altered upon association‘with the steroid.
Other possible roles for the cytoplasmic rnacromolecules include:-
1 ) serving as a storage mechanism that regulate the intracellular 
concentration of free hormone;
2 ) functioning as modulators of protein synthesis at the level of 
translation;
3 ) serving as a transport mechanism to move specific steroids from 
the cell membrane to the nucleus of the target tissue.
This latter role has been postulated for estrogen-binding 
rnacromolecules found in the cytosol fraction of target tissues 
(Noteboom 8c Gorski, 1983; Maurer 8c Chalkley, 1987; Shyamala 8c 
Gorski, 1968; Jensen, et.al., 1988), and for cortisol-binding 
rnacromolecules found in the cytosol fraction of liver (Beato, et.al., 
.1970)* Preliminary evidence'on the time course of renal binding of 
[^H]aldosterone (Swaneck, et.al., 1970; Marver, e_b.aJL., 1972) 
indicates that a cytoplasmic aldosterone binding protein complex is 
formed first, followed by formation of a soluble nuclear 
aldosterone-binding protein complex, and finally by formation of a 
chromatin, aldosterone-bindingjproteihi complex.
Clearly, aldosterone-binding proteins are involved in the 
mechanism of action of this steroid. The studies inthis chapter 
investigate the ability of carbenoxolone to either 1) displace
aldosterone from aldosterone-binding proteins, or 2 ) to increase 
aldosterone bound to aldosterone-binding proteins, by displacement 
of aldosterone from other intracellular binding sites.
2. EXPERIMENTAL
a) Materials *
Bovine serum albumin was supplied by Koch Light. Other chemicals 
and organic solvents used, were described in chapter four.
Adrenalectomised female Wistar albino rats (180-200 g), were;
maintained on 0»9% saline and small animal diet ad.lib., and used
3-k  days after bilateral adrenalectomy.
b) Methods i
Extraction of [^H]aldosterone, thin-layer chromatography and ;
scintillation counting techniques, were as described in chapter four.
i) In Vitro Preparation of Kidney Cell Fractions
Adrenalectomised rats were decapitated and both kidneys removed j
and weighed. All isolation and fractionation procedures were carried 
out at 0-^°. The kidneys were homogenised for 15 sec. in ^ ml of 
0.25 M sucrose per g wet wt. of kidney in a Teflon-glass Potter. j
Elvehjem homogeniser. The renal homogenate was centrifuged at *
600 g for 10 min. The 600 g sediment was resuspended in 5 ®1 of |
0.25 M sucrose and centrifuged at 600 g for 10 min. The resulting j
sediment consisted of a crude nuclear preparation. The 100,000 g 
supernatant (cytosol fraction) was obtained by centrifugation of the. |
600 g supernatant at 10,000 g for 10. min., collection of the 
supernatant, and recentrifugation at 100,000 g for 60 min. !
Crude nuclear fractions from individual pairs of rat kidneys 
were suspended in 6 ml of 0.1 M Tris-3 m M CaCl^ buffer, titrated 
to pH 7.4- with HC1 (Tris-CaCl^ buffer), and sonicated for 5-10 seconds
using a mechanical sonicator (Polytron). The nuclear residue was 
then removed by centrifugation at 26,000 g for 15 min. To the 
•resulting supernatant (Tris-CaCl^ buffer extract), an equal volume, 
of'.’a saturated solution of (NH^^SO^, titrated to pH 7 with NH^OH, 
was added and kept at 0° for J>0min. The -50^  ■ (NH^^SO^ precipitate, 
was sediraented by centrifugation at 2 6 ,0 0 0 g for 15 min. and 
resuspended in 5 nil1 of the Tris-CaCl^ buffer. Thus, from a kidney 
crude nuclear fraction the following three fractions were obtained:
1) a nuclear residue fraction after Tris-CaCl^ buffer extraction;-
2) a 50;o (NH^^SO^ precipitate;
3) a 50yo (NH^J^SO^ supernatant.
Herman, et.al. , (.1988) have shown the 50% (NH^^SO^ precipitate, 
fraction to contain specific mineralocorticoid-binding proteins.
3ii) Measurement of f H]Aldosterone and Protein
r 3[ H] Aldosterone, administered to adrenalectomised rats by 
subcutaneous injection, was extracted from plasma and kidney cell. 
fractions with, dichloromethane (5 vol) . Thin-layer chromatography of 
kidney extracts, showed the radioactivity in the nuclear fractions; 
was always >97% [ H] aldosterone, while the extracts of cytosol 
fractions contained > 90% [^H]aldosterone. Radioactivity in 
dichloromethane extracts was measured as described in chapter four.
Protein concentration in tissue fractions was determined by the; 
method of Lowry, et.al. (1951)« Suitable aliquots of tissue samples 
containing 2-3 mg protein, were diluted to 10 ml with 0.2 M. NaOH.
The diluted solution (1 ml) was taken for protein determination.
The following four reagents were used:-
A. 2/o w/v Na^CO- in 0.1. M NaOH.2 5
B. 2% w/v- NaK tartrate
C. 1% w/v CuSO^. 5H20
D. Folin 8c Ciocalteau's reagent (B.D.H.) used as supplied.
A mixture of solutions A (100 ml), B (1 ml) and G (1 ml) v/as 
freshly prepared for the assay. This reagent (10 ml) was mixed v^ ith 
1 ml of the diluted protein solution, and left to stand for 15 min. 
Solution D (0.5 ml) was then added, thoroughly mixed, and left to 
stand for kO min.• ;
The optical density of the solution at 750 mn v/as then measured 
in glass cells. (1; cm light path), using a.Pye-Unicam 3P 500 
spectrophotometer. A. standard curve v/as prepared using bovine serum • 
albumin (50-500 Mg) dissolved, in 1. ml 0.2 M NaOH.
7
iii) Carbenoxolone and the in Vivo Binding of [ HjAldosterone
[ H^] Aldosterone was administered by subcutaneous injection to
ensure direct absorption into the systemic blood circulation.
Preliminary studies (table 5-1) revealed that at 0.5 h after/
[ II] aldosterone administration, the content of radioactivity in the
3kidney was maximal and represented mainly [ H]aldosterone. The dose.
3of aldosterone administered per rat, consisted of 5 pCi ["HI]aldosterone
and varying amounts of non-radioactive aldosterone, made up in
0.5 ml 0.9% saline containing 5% V/v ethanol. A dose of aldosterone
— 9(3 x 10 mol) to adrenalectomised rats, produced a plasma aldosterone
-9 ‘ .
concentration of 5 x 10 M and was the minimal dose re.quired for
maximum sodium retention (Fanestil & Edelman, 1966b).
In the experiments, 96 adrenalectomised rats were; injected 
subcutaneously in groups of eight with [ If] aldosterone over the 
dose range:- 0.A x 10~^ mol to 1.1 x 10~^ mol. Half of each group 
simultaneously received carbenoxolone (50 rag/kg) in propylene glycol 
by intraperitoneal injection, i^ hile the other half received propylene 
glycol only. Thirty minutes later, the rats v/ere decapitated, a 
sample of heparinised blood was collected, and the kidneys removed. 
Plasma, and various kidney cell fractions were prepared as previously.
mZ
described, and assayed for content of protein and [H]aldosterone.
The experiment above was designed to investigate: any competition
occurring between carbenoxolone and [ Hjaldosterone for renal
uptake and binding. To determine the effect of carbenoxolone on the
intracellular distribution of [^H]aldosterone already bound in the
kidney, the following experiment was performed. Adrenalectomised
rats were given a low physiological dose of [^H] aldosterone 
—10(1.6 x 10 mol) subcutaneously, then anaesthetised with 
pentobarbitone (60 mg/kg) administered intraperitoneally. Thirty; 
minutes later, the rats received, by injection into the jugular vein, 
either carbenoxolone sodium (5 mg/kg) in 0.9/£ saline or vehicle only. 
Ten minutes lateT a heparinised blood sample was obtained from the 
posterior vena cava, and both kidneys, removed*. Plasma and various, 
kidney intracellular fractions were assayed for content of protein
and [^Hjaldosterone. The ratio of the amount of [^Hjaldosterone 
between various intracellular fractions was calculated for the 
control.and carbenoxolone-treated groups. This would indicate 
whether carbenoxolone had changed, the intracellular distribution of • 
[ ?H]aldosterone bound in the kidney*
iv) Carbenoxolone and the in Vitro Binding of [^ II] Aldosterone 
3The binding of [ H] aldosterone to components of renal nuclear.
5 . ' ' .
fractions was also studied in vitro. Tris-CaCl^ buffer extracts of 
kidney crude nuclear fractions were prepared as previously described. 
To ml of Tris-CaCl^ buffer extract (from approximately 0.5 g wet wt
of kidney) containing 2.5 x 10 mol. [ Hjaldosterone, carbenoxolone
-11 -8in amounts ranging from 5 x 10. mol to 2 X-10 mol was added*
The tissue fraction was then left for 2 h at 0° to allow 
[ H^] aldosterone binding to attain a maximum (Herman, et_.al. , 1968). 
Then aldosterone-binding proteins v/ere precipitated by the addition 
of an equal volume of saturated (NH^^SO^ solution and left at 0° 
for 30 min. The precipitated aldosterone-binding proteins were;; 
sedimented by centrifugation at 26,000 g for 15min. The precipitate 
v/ere resuspended in 0.1 K Tris-5 inl*l CaGl^, pH. 7.^ buffer, and assayed 
for [Hjaldosterone and protein content.
The amount of [^Hjaldosterone bound, in the resulting 50$>
supernatant was determined as follows. Lengths of dialysis 
tubing (20 x4cm) v/ere soaked overnight in deionised water* and then 
for a few hours in 0.1MTris-3 mM CaCl^ buffer, containing 50?6 
(NH^^SO^. The tubing was wiped dry with tissue and a. knot carefully/ 
tied at one end. The other end was opened and the tube inflated by 
blowing into it. The sample (6 ml) was pipetted into the open end 
of the dialysis tube, and a knot tied after excluding as much air as
possible to sqal the dialysis bag. The bag was folded into a 
U-shape with the knotted ends secured together with a rubber band, 
and pushed onto a sintered glass disc, 2. cm above the bottom of a.
50 ml polycarbonate centrifuge tube. The ultrafiltration of the 
samples v/as then carried out at 2°, by centrifugation for 1 h at 
800 g. This produced an ultrafiltrate sample of about 0.3 ml.'
The concentration of [Hjaldosterone in the initial sample and in 
the ultrafiltrate sample v/as determined as previously described by 
liquid scintillation counting.
■7
The percentage of [ Hjaldosterone unbound in the ^0% (NH^^SO^ 
supernatant fraction was calculated as follows:-
- tt 1- j /rt/\ d.p.m./rnl ultrafiltrateUnbound (%) = y—1---/r-=-- ------------r— r~.---  X- 100d.p.m./ml 01 initial solution
In this jjti vitro' experiment, the amount of [^Hj aldosterone bound 
to the 50% (NH^ ),,;S0^  precipitate and supernatant, with carbenoxolone 
present, was expressed as percentage of the value when no
"Z
carbenoxolone was present. The amount of [Hjaldosterone added to
this in vitro system produced .a concentration similar to that found
in kidney nuclear fraction,after subcutaneous administration of 
—102.8 x 10 mol aldosterone.
RESULTS
Table 5-1- Radioactivity in Plasma and Kidney after Subcutaneous 
Administration of f^E~\Aldosterone to Adrenalectomised
iats
Nature of 
Radioactivity
Percentage of Dose in Kidneys at various. Times after 
[ ^ H]Aldosterone Administration
15 30 4-5 minutes
Free Steroid 
Polar Metabolites
0.71 + 0 o08 
0 .21 + 0 .0 2
1 .0 6 + 0 .0 9  
0.25 +:0 .0 3
0 .7 6 + 
0.4-1 +
0 .0 6
0 .0 6
P-Hn' Free Steroid ■ 
Polar Metabolites ' 4-.2 1.9
Percentage Dose in Plasma of Free Steroid after 
[^H]Aldosterone Administration
Time after 
Administration 
(min)
Dose Present in 
Total Plasma 0.70-+0.06
1£
1.31
+0 .0 8
25
1.4-3
+0 .1 0
30 35
1.57 1.93 0 .81
+0.14- +0 .21 +0 .0 5
The values given are the mean of 3 rats + S.E.M.
Pift* 5-1 Effect of Carbenoxolone Treatment on the Plasma
• ........   ■■■■ l -  - . —  .--.II-.-— - - - - - i.,.-,--.—  .- -
r 3Concentration of 1 H]Aldosterone'over a Ran^e of 
Physiological Doses
o
Carbenoxolone
12
Control
321
[^HjAldosterone administered (mol x 10
Each point represents the,mean value from k rats
Table 5-II Plasma Concentration of [^ II] Aldosterone 30 minutes
■3
after Various Subcutaneous Doses of [ H] Aldosterone;
Dose of [^H] Aldosterone.- [_?H] Aldosterone Plasma Concentration
. Administered 
(mol x- 10~10) (M x 10“10)
[^H]Aldosterone
*7
[ H ]Aldosterone +
alone Carbenoxolone (30 mg/kg]
0.4-1. 1.1 + 0.1 1 .3 + 0.1.
0 .8 2 2 .3 i  0.1 2.6 + 0.2-
1.3 3.1 + 0.1; 3.6 +0.3
1.3 k A  + 0 .3 3 .8  + 1 .0
2.0 3 .2 + 0 .7 7 A  + 1 .5 -
2.1 3 A  + 0.7 7.6 + 0.8*
2.8 7.3 + 0 .8 9 .6 + 0.8*
3.2 CO • l+ 0 • C
O 1^.3 + 2.7 *
6 .7
CVJ+l
0
0V
19 + 1
12 26 + 7 4-8 + 1 0
63 180 + 3 0 190 ’+ 29
107 250 + 1 0 34-0 + 18*
The mean values of ^ rats _+ S.E.M. are given*.
* Values are significantly, different from control- group P^O.03
Table 5-IH r3Hl Aldosterone Content of Kidney Crude Nuclear.
Fraction
[ H]Aldosterone 
Administered 
(mol x 10“ )
[ h ]Aldosterone Concentration in Crude 
Nuclear Fraction _
(mol x 10 /mg protein)
[3H jAldosterone 3[H]Aldosterone +
alone Carbenoxolone (50 mg/kg)
0.41 1.1 + 0 .2 0.9 + 0.1
0*82 2 .7 + 0 .2 2 .0  + 0 .2
1.3 3.2 + 0.4 2.9 + 0.7
1.5 4.9 ± 0 .6 4.3 + 0.3 ‘
2 .0 6 .1 ± 0 .6 4.5 + 0.7 .
2.1 6*7 + 1.1 5.2 + 0.5
2 .8 8 .8 + 1 .0 6 .6 +_ 1 .0
3.2 10 _+ 2.4 8 .6 +. 0 .8
6.7 15 + 1.5 12 + 1.4
12 2 3 + 2 .0 19 + 1 .8
63 67 + 6 .49 + 1 3
107 81 + 7 74. + 7
The mean values of four animals + S.E.M. are given*
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Table 5-IV Concentration of [~3HlAldosterone in Cytosol Fraction
of Rat Kidney
[3H] Aldosterone; 
Administered 
(mol x 10"*10)
[ h ]Aldosterone Concentration in Kidney 
Cytosol Fraction _
(mol x 10“ /mg protein)
*7
[•^II] Aldosterone
*7
[ H jAldosterone. +
alone Carbenoxolone (50 mg/&g
oA 'l 1.8 + 0.2 1 .3 + 0.1 *;
0.82. 3.2 + 0.1 1 .9 + 0.1*
1.3 3.8 +0.3 2.6 + 0.1* ‘
1.5 ^.0 + 0.5 3.1 + 0.2
2.0 6 .3 + 0 .5 *+.6 + 0.6
2.1 7.0 + 0.9 6 .3  + 0 .7
2.8 9.1 0.6 8.6 jh 0.9
3.2 .10 .7 + 0 .8 8.8 0.6
6.7 21.0 + 1.2 15*7 + 0.3*’
12. 22.8 + 1.6 2 ^ .3 + 2.6
63 107 + 4 94. + 5*
107 205 + 3 ! 183 + 7*
The values given represent the mean of k animals _+ S.E.M*.
* Values are significantly different from control group P < 6.05
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Fig. 5-HI Effect of Carbenoxolone Treatment on the Concentration of
3f IIlAldosterone in Kidney Cytosol Fraction over a Range of 
T HlAldosterone Plasma Concentrations
Control
Carbenoxolone
7
Pla sma [ HjAldosterone Concentration (m )
Each point represents the mean value from 4 rats.
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/Table 5-VI The 3jn. Vitro Binding of [^Hjaldosterone. to Tris-CaCl^
Extract ofyKidney Nuclear Fraction measured by
Ultrafiltration
Carbenoxolone
Added
(mol)
50/a (NH^y^SO^ precipitate ^  
(/3 control)
50>p (NH^^SO^ supernat­
ant.
(% control)
None 100 100
5 x 1Cf11 100 + k .6 99 + 2*8
*1 x. 10~10 93 + 3.0 76 _+
2 x 10“8 96 • ■+ .1 #0 66 + 3.2*
The values given are the mean of 5 experiments _+ S.E.M.
* Values are significantly different from control P<0.01 
^ This amount of carbenoxolone is at a similar concentration to 
that, found in kidney nuclear fractions 30 min* after, 
intraperitoneal administration of carbenoxolone (5 0 mg/kg). 
^  Aldosterone-binding proteins.
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k. DISCU3SIQN
YJhen [^Hjaldosterone was injected subcutarieously into 
adrenalectomised rats, the amount of free steroid in the plasma at 
13 to after administration was nearly constant, and
this indicated that the rate of absorption and rate of metabolic 
removal of the hormone were in equilibrium (table 5 -1 ).
After 30 minutes,a gradual clearance of ^Hjaldosterone from the 
plasma occurred. The plasma concentration of [^Hjaldosterone at 
30 minutes after administration has a-linear>relationship.to the dose, 
given (Fig. 3-1 & table 3-H)* Acute carbenoxolone treatment 
resulted in elevated plasma concentrations of [Hjaldosterone
■ ’ . 1
(Fig. 5-1 & table 3-II) j which were significantly different from 
control values, at dose levels of aldosterone approaching the upper 
limit of the physiological range. This reduced plasma clearance of 
[ Hjaldosterone with acute carbenoxolone treatment correlates v/ith 
the findings described in chapter four.. Since the plasma concentration' 
of aldosterone is directly proportional to the tissue concentration, 
then the carbenoxolone treated rats may show, greater uptake of 
[•^Hjaldosterone into the kidney than control rats.
However, the mean aldosterone content of the kidney nuclear* 
fraction was lower in carbenoxolone treated rats over the dose range; 
of [^Hjaldosterone employed, but it was not significantly different 
statistically from the control rats (table 3-HI)* Thus, in view of:, 
the significantly higher plasma concentration of [^Hjaldosterone in 
treated rats, carbenoxolone was inhibiting the uptake of aldosterone 
into the kidney nuclear fraction. In control rats, a plot of 
[^Hjaldosterone in the kidney nuclear fraction against plasma
[pH]aldosterone concentration yielded a characteristic biphasic curve
as described by Fanestil & Edelman (1966b). A similar plot was
obtained in carbenoxolone treated rats (Fig. 5^-11), but the.
concentration of [pEL]aldosterone in the nuclear fraction,at a given
plasma concentration, v/as always at least 30/6 lower than that
observed for control rats. The pattern of kidney nuclear uptake is
considered to be a combination of high affinity saturable binding
with a lower affinity, nonsaturable component. In contpol rats ,
saturation of nuclear binding occurred at a plasma concentration of 
—108 .3 x 10 M, while carbenoxolone treatment reduced this; value to^
-10 '
3.2 x 10 ' M.
Carbenoxolone treated rats also showed a significantly lowered 
concentration of [^Hjaldosterone in kidney cytosol fraction at five 
of the dose levelsr of aldosterone investigated (table 3-IV). At. 
other dose levels of aldosterone, there v/as a trend towards lowered 
[?H] aldosterone content of the cytosol fraction. When aldosterone 
concentration of cytosol fraction was plotted against [^H]aldosterone 
plasma concentration (Fig. 3-IH)» a- straight line was obtained, 
which was significantly lowered (k0%) in the carbenoxolone treated rats
Since both the nuclear and cytosol fractions of kidney are 
thought to contain receptor sites, necessary for the action of 
aldosterone, it was necessary to determine the binding sites for.' 
which carbenoxolone and [ II] aldosterone were mutually competing. 
Therefore,a more detailed study of carbenoxolone inhibition of the 
kidney nuclear uptake of [ H^] aldosterone was carried out, by 
fractionating a.crude nuclear preparation into three fractions;
(table 3-V). The effect of acute carbenoxplone treatment on 
aldosterone uptake into these three fractions is discussed below.
1 ) Nuclear Residue
3
Carbenoxolone had no effect on the amount of [ H ]aldosterone 
bound in the.nuclear residue fraction. This fraction contains 
the nuclear'aldosterone not extracted into Tris-CaCl^ £mffer, 
and represents about 20% of total nuclear aldosterone.
2 ) Aldosterone-binding Proteins
The amount of [^Iljaldosterone bound to the ^0% (NH^)^SO^
precipitate fraction was significantly lowered by 30/® by -
carbenoxolone treatment, when low doses of [^H]aldosterone 
-10(O.^ f & 1*3 x 10 mol) v/ere administered. The effect was less
apparent when higher doses of [^H]aldosterone were administered 
—10e.g. 2 .8  x 10 mol,whih.may be due. to the significantly higher 
plasma concentration of [^H]aldosterone observed in the treated - 
rats at this dose level. Herman, et.al. (1968) have demonstrated 
that this (NH^^SO^ precipitate fraction contains stereospecific ' 
raineralocorticoid-binding macromolecules, which may be involved 
in the action of aldosterone. Acute carbenoxolone treatment 
reduces the kidney uptake of [^H]aldosterone into this fraction, 
but the significiintly higher plasma [pH Jaldosterone concentration 
in treated rats indicates that,at a normal physiological dose; 
of (plljaldosterone, the amount of [pH Jaldosterone bound to the 
aldosterone-binding protein is not significantly altered.
.Non-specifi6 Binding Proteins
*2 • '
A significant reduction in [Hjaldosterone content of the 50%
• . ot-
(NH^y^SO^ supernfent fraction was observed in carbenoxolone treated
rats, which was still api^arent when.maximal physiological doses;
3of [Hjaldosterone were administered.
Thusicarbenoxolone was found to reduce the content of
3
[Hjaldosterone in two fractions separated from kidney nuclei. Since
all types; of aldosterone binding sites in the kidney are presumably
3 *; '
involved in the in vivo uptake of [Hjaldosterone from the plasma
into the kidney cells, and from the cell cytoplasm into the nuclei,
■2
the reduced amount of [Hjaldosterone in the nuclear fraction may
3not be due to carbenoxolone inhibition of [Hjaldosterone nuclear 
binding, but to an inhibition of total uptake by the kidney cell. 
Therefore, experiments were carried out in vitrot on [pH]aldosterone 
binding to kidney nuclear preparatiors,in the presence of carbenoxolone
3[ HjAldosterone v/as incubated with a Tris-CaCl^ buffer extract 
of a kidney nuclear fraction (which normally contains &0% of 
aldosterone nuclear binding), for 2 hours at 0°. The amount of 
[^Hjaldosterone bound to the 50% (NH^^SO^ precipitate was determined 
directly, while the amount bound in the resulting supernatant was 
determined by ultrafiltration. Carbenoxolone, added in amounts 
greater than that found in the nuclear fraction in the in vivo 
carbenoxolone distribution experiments, did not significantly reduce, 
the amount of*[ Hjaldosterone bound to the aldosterone-binding 
protein fraction. Thus the reduced amount of [^Hjaldosterone bound 
to nuclear aldosterone-binding proteins in the in vivo experiments
v/as probably a result of reduced, kidney and nuclei uptake of 
aldosterone, due to carbenoxolone induced inhibition of non-specific 
binding. Carbenoxolone,in concentrations similar to that found 
in vivo, reduced by 23% the binding of [^H]aldosterone tovthe 30% 
(NH^^SO^ supernatant fraction jn vitro, which correlates to the 
findings of the in vivo study. This reduction in nuclear non-specific '!
“7
binding of f^Hjaldosterone in vitro by carbenoxolone did not 
apparently result in increased [^Hjaldosterone binding to the nuclear 
aldosterone-binding protein fraction. A possible reason is that the 
[^Hjaldosterone, although present in a physiological concentration, 
was mainly unbound (60%) in this in vitro system. '■
However, since carbenoxolone inhibition of non-specific nuclear- 
binding of [^Hjaldosterone, has. been demonstrated, it .is possible 
that in vivo endogenous aldosterone in the kidney will be displaced j 
from non-specific binding sites onto the specific sites by carbenoxolone. 
Therefore, an in vivo experiment was designed to mimic the effect of 
an absorbed dose of carbenoxolone on endogenous aldosterone in the 
rat kidney. Carbenoxolone (3 mg/kg) was administered intravenously 
30 minutes after (flijaldosterohe administration, at which time the 
kidney uptake < f subcutaneously administered [ ^Hj aldosterone had. I
previously been shoYm to reach a maximum. Ten minutes after the 
administration of the carbenoxolone, the distribution of_
[■^ H] aldosterone betv/een either the kidney cytosol, and nuclear fraction^ 
or the specific and non-specific kidney nuclear binding, was unaltered 
in treated rats compared to the control group (table 5-VII).
However, in this experiment carbenoxolone did appear to slightly 
increase the plasma and kidney content of
[^Hj aldosterone (table 5-VTI). Thus carbenoxolone appears to have an
Iimmediate effect on plasma clearance of aldosterone*
Previous experiments demonstrated significantly higher plasma
•z
concentrations of [Hjaldosterone in carbenoxolone treated rats
(Fig. which have been suggested in chapter four to be a result
of carbenoxolone inhibition of the metabolism and excretion of 
aldosterone. Therefore, if carbenoxolone inhibits the plasma^ 
clearance of aldosterone in man, as has been demonstrated for the. 
rat, this is likely to be the primary cause of the occasional 
mineralocorticoid -like side effects observed.
Carbenoxlone potentiation of aldosterone,by intracellular 
displacement of aldosterone in its target organs from non-specific 
binding sites onto receptor sites, cannot be excluded as a possible 
mechanism for the aldosterone-like effects, because carbenoxolone was 
shown, both in vivo and in vitro to inhibit kidney binding of 
[^Hjaldosterone. The present study did not demonstrate such a. 
mechanism in vivo or jln vitro, although other experimental designs 
may demonstrate that carbenoxolone can displace aldosterone onto its 
receptor sites. For instance, specific mineralocorticoid binding 
proteins are known to occur in the cytosol (Herman, et.al., 1968; 
Ludens & Fanestil, 1971)» and more recently in .the plasma membrane 
(Forte, 1972), fractions of kidney, but these were not investigated in 
this study. An interaction of carbenoxolone with bound aldosterone, 
does appear to be the most plausible explanation for carbenoxolone 
potentiation of aldosterone action in toad skin. Nevertheless, the 
present investigations indicate that carbenoxolone potentiation of 
aldosterone action, as suggested by the studies of Porter (1970) ia 
the toad skin, is likely to play only a secondary and possibly minor 
role in the manifestation of aldosterone-like effects in the rat.
CHAPTER SIX
This final chapter presents a brief review of the main 
'experimental, findings together with a final discussion.
Absorption and Distribution of Carbenoxolone in the Rat
Investigation of the absorption of [^C Jcarbenoxolone in the 
rat by in vitro and in vivo techniques, established that in rat and 
probably also in.man, oral carbenoxolone is absorbed primarily 
from the intestine. Measurement of intestinal absorption of 
[ C]carbenoxolone ,from a range of buffered solutions (pH 5-8), revealed 
that this weak acid was most rapidly absorbed at more alkaline pH. 
values. This finding was not in agreement with the widely accepted 
pH-partition hypothesis of drug absorption (Schanker, et.al.,,1957, 
199?;. Shore, et.al., 1997; Hogben, ejt.al., 1997, 1999)* The 
increase in carbenoxolone absorption with increase in pH of the 
solution.was related to the increase in water solubility of the drug, 
and the absorption of the ionised molecule.
rlif
An intravenously administered dose of [ Cjcarbenoxolone was
initially confined to.the plasma compartment, and confirmed that this
. Q
drug is highly bound to plasma proteins (Li'ndup, 1971)* Distribution 
studies on [^CJcarbenoxolone,after administration by various routes, 
confirmed that this drug is almost entirely located in the 
gastrointestinal tract, liver and the blood plasma. No significant-
• r1*f -idistribution of [ CJcarbenoxolone m  the kidney, body fat, brain, 
musculature or tissues other than those previously mentioned, was 
detected. Obviously,the protein-binding characteristics of the drug 
are of much greater importance than its lipid solubility in 
determining its tissue distribution.
Zj.
[ ClCarbenoxolone was found to be rapidly accumulated by the. 
liver, from the blood plasma,and excreted in the bile. These, 
investigations indicated the possibility that carbenoxolone is bound, 
in. the liver,by anion binding proteins, as described by 
Litwack, et.al. (1971)• It would be of interest to investigate the? 
hepatic proteins involved in the uptake of carbenoxolone, and the 
possible interaction of carbenoxolone at this site with other highly
•z
protein-bound drugs. The biliary excretion of both [ Hj corticosterone
•Z *
and [ Hjaldosterone was markedly (50/6) reduced after acute 
carbenoxolone treatment. These investigations indicated that 
carbenoxolone was inhibiting the biliary excretion of the steroid, 
conjugates, rather than the hepatic uptake and metabolism of the 
free steroids.
Experiments in which the [^CJcarbenoxolone was administered 
parenterally to rats have shown that the radioactive drug, possibly 
as conjugates, migrates back into the gastrointestinal mucosa, and 
in particular, into the gastric mucosa. This would suggest that there* 
may be proteins present in the stomach mucosa which have a special 
affinity for carbenoxolone. It would now be of value to investigated 
the mode of action of carbenoxolone on the cells of the gastric 
mucosa. An investigation of the effect of carbenoxolone on 
gastrointestinal mucus should be carried out,to determine any 
quantitative or qualitative changes. Such effects may be the result 
of carbenoxolone derepression of chromosomal DNA stimulating new 
messenger HNA and protein biosynthesis. A. study of the intracellular 
location of carbenoxolone in the gastric mucosa, may .indicate the site 
of action of this drug. However, radioactively labelled carbenoxolone
\
of high specific activity is required for such studies. At present, 
synthesis of [^C-]labelled material with a specific activity 
> 2 5 0 |iCi/m mol is very expensive, and therefore it is suggested that 
[^Hjcarbenoxolone (10 Ci/m mol) should be used for future studies.
Carbenoxolone and the Metabolism of Corticosteroids
Short term carbenoxolone treatment of rats had no significant
effect on endogenous plasma corticosteroid concentrations, or on
3
the plasma turnover and biliary excretion of [ Hjcorticosterone.
Acute carbenoxolone treatment significantly reduced the rate of 
plasma disappearance (30/6) and biliary excretion (50/6) of 
[^Hjcorticosterone. In view of the direct feedback control of the 
plasma concentration of glucocorticoids on the adrenal secretion 
rate, it is unlikely that carbenoxolone would produce glucocorticoid­
like side effects* Nevertheless, the finding are consistent with 
the reports that carbenoxolone or glycyrrhetic acid in humans can 
produce transient rises in 17-hydroxycorticosteroids (Kumagai, et.al*, 
1957; Mattingly, et.al., 1970), and potentiate the action of small, 
doses of cortisol (Hudson, et.al., 195^J Kumagai, et.al., 1957)»
Short term carbenoxolone treatment of rats significantly increased 
the plasma half-life of [^Hjaldosterone (50%') 9 but had no significant 
effect on the biliary excretion of [^Hjaldosterone. Acute 
carbenoxolone treatment greatly reduced the biliary excretion of
■Z
[ Hjaldosterone (50/£). Preliminary evidence indicated that the main 
site of carbenoxolone inhibition of aldosterone metabolism was the 
conjugation of aldosterone in the intestinal mucosa. Since the rate 
of aldosterone secretion from the adrenal gland is not controlled 
directly by the plasma concentration of the steroid, b^t by the water
and electrolyte balance of the body, one would expect carbenoxolone 
inhibition of aldosterone metabolism to produce mineralocorticoid 
side-e'ffects, especially; in patients with a tendency tov/ards 
hypertension* . However, further studies will be required to determine 
the effect of carbenoxolone on the metabolism of aldosterone in man, 
since there is a species variation in both the metabolism of 
aldosterone and carbenoxolone. A reduced rate of aldosterone 
metabolism in man is consistent with the reduced aldosterone secretion 
and excretion rates observed v/ith carbenoxolone therapy.
The inhibition of both corticosterone and aldosterone metabolism 
and excretion in the rat, was most marked after an acute dose of 
carbenoxolone. Thus, very high plasma concentrations of the drug in 
man, during carbenoxolone therapy, may have a pronounced effect on 
plasma levels of corticosteroids. It is relevant that other 
corticosteroids, like corticosterone and deoxycorticosterone,have saLt 
retaining properties analogous to aldosterone. Furthermore, cortisol. 
is capable of acutely increasing glomerular filtration rate," thus- 
increasing the filtered load of potassium, and augmenting urine 
potassium loss* Therefore the severe cases of hypokalemia and muscle 
weakness found occasionally v/ith "Duogastrone11 therapy, may be a direcv. 
result of high plasma concentrations of carbenoxolone acutely 
increasing the plasma concentrations of corticosteroids. Such severe 
side effects appear to be rare with "BiogastrOne” therapy, and indicate 
the importance of the mode of absorption of this drug to the 
production of side effects. The slow release of* carbenoxolone from 
the stomach into the intestine would possibly 'favour absorption of 
the drug from the gastrointestinal tract as the glucuronide, which 
would then be rapidly excreted in the bile. On the other hand, rapid
release of the drug into the small-intestine, as occurs with 
Duogastrone, would favour rapid absorption and hence absorption of ‘ 
the non-conjugated drug. This would create a demand for hepatic 
conjugation and may delay biliary excretion, giving rise to high 
plasma levels of the drug, and hence more mafrked corticosteroid 
side-effects.
Carbenoxolone and the Tissue Distribution of Corticosteroids.
Carbenoxolone had no effect on the binding of [ Hjcortisol to 
human plasma proteins. Displacement of [^Hjaldosterone from plasma 
protein binding sites by carbenoxolone was demonstrated, although 
this was considered to be of little clinical significance. Short 
term treatment of rats-with carbenoxolone increased the concentration 
of [^Hjaldosterone located in the target organs of this steroid, 
and this change seems to be a result of reduced metabolism. Studies 
both in vivo and in vitro demonstrated that carbenoxolone can inhibit 
non-receptor binding of [ Ilj aldosterone ;in the nuclear, and possibly 
also the cytosol fraction of rat kidney. Therefore,there is 
indirect evidence that carbenoxolone can potentiate the action of 
aldosterone,by displacing this'steroid from protein binding sites 
onto its receptor sites. However, in vitro and _in vivo experiments 
did not demonstrate increased nuclear binding of aldosterone to 
mineralocorticoid specific binding proteins, by an intracellular 
displacement effect of carbenoxolone. The general conclusion , from 
the present investigations,was that carbenoxolone inhibition of the 
metabolism of endogenous aldosterone was the primary cause, of the 
mineralocorticoid effects observed in rats.
\
Recently, the relevance of the safety of drugs to their 
therapeutic use has become of increasing importance. It is hoped . 
that these studies increase'our:understanding of the likely 
interaction of carbenoxolone v/ith endogenous and foreign compounds. 
Improvements in the management of carbenoxolone therapy have now 
greatly reduced the incidence of side effects, and future studies 
must investigate the mode of action of this drug in ulcer healing. 
An insight into the mode of action of carbenoxolone would comprise 
a discovery of considerable theoretical and practical significance, 
since it would increase the knowledge of the aetiology of gastric 
ulcer disease and furthermore aid the design of more effective 
drugs.
\
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